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QUILL ON SCALPEL
This section provides a medium through which Canadian 
surgeons can declare themselves, briefly and informally, on 
the day-to-day affairs of surgery.
This issue of the Journal (pages 165 to 
175) includes what I believe is a landmark 
initiative regarding access to surgical care 
in communities away from large centres.
The report by Inglis (pages 166 to 168) 
gives important background information 
and highlights the attitudes of surgeons 
practising in communities with fewer than 
40 000 people. Such communities gener­
ally cannot attract or support the full 
spectrum of subspecialty surgeons and yet 
their hospitals serve populations some­
times exceeding 100 000. Most of the 92 
surgeons who responded to the survey 
expressed positive attitudes towards the 
professional rewards of their surgical 
practice. This is an important observa­
tion. It would be interesting to compare 
their responses with those of general sur­
geons in large centres.
Another interesting observation is that 
the spectrum of surgical procedures, as 
reflected in the 10 most commonly per­
formed operations, depended upon the 
size of the centre. In the smaller centres 
the scope of surgical procedures was 
broader than in the larger centres. 
Regardless of the reasons for these vari­
ations, it is evident that the information 
from this kind of review should provide 
guidance for those who wish to train sur­
geons to meet the needs of smaller com­
munities. A true population-based study 
of surgical problems in various regions 
would be invaluable bu t, to my 
knowledge, this has not yet been done in 
Canada. None the less, the survey by 
Inglis provides us with information essen­
tial to planning for training and 
management.
O ’Brien (pages 171 and 172) has 
reviewed his own experience in a small- 
community surgical practice. Twenty-five 
percent of his procedures were for frac­
tures, other limb trauma and elective limb 
surgery other than varicose veins, and
15% were gynecologic surgery or oper­
ative obstetrics, especially cesarean sec­
tions. He also points out the importance 
of being able to deal with urologic emer­
gencies and acute head injuries. It is clear 
that the kind of training provided in 
Canadian general surgical residency pro­
grams does not cover the spectrum of sur­
gical cases being treated by Dr. O ’Brien 
and surgeons like him in smaller centres.
Cutler (pages 172 and 173) has offered 
several challenging and creative sugges­
tions, perhaps the most controversial 
being that small-community surgeons 
should be affiliated with a tertiary care 
hospital with privileges to admit and treat 
patients in that hospital. He also points 
out that competent anesthesia is part of 
the whole issue relating to surgery in 
smaller communities.
The issues raised by the papers from 
this symposium on surgical manpower in 
smaller communities are not confined to
The Canadian Journal of Surgery 
Tel.: (613) 731-9331
The Canadian Journal o f Surgery is published by the Canadian Medical Association 
and sponsored by the Royal College of Physicians and Surgeons o f Canada. The es­
tablishment o f editorial policy is the responsibility o f the Royal College. The objec­
tives o f the Journal, endorsed by the Council o f the College, are: (1) to contribute 
to the effective continuing education of Canadian surgical specialists, using innova­
tive techniques when feasible and (2) to provide Canadian surgeons with an effec­
tive vehicle for the dissemination o f their observations in the area o f clinical research.
Published every 2 months by the Canadian Medical Association, PO Box 8650, 
Ottawa, Ont. K1G 0G8. Printed by Harpell's Press Cooperative, Gardenvale, PQ 
HOA 1BO. Second-class mail registration No. 5375. Return postage guaranteed. All 
reproduction rights reserved. Subscription rate for Canada and USA $30.00 per year 
($15.00 per year for trainees in surgery in Canada only), for all other countries $35.00 
per year. Single copies (current issue) available at $5.00 each, back issues at $6.00
each.
Detailed instructions to contribu­
tors, in English and French, appear 
on page 56 o f the January 1986 
issue.
All prescription drug advertisements 
in the Journal have been precleared 
by the Pharmaceutical Advertising 
Advisory Board.
ccab
PAAB
CCPP
Afilfil
l+l
WARRANTY
"The publisher warrants 
that the deduction of ad­
vertising costs for advertis­
ing in this periodical is not 
restricted by Section 19 of 
the Canadian Income Tax 
Act."
"Advertisers who file Cana­
dian tax returns can claim 
the advertising costs of 
this publication as a busi­
ness expense."
Coeditors
L.D. MacLEAN, Montreal, PQ
C. B. MUELLER, Hamilton, Ont.
Consulting Editor
D. D. CURRAN 
Associate Editor 
G. PANCIROV 
Editorial Assistant
L. WILLIAMSON 
Editorial Researchers 
K. BEAUDOIN
M. McCART
Editorial Advisory Board
R.J. BLANCHARD, Winnipeg. Man.
M . M. COHEN, Toronto, Ont.
P.J.E. CRUSE, Calgary, Alta.
A.C.H. DURANCEAU, Montreal, PQ 
G.A. FARROW, Toronto, Ont.
J.B. FREEMAN, Ottawa, Ont.
R.G. KEITH, Toronto, Ont.
N. M. SHEINER, Montreal, PQ 
C. SORBIE, Kingston, Ont.
P.J. TAYLOR, Calgary, Alta.
G.F.O. TYERS, Vancouver, BC 
P.P. MORGAN (ex officio)
The Canadian Medical Association
President
W.J. VAIL, MD, FRCSC
Secretary General 
B.E. FREAMO
Director o f Publications 
DAVID WOODS 
Director, Advertising Sales 
PAUL GRIFFIN - (416) 598-9870
Montreal Sales Manager
ROBERT STAPLETON - (514) 620-8877
Production Manager 
KATHRYN A. FREAMO 
Assistant Production Manager 
NANCY WALLACE 
Publication Systems Manager 
LEESA D. CUNNINGHAM  
Manager, Classified Advertising 
ANN ANDERSON
The Royal College of Physicians 
and Surgeons of Canada
President
J.G. COUTURE, MD, FRCSC
Executive Director
J.H. DARRAGH, MD, FRCPC
VOLUME 29, NO. 3, M A Y  1986 /  THE CANADIAN JOURNAL OF SURGERY 145
Persantine/ 'Asasantine'
B r i e f  P r e s c r i b i n g  I n f o r m a t i o n
Therapeutic or Pharmacological Classification:
Persantine: 1. Coronary vasodilator
2. Inhibitor of platelet adhesion & aggregation 
Asasantine: 1. Inhibitor of platelet adhesion & aggregation 
Indications and Clinical Uses 
Oral Dose Forms:
•  Coronary Artery Disease —  Combined therapy with di­
pyridamole and ASA (Asasantine) is indicated in patients who 
are recovering from a myocardial infarction. The rate of re- 
infarction is significantly reduced by such therapy.
•  Coronary Artery Bypass Surgery —  Combined treatment with 
dipyridamole and ASA (Asasantine) is indicated for the 
prevention of occlusion of saphenous vein coronary artery 
bypass grafts.
•  Chronic Angina Pectoris —  Persantine (dipyridamole) has 
been used successfully in the long-term treatment of a variety 
of clinical conditions caused by decreased coronary flow. In 
chronic angina pectoris, dipyridamole may often eliminate or 
reduce the frequency of anginal attacks and improve exercise 
tolerance, as well as lessen nitroglycerin requirements. 
Dipyridamole is not intended to abort the acute anginal attack.
Patients recuperating after the acute phase of myocardial 
infarction may benefit from the coronary dilating effect of 
dipyridamole and its potential ability to improve collateral 
circulation in the myocardium.
In therapeutic doses, dipyridamole does not produce a fall in 
blood pressure or an increase in heart rate. However, in the 
acute phase of myocardial infarction the blood pressure may be 
quite labile and the possible hazards of dipyridamole under 
these conditions have not been fully evaluated. Dipyridamole is 
not recommended, therefore, in the treatment of acute 
myocardial infarction.
•  Thromboembolic Disease —  Persantine is indicated for the 
prevention of post-operative thromboembolic complications 
assicated with prosthetic heart valves.
C O N T R A I N D I C A T I O N S  —  Salicylate sensitivity, active peptic 
ulcer, hypersensitivity to dipyridamole.
W A R N I N G S  —  Patients should be cautioned about the 
possibility of additional toxic effects of ASA if they are taking 
"over-the-counter1’ ASA containing remedies, including cough 
and cold medications.
P R E C A U T I O N S  —  Since excessive doses of dipyridamole can 
produce peripheral vasodilation, it should be used with caution 
in patients with hypotension.
ASA should be administered cautiously to patients with 
asthma and other allergic conditions, a history of gastro­
intestinal ulcerations, bleeding tendencies, significant anemia 
or hypo-prothrombinemia.
Patients taking 2 to 3 g of ASA daily are at an increased risk 
of developing severe gastrointestinal bleeding following the 
ingestion of alcohol.
Since salicylates interfere with maternal and infant blood 
clotting and lengthen the duration of pregnancy and parturition 
time, they should not be administered during the last trimester 
of pregnancy unless the need outweighs the potential risks.
Caution is necessary when salicylates and anticoagulants 
are prescribed concurrently, as salicylates can depress the 
concentration of prothrombin in the plasma.
Patients receiving concurrent salicylates and hypoglycemic 
therapy should be monitored closely, since reduction of the 
hypoglycemic drug dosage may be necessary.
Although salicylates in large doses are uricosuric agents, 
smaller amounts may depress uric acid clearance and thus 
decrease the uricosuric effects of probenecid, sulfinpyrazone, 
oxyphenbutazone and phenylbutazone.
Caution should be exercised when corticosteroids and 
salicylates are used concurrently. Acute hepatitis has been 
reported rarely in patients with systemic lupus erythematosus 
and juvenile rheumatoid arthritis with plasma salicylate con­
centrations above 25 mg/100 mL. Patients have recovered 
upon cessation of therapy.
Salicylate ingestion should be restricted in patients receiv­
ing indomethacin (and perhaps other non-narcotic analgesics) 
for conditions such as rheumatoid arthritis. Salicylates can 
produce changes in thyroid function tests.
Sodium excretion produced by spironolactone may be 
decresed by salicylate administration. Concomitant ingestion of 
salicylates and aminosalicylic acid (PAS) or aminobenzoic acid 
(PABA) in normal doses may lead to increased toxicity and 
salicylism.
Salicylates reportedly displace sulfonylureas, penicillins 
and methotrexate from their binding sites on plasma proteins. 
Salicylates also retard the renal elimination of methotrexate. 
A D V E R S E  R E A C T I O N S  —  In a trial of 2026 patients in which 
dipyridamole was used in combination with ASA for the 
prevention of recurrent myocardial infarction, the most 
common patient complaints, except for headaches, were those 
associated with ASA administration. In order of frequency of 
occurrence, these were stomach pain, headaches, heartburn, 
dizziness, constipation, hematemesis, bloody stools and/or 
black, tarry stools, nausea and vomiting. An increased 
frequency of elevations of serum urea nitrogen, uric acid and 
creatinine were noted in the active treatment groups but 
increases for individual patients were small and not associated 
with clinical problems. There was also a slightly greater 
frequency of elevated systolic blood pressure readings in the 
active treatment groups.
When dipyridamole has been used alone, headache, dizzi­
ness, nausea, flushing, syncope or weakness and skin rash
have occurred during initiation of therapy. In most cases, these 
tend to be minimal and transient. Gastric irritation, emesis and 
abdomi al cramping may occur at high dosage levels. Rare 
cases of what appears to be an aggravation of angina pectoris 
have been reported, usually at the initiation of therapy. On 
those uncommon occasions when adverse reactions have been 
persistent or intolerable to the patient, withdrawal of medi­
cation has been followed promptly by cessation of the 
undesirable symptoms
For ASA alone the following side effects have been reported: 
gastrointestinal —  nausea, vomiting, diarrhea, gastrointes­
tinal bleeding and/or ulceration: ear —  tinnitus, vertigo, hearing 
loss; hematologic —  leukopenia, thrombocytopenia, purpura; 
dermatologic and hypersensitivity —  urticaria, angioedema, 
pruritis, skin eruptions, asthma, anaphylaxis; miscellaneous —  
acute, reversible hepatotoxicity, mental confusion, drowsiness, 
sweating, thirst.
At the higher doses of Persantine recommended for use in 
patients with artificial heart valves, there may be an increase in 
the incidence of adverse reactions.
S Y M P T O M S  A N D  T R E A T M E N T  O F  0 V E R 0 0 S A G E  —  Hypotension, 
as a result of high serum levels of dipyridamole, is likely to be of 
short duration if it occurs but vasopressor substances may be 
used if necessary.
Salicylate overdosage SYMPTOMS may include rapid and 
deep breathing, nausea, vomiting, vertigo, tinnitus, flushing, 
sweating, thirst and tachycardia. In more severe cases, acid- 
base disturbances including respiratory alkalosis and meta­
bolic acidosis can occur. Severe cases may show fever, 
hemorrhage, excitement, confusion, convulsions or coma and 
respiratory failure. TREATMENT of salicylate overdosage con­
sists of prevention and management of acid-base and fluid and 
electrolyte disturbances. Renal clearance is increased by 
increasing uring flow and by alkaline diuresis but care must be 
taken in this approach to not further aggravate metabolic 
acidosis and hypokalemia. Acidemia should be prevented by 
administration of adequate sodium containing fluids and 
sodium bicarbonate.
Hypoglycemia is an occasional accompaniment of salicylate 
overdosage and can be managed by glucose solutions. If a 
hemorrhagic diathesis is evident, give Vitamin K. Hemo­
dialysis may be useful in complex acid-base disturbances 
particularly in the presence of abnormal renal function. 
D O S A G E  A N D  A D M I N I S T R A T I O N
Coronary Artery Disease —  The recommended oral dose is 75 mg 
of Persantine together with 325 mg ASA or one Asasantine 
capsule three times a day, in patients who have suffered a 
previous acute myocardial infarction.
Coronary Artery Bypass Surgery
For 2 days pre-operatively: Persantine 100 mg (oral)
Q.I.D.
Day of surgery: morning of
operation: Persantine 100 mg (oral)
1 hour post-op: Persantine 100 mg 
(via nasogastric tube)
7 hours
post-op: 1 Asasantine capsule
Daily maintenance dosage: 1 Asasantine capsule T.I.D.
(for the next 12 months)
Chronic Angina Pectoris —  The recommended oral dose is 50 mg 
t.i.d„ taken at least one hour before meals. In some cases 
higher doses may be necessary. Clinical response is gradual, 
reaching a maximum effect within three months of unin­
terrupted therapy.
Thromboembolic Disease —  The recommended oral dose is 100 
mg q.i.d., one hour before meals. A lower dose of 100 mg of 
Persantine daily together with 1 g ASA daily, prolongs platelet 
survival to the same extent.
Availability
1. 25 mg tablet: An orange, round sugar-coated tablet, 
imprinted with the Ingelheim tower.
2. 50 mg tablet: A coral, round sugar-coated tablet, imprinted 
with the Ingelheim tower.
3. 75 mg tablet: A red, round sugar-coated tablet, imprinted 
with the Ingelheim tower.
4. 100 mg tablet: A white, round sugar-coated tablet, 
imprinted with the Ingelheim tower.
5. Asasantine: an opaque orange and yellow hard gelatin 
capsule. Each capsule contains 75 mg Persantine and 330 
mg ASA.
P E R S A N T I N E  25 mg, 50 mg and 75 mg are supplied in bottles 
of 100 and 500 tablets.
P E R S A N T I N E  100 mg is supplied in bottles of 100 tablets. 
A S A S A N T I N E  C A P S U L E S  are supplied in boxes of 100. 
PRODUCT MONOGRAPH AVAILABLE ON REQUEST.
I  Boehringer 
Ingelheim PAABCCPP
Boehringer Ingelheim (Canada) Ltd./ttee.
977 Century Drive, Burlington, Ontario L7L 5J8
1885-1985
Cardio/Vascular B-416/85
Canada. I took part in a survey of sur­
gery performed in district hospitals of 
Pakistan during 1984. It revealed that 
only 38% of operations were “ general” 
surgery, 30% were gynecologic proce­
dures or operative obstetrics, 19% were 
urologic procedures and 13% orthopedic 
procedures. Surgeons trained in current 
general surgical programs, sent to district 
hospitals, found themselves ill equipped 
to deal with the problems confronting 
them. We proposed that the training of 
a surgeon for district hospital service in 
Pakistan should be broader than the cur­
rent general surgical programs and should 
include procedures identified by our sur­
vey. Such trainees could be designated 
“ comprehensive surgeons” .
There appears to be good reason to 
consider such an approach in Canada. 
The problem will be to negotiate with our 
subspecialty colleagues to have such a 
“ comprehensive-surgeon” training pro­
gram include appropriate hands-on 
experience. It appears that major rota­
tions should be urology, obstetrics, gyne­
cology and orthopedics. Trauma care 
should also be a component of such train­
ing; in fact, many smaller communities 
with surgical specialists could be desig­
nated regional trauma centres. I suggest 
that university surgical departments 
should “ adopt” many of the smaller 
regional centres within their referral area 
and provide back-up consultation, con­
tinuing education and referral services. 
The University of Manitoba has, in addi­
tion to this approach, appointed surgeons 
from smaller communities to the univer­
sity teaching staff. Communications such 
as library services, continuing education 
programs and assignment of residents for 
periods in surgical units of the small com­
munities could be mutually beneficial to 
programs in the tertiary centres and the 
smaller community hospitals.
Canada is a vast country with widely 
separated smaller communities. I agree 
with Dr. Cutler that the best option for 
providing surgical care to such commu­
nities is an on-site surgical unit with an 
appropriately trained comprehensive sur­
geon. We should expand our knowledge 
of surgical requirements, identify trainees 
who wish to practise in smaller commu­
nities and tailor their training to meet the 
surgical problems that will face them.
R.J. B l a n c h a r d , m d , f r c s c , f a c s
Member, 
Editorial Board.
Head,
Department of Surgery, 
University of Manitoba, 
Winnipeg, Man.,
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CORRESPONDENCE
Contributions to the Correspondence section are welcomed. 
They should be typewritten and double spaced.
Trauma Care
To the editors.—The symposium on the 
organization of trauma care in the 
November 1985 issue (pages 477 to 489) 
prompted me to file the following account 
of a local accident, which contained some 
features of interest.
On Oct. 1, 1985, a small plane took off 
from Lake Temagami on a sight-seeing 
flight. Aboard were an experienced pilot 
and three passengers. A fog closed in and 
the pilot was unable to return to the lake. 
In his search for an alternative landing 
site he hit the top of some trees and 
crashed.
Oddly, the signal of the downed air­
craft was detected by an orbiting Russian 
satellite. The information was relayed to 
the Canadian Forces and a search aircraft 
dispatched to the site. Rescue was not 
possible until the following morning.
The casualties were lifted out by an 
armed forces helicopter and brought one 
by one to the Temiskaming Hospital, 
about 45 km away. The first to arrive, a 
woman in her 60s, had a pneumothorax 
and a fractured tibia. She was treated by 
closed chest drainage, and a plaster cast 
was applied to her lower limb. Next was a 
75-year-old woman who had a fractured 
radius and ulna and was experiencing 
considerable respiratory difficulty. Roent­
genography suggested a ruptured 
diaphragm and this was confirmed at 
laparotomy when a large tear was 
repaired from below. The third arrival, 
a 55-year-old woman, had abdominal 
pain. Laparotomy disclosed a rupture of 
the middle portion of the ileum that was 
repaired after peritoneal toilet.
The pilot, a 45-year-old man, had 
severe facial lacerations and a fracture of 
the upper end of the femur. After a 
Thomas splint had been applied and his 
lacerations sutured, he was transferred 
elsewhere for treatment by an orthopedic 
surgeon. Within a couple of days the 
other two patients with fractures were 
also transferred for more specialized 
treatment.
In this instance some confusion was 
engendered by three of the victims hav­
ing the same surname and three having 
the same Christian name! Extreme care 
must be taken by the staff in such circum­
stances to keep the charts accurate.
The Temiskaming Hospital has 137 
beds and is served by one general surgeon 
and 15 general practitioners. Although it 
is unlikely that it would ever be designated 
a regional trauma centre, the vagaries of 
chance and weather have, over the years, 
brought us many trauma cases so that the 
hospital staff have special interest in 
trauma. Indeed, in 1983, two instructors 
from the advance trauma life support 
course were persuaded to teach the course 
in our institution and each year since then 
a 10-week course has been provided for 
all nursing staff working in the emergency 
department and has been attended by 
several members of the medical staff.
The following points emerged from the 
accident described:
• Rescue and management of these 
accident victims were accomplished with 
no deaths and minimal morbidity. This 
was partly due to the high level of interest 
our hospital staff has in trauma.
• Three of the four casualties sus­
tained bursting-type injuries—pneumo­
thorax, ruptured diaphragm and ruptured 
intestine—a combination of high impact 
and use of seat belts.
• Airplane crashes do not invariably 
bring the swift and certain death that the 
aviation history of 1985 might suggest.
H.F. Jeffery, md, frcs, frcsc 
A. Hurtubise, md, ccfp 
J.T. Ross, MD
Temiskaming Hospital,
New Liskeard, Ont.,
POJ IPO
Silicone Synovitis
To the editors.—In the January 1986 
issue (pages 45 to 47) Wright and Wilgis 
reported on erosive silicone synovitis 
affecting the distal radius or carpal bones 
(or both) adjacent to w rist-bone
prostheses (scaphoid and trapezium) 
made of silicone elastomer.
The title of their paper reminds us of 
a hitherto undescribed complication of 
silicone prostheses of the metacar­
pophalangeal joints, namely, erosion 
through soft tissue.
This was an incidental finding at 
autopsy in a 73-year-old woman with 
long-standing rheumatoid arthritis, who 
died in a nursing home reportedly of “ old 
age” . The same patient was previously 
reported as an example of silicone lym- 
phadenopathy resulting from finger-joint 
prostheses.1 A Silastic implant of the 
metacarpophalangeal joint of the right 
index finger had eroded through the skin.
A drian J. Christie, m d ,
FRC PATH, FRCPC
Department of Pathology,
South Macomb Hospital,
Warren, MI 48093,
USA
Marven Oxley, m d , frcpc
Department of Pathology,
The Grace Hospital,
Windsor, Ont.,
N9A 5C6
Reference
1. Christie AJ, Weinberger  KA, Dietrich  M: Compli­
cations of silicone elastomer prostheses (C). JAM A  1977; 
238: 939
Pilonidal Disease
To the editors.—I feel obligated to reply 
to Dr. Salvati’s response to my letter (Can 
JSurg  1985; 28: 466) regarding the treat­
ment of pilonidal disease.
During service with the RCAMC from 
1944 to 1946, I had an opportunity to see 
many cases of pilonidal disease. Since 
then my interest has continued, and I 
have found that certain basic principles 
of treatment should always be considered.
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As the name indicates, it is the “ hair” , 
acting as a foreign body, that causes the 
problem. I agree that in some instances 
there are no “ pits” and therefore treat­
ment should be designed to remove the 
internal hairs and the inflammatory reac­
tion that is created.
Dr. Salvati asks how I would treat a 
“ large, dirty, recurrent pilonidal cyst with 
a 2-cm ‘midline pit’ ” . This is certainly not 
a “ pit” and represents a chronic inflam­
matory reaction, possibly due to several 
factors. The likeliest cause is retained hair 
deep within the wound plus irritation 
from adjacent hairs and lack of cleanli­
ness on the part of the patient. In this case 
the etiology of the draining area should 
be explained to the patient and a plan 
made for the area to be shaved and 
cleansed and the patient to take soapy 
baths once or twice a day. Treatment can 
be facilitated by use of a Water-Pik with 
which another member of the family can 
irrigate the area. I believe that a 2-cm 
opening would quickly close once this 
regimen had been adhered to.
I have found that a Guthrie hook is a 
wonderful instrument to remove the deep 
pockets of hair. This small, sharp instru­
ment with double-pronged hooks, which 
is used primarily for delicate eye surgery 
or in plastic surgery, works best if one 
hook is removed. On numerous occasions
I have seen patients who have had drain­
ing, necrotic wounds for months or even 
years, but with removal of the hair and 
the regimen I have described the disease 
is manageable.
I reiterate that extensive major proce­
dures are rarely indicated in the treatment 
of pilonidal disease, and midline incisions 
should be avoided.
M .J. F u r m a n , m d , f r c s c , f a c s
960 East Green St.,
Pasadena,
CA 91106,
USA
O ccu lt B reast C ancer
To the editors.—Further to the paper 
“ Intraoperative localization of occult 
breast tumours” (Can J Surg 1985; 28; 
329-330) by L.J. Mahoney and his letter 
on page 300 of the same issue, the 
problem concerns marking of nonpalpa- 
ble breast lesions seen mammographi- 
cally by inserting a needle (additional 
injection of blue dye or insertion of a 
hooked wire are variations of the same 
method). The emphasis is on nonpalpa­
bility of the lesion; that is the reason for
the procedure, and to prove the accuracy 
of localization the position of the needle 
has to be demonstrated radiologically. If 
this is not done the exercise is futile and 
essentially blind. The added benefit of the 
procedure is that it enables the surgeon 
to remove the smallest amount of tissue 
adjacent to the lesion to achieve removal 
of a potentially malignant tumour; that 
is, lumpectomy with the best possible cos­
metic result.
Whether the incision will be areolar or 
a more peripheral one depends on the 
location of the abnormality in the breast 
and on the surgeon’s preference. The 
point is that the location of the lesion is 
identified by the needle and this relation­
ship is proven radiologically. This way 
even small deep lesions are rarely missed 
and the cosmetic result is excellent. The 
pathologic nature of the tissue thus 
removed may necessitate additional axil­
lary node dissection later.
With cooperation between surgeon and 
radiologist this accurate procedure is suc­
cessful in a high percentage of cases.
I .S .  SlMOR, MD, FRCPC
Department of Radiological Sciences,
Mount Sinai Hospital,
600 University Ave.,
Toronto, Ont.,
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Maxillo facial fractures 
Infected fractures  
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Micro surgery  
M inifixation.
Expanded Indications for External 
Fixation.
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C hange of Trea tm en t Following External 
Fixation.
Risks and C om plications of External 
Fixation, 
n u rsin g .
Presentation of Unusual Cases. 
W orkshops.
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p le a s a n t  s e a s o n  of  th e  year.
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Prof. M. Dick U S A Prof. B. M cKibbin U K Prof. R. Sp inelli Italy
Prof. C. Edw ards U S A Dr. D. Mears U S A Prol. R. Szyszkowitz AustriaDr. S. Green U S A Dr. C. M ialhe France Prof. J .  Vidal France
Prof. G. H ierholzer F R G Prof. G. M onticelli Ita ly Dr. Z. Zaborszki Hungary
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Murnau, Bavaria. West Germany
(Congress President:  Prof. J .  Probst;  C o n g ress  Secretary: Dr. G. Hofmann)
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SURGEONS’ UPDATE
What's new in surgery is the subject of this column. The short items are designed to let readers know 
who's doing what and why. Surgeons are interested in what other surgeons are doing in 
research, education, practice and administration. Surgery is a vibrant specialty, and, as 
its practitioners, you must be the source as well as the readers of this column.
General Surgery Places First-Year Training 
Positions in Canada-Wide Match
Next month, departments of general sur­
gery will officially register their first-year 
training positions with the Canadian 
Intern Matching Service (CIMS), leading 
the way among specialties toward central 
processing of residents’ training—a route 
some consider the only way to a rational 
system of physician manpower planning.
June 1 is the deadline for registering 
positions, according to C.A. Casterton, 
retiring executive director of CIMS. Of 
the 16 medical schools, 12 to 14 are 
expected to participate, with about 80 
spots in all. The match will be done in 
much the same way as for medical school 
graduates seeking internships. The timing 
will be different, however, since the selec­
tion of candidates for training has tradi­
tionally been in November.
A directory of the programs in the 
match will be circulated. Candidates 
searching for a position in general surgery 
will be invited to register (the proposed 
deadline is Aug. 30) and to rank their 
choices (by Sept. 15). The program direc­
tors then have an opportunity to consider 
the candidates and submit their choices. 
The match, complete with contracts 
signed by the institution and student, 
would be finalized by Nov. 1, without the 
telephoning and sometimes the pressure 
associated with the confirmation of can­
didacies in the past.
Last year, Canadian medical schools 
produced 1773 graduates, many of whom 
sought postgraduate training to fulfil 
requirements for licensure or to pursue a
Contributions to this column are welcome. 
Please send your material to: Mrs. Amy 
Chouinard, Canadian Journal o f  Surgery, PO 
Box 8650, Ottawa, Ont. K1G 0G8.
specialty. The numbers of positions 
(straight and rotating internships, first- 
year residencies) are just under 3000, 
according to figures from the Association 
of Canadian Medical Colleges, but the 
prerequisites for entry vary widely by 
province and program.
According to Casterton, differences in 
selection criteria are a stumbling block for 
specialties that have considered using the 
services offered by CIMS. Some specialty 
programs accept students directly from 
medical school, although all surgical resi­
dents must have completed a rotating 
internship. He believes that a successful 
result in general surgery will encourage 
other specialties to join the match.
He also notes that the intern match has 
become increasingly effective, as the num­
ber of participating programs has grown 
over the years. In 1986, for example, the 
University of Alberta re-entered the 
match, bringing 57 new positions and 
boosting the total within CIMS to 1330. 
The result was that almost 99% of the 
graduates from Canadian medical schools 
who entered the mate! found positions 
of their choice immediately.
The picture for graduates of foreign 
medical schools is less pleasant, with only 
22 of 481 finding spots through CIMS this 
year. Casterton is troubled by the grow­
ing numbers of foreign-trained physicians 
searching for positions, especially as the 
federal government is moving to relax res­
trictions on immigration. “ If we admit 
people on humanitarian grounds, we can­
not continue to exclude them from posi­
tions in their profession” , says Casterton, 
noting that Quebec is the only province 
that earmarks some of its positions for 
foreign graduates.
Charles Drake, FRCSC
Drake to Receive F.N.G. 
Starr Award
Charles G. Drake of London, Ont., 
this year will receive the highest award 
bestowed by the Canadian Medical 
Association, adding the F.N .G . Starr 
award to his long list of honours.
Drake was chosen for the award at the 
CMA board meeting held at the end of 
March, in recognition of his contributions 
to neurosurgery and particularly the treat­
ment of cerebral aneurysms.
The native of Windsor, Ont., formerly 
chaired the Department of Surgery at the 
University of Western Ontario, where he 
received his first medical degree in 1944, 
and still is professor.
He also has had an active career in 
organized medicine, serving, for example, 
as the president of the American College 
of Surgeons last year.
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Beware When Inserting Cathe­
ters in Central Venous System
who may dislodge the catheters by bend­
ing or rolling.
have since died out” , probably because 
of improved electronic means to share 
information.
The Health Protection Branch (HPB) 
recently alerted surgical and other hospi­
tal staff about deaths caused by catheters 
inserted in the central venous system to 
monitor pressure and to deliver parenteral 
fluids. The message was a reminder of 
basic rules, such as confirming radiolog- 
ically the position of the catheter and 
ensuring that for parenteral therapy the 
tip of the catheter is inserted not much 
beyond the subclavian or jugular vein and 
for pressure monitoring not beyond the 
entrance to the right atrium.
The HPB reported that the rigidity of 
the materials currently used in the 
catheters has increased the need for cau­
tion, particularly with mobile patients
U.S. Surgical Club to 
Visit Canadian West
The Wisconsin Surgical Club will be 
touring medical centres in Winnipeg, Cal­
gary and Edmonton next month in their 
biennial trip to search for innovative tech­
niques in the surgical world.
Peter J. Cruse, FRCSC, head of the 
Department of Surgery, University of 
Calgary, says his group will feature 12 
research projects in 15-minute presenta­
tions.
“ Travelling clubs, like this one from 
Wisconsin, were very popular in the late 
40s, early 50s,” commented Cruse, “ but
Foothills Surgeons to be 
Featured in CBC Eye-Opener
As part of its 20-year celebrations next 
month, Foothills Hospital in Calgary has 
struck an agreement with the Canadian 
Broadcasting Corporation to interview 
members of the staff each morning 
between June 9 and 13 on its eye-opener 
program.
D. Birdsell, FRCSC, who is chief of 
plastic surgery and the burn unit at the 
hospital, is one of the planned speakers.
A my C h o u in a r d
J. Edward Mullens, FRCSC, assistant 
secretary-treasurer for the Canadian Med­
ical Protective Association, has been named 
1986 Janes Surgical Visiting Professor. The 
award from the Royal College of Physi­
cians and Surgeons of Canada gave Mullens 
the opportunity to visit medical faculties in 
Hamilton, Winnipeg and St. John’s in 
March.
Low-voltage machines for continuous passive motion are being developed in conjunction 
with the Hospital for Sick Children in Toronto; these two contraptions are for passive move­
ment of hand (left) and leg (right).
Healthy
Aging?
A sound mind and a 
sound body are the 
keys to independence. 
Learn to adapt to your 
changing lifesty le  as 
you reach retirement. 
Take H ealthy A g ing , 
your key to an indepen­
dent future!
St. John Ambulance
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Phosphate S.S.
enhances 
HOST DEFENSE
Recent in-vitro research has shown that clindamycin concentrates within 
the PMN in amounts greater than are found outside of the PMN.1 The 
rates of chemotaxis, phagocytosis and killing of bacteria by PMNs are also 
enhanced by the presence of this antibiotic.2’3 These characteristics may 
help explain clindamycin’s outstanding record of clinical efficacy in both 
anaerobic and gram-positive aerobic infections.
Since host defense factors may be crucial in determining the outcome of 
an infection, selection of antibiotics based on host defense parameters 
may become a trend in infectious disease therapy.
1) Klempner MS, et al (Nov 1981) J Infect Dis 144(5)
2) Johnson JD, et al (March 1980) J l_ab Clin Med 95(3)
3) Gemmell C, et al (1980) Current Chemotherapy and Infectious Disease 
(eds. J Nelson, C Grass!) Am Soc Microbiol Vol 2
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REVIEW ARTICLE
C. T id ia n e  To u r e , m d ;* G illes Be a u c h a m p , m d , f r c s c ;!  Maryam  A ro ichanei:
Physiopathologie et correction chirurgicale 
du reflux gastro-oesophagien: revue de la question
Les auteurs font un rappel de la phys­
iopathologie du reflux gastro- 
oesophagien en soulignant le role 
preponderant du sphincter inferieur de 
I'oesophage au sein des mecanismes 
antirefiux. Le diagnostic de reflux gastro- 
oesophagien doit se baser sur un 
faisceau d'arguments issus d'un ques­
tionnaire minutieux et d'une batterie de 
tests dont les plus importants sont I'en- 
doscopie et la pH-metrie. Des recomman- 
dations sont faites quant aux gestes 
chirurgicaux afin de prevenir les compli­
cations. Les operations de Hill, de Belsey 
et de Nissen, designees sous le terme 
generique de valvuloplastie, ont fait la 
preuve de leur plus grande efficacite 
dans la correction du reflux gastro- 
oesophagien. Une revue de la litterature 
confirme les meilleurs resultats obtenus 
avec la fundoplicature totale de Nissen.
The authors review the pathophysiology 
of gastroesophageal reflux, pointing out 
the predominant role of the lower 
esophageal sphincter in antireflux 
mechanisms. The diagnosis of gas­
troesophageal reflux must be based on
Du departement de chirurgie, Hopital 
Maisonneuve-Rosemont, Montreal, PQ
*Assistant chef de dinique chirurgicale, 
University de Dakar. Stagiaire, Hopital 
Maisonneuve-Rosemont, Universite de 
Montreal, Montreal, PQ
t Professeur agrdge de clinique, departement 
de chirurgie, section de chirurgie thora- 
cique, Hopital Maisonneuve-Rosemont
XEtudiante en medecine, Universite de 
Montreal
Accepts pour publication le 22 octobre 
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Les demandes de tires-a-part doivent etre 
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the results of detailed examination and 
other tests of which endoscopy and 
esophageal pH monitoring are the most 
important. The authors describe how to 
manage operation for gastroesophageal 
reflux so as to prevent complications. 
Although the Hill, Belsey and Nissen 
operations, referred to as valvuloplasties, 
have proved their effectiveness in curing 
gastroesophageal reflux, a review of the 
literature shows that better results are 
achieved by Nissen total fundoplication.
L’essor des nouvelles methodes d’inves- 
tigation a permis une connaissance plus 
approfondie de la physiopathologie du 
reflux gastro-oesophagien, un diagnostic 
plus precis et une meilleure comprehen­
sion des mecanismes d ’action des 
differentes methodes therapeutiques tant 
medicales que chirurgicales. II en a 
decoule une amelioration de ces traite- 
ments et des indications plus pertinentes 
grace notamment a une definition plus 
precise des objectifs therapeutiques et a 
un meilleur choix des candidats chirur­
gicaux. Actuellement, les techniques 
chirurgicales qui ont fait la preuve de leur 
efficacite sont celles qui component une 
valvuloplastie, c’est-a-dire les techniques 
de Hill, de Belsey et de Nissen, precedes 
dont nous parlerons ici. La technique de 
Nissen est la plus performante quant a la 
correction du reflux. Toutefois, la chirur­
gie de cette affection, benigne initiale- 
ment, comporte une certaine morbidity 
qu’une rigueur dans l’execution et les 
indications peut amoindrir.
Physiopathologie
Le reflux gastro-oesophagien cor­
respond a un renvoi de liquide gastrique 
dans la lumiere oesophagienne. Le reflux 
survient chez les individus normaux.1'2 
Le reflux physiologique est transitoire et 
n ’occasionne pas de degdts sur 
I’oesophage. Toutefois, le reflux peut
evoluer vers un desordre clinique si les 
mecanismes de defense sont debordes. 
Ces mecanismes en question sont anato- 
miques et physiologiques.
Les facteurs anatomiques 
de continence cardiale
Au nombre de ces facteurs ont ete cites: 
la fronde du pilier droit du diaphragme, 
Tangle de His, Timplantation particuliere 
de I’oesophage sur Testomac, la mem­
brane phreno-oesophagienne, la rosette 
muqueuse oesophagienne au niveau du 
sphincter inferieur de I’oesophage et Tex- 
istence d’un segment abdominal suffisam- 
ment long pour subir la pression intra- 
abdominale. Ces facteurs anatomiques ne 
sont pas toujours les plus importants. Par 
example, il existe des hernies hiatales 
(anomalie d ’un ou plusieurs facteurs 
anatom iques) sans reflux gastro- 
oesophagien et vice versa. II y a souvent 
une absence de correlation entre les fre­
quences respectives de ces deux affec­
tions; la hernie hiatale etant plus souvent 
rencontree.3'4 Le facteur anatomique le 
plus important semble etre la longueur 
d’oesophage abdominale. Bonavida et 
collaborateurs5 ont demontre experimen- 
talement qu’une longueur d’oesophage 
abdominal inferieure a 2 cm constituait 
une predisposition anatomique au reflux 
et ne permettait pas de contrecarrer la 
pression intra-gastrique. Au cours des 
dernieres annees, on s’est surtout interesse 
au sphincter inferieur de I’oesophage mais 
on s’est apergu de la necessite de la coex­
istence d ’une longueur suffisante 
d’oesophage abdominal et d’un tonus 
adequat du sphincter inferieur de 
I’oesophage pour controler le reflux 
gastro-oesophagien.
Les facteurs physiologiques s ’opposant au 
reflux et a ses effets
Le sphincter inferieur de I’oeso­
phage.—Ce sphincter est un element
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essentiel de la continence cardiale. Les 
travaux d’Atkinson et collaborateurs,6 
de Botha et collaborateurs,7 et de Fyke 
et collaborateurs8 ont montre que le 
sphincter inferieur de l’oesophage main- 
tient un tonus basal plus eleve que la pres- 
sion intra-gastrique. Le sphincter se 
relache avec la survenue d ’une onde 
peristaltique et se referme apres cette 
relaxation. II subit deux types de controle, 
l’un intrinseque, l’autre extrinseque;9' 11 
celui-ci se faisant par le biais du vague. 
Le tonus du sphincter inferieur de 
1’oesophage est en outre influence par 
differentes hormones, dont la gastrine, la 
motiline et la bombesine qui l’elevent; la 
secretine, la cholecystokinine, le peptide 
intestinal vasomoteur, le “ gastric inhibi­
tory peptide” et le glucagon qui 
l’abaissent.12
Dans le reflux gastro-oesophagien, le 
plus souvent, le tonus du sphincter gastro- 
oesophagien est bas, et l’absence de gra­
dient de pression oesophago-gastrique 
permet la survenue du reflux.13
Les autres facteurs physiologiques. — 
Chez un sujet normal, lorsqu’un reflux 
survient, la vidange oesophagienne se fait 
grace aux contractions primaires ou 
secondaires ou par gravite s’il est en 
orthostatisme. Chez l’individu presentant 
un reflux gastro-oesophagien, il existe 
souvent une vidange oesophagienne 
defectueuse14,15 et cette anomalie s’ag- 
grave lo rsqu’il s’y associe une 
oesophagite.16-18
La salive joue un role de lavage et de 
neutralisation du sue gastrique reflue.19
Une fonction antro-duodenale normale 
est necessaire. Le passage normal des ali­
ments vers le duodenum permet 1’inhibi- 
tion de la secretion acide, empeche le 
reflux duodeno-gastrique et le passage des 
secretions biliaires et pancreatiques dans 
le liquide gastrique reflue. Un transit 
gastro-duodenal normal autorise une ele­
vation du tonus du sphincter.20 Un pas­
sage antro-duodenal defectueux provoque 
une distension gastrique, une baisse du 
gradient oesophago-gastrique et aug- 
mente la quantite de liquide gastrique dis- 
ponible pour le reflux.21
Les consequences locales du reflux
L’intensite des desordres cliniques et 
anatomiques, e’est-a-dire la production 
d’oesophagite occasionnee par le reflux 
gastro-oesophagien, depend de la quan­
tite de liquide reflue, de la nature des 
substances qu’il renferme et du temps de 
contact de ces substances avec la 
muqueuse oesophagienne. L’association 
de sels biliaires, d’enzymes pancreatiques 
et d’acide chlorhydrique est particuliere- 
ment nocive.22,23
Consequences sur la parol oesopha­
gienne.—Le contact prolonge des subs­
tances, telles que l’acide chlorhydrique, 
la pepsine et les sels biliaires, avec la
muqueuse oesophagienne altere celle-ci 
aux niveaux macroscopique et microsco- 
pique.16 II se produit alors des ulcera­
tions qui vont se creuser davantage pour 
interesser finalement toute la paroi 
oesophagienne et le tissu peri- 
oesophagien.24-26 Lorsque 1’irritation dis- 
parait, le processus de guerison se fait par 
le developpement de Pepithelium voisin. 
Un autre processus de cicatrisation, sur- 
venant apres une irritation de duree plus 
prolongee, est la constitution d ’un tissu 
de granulation qui conduit a la sclerose 
et a la stenose. Une autre eventualite, 
enfin, est le remplacement de la perte de 
substance parietale oesophagienne par de 
Pepithelium cylindrique gastrique: e’est 
l’endobrachy-oesophage (oesophagite de 
Barrett).12
Les troubles moteurs oesophagiens. — 
L’oesophagite creee par le reflux gastro- 
oesophagien finit par alterer la muscula­
ture oesophagienne. II s’ensuit une baisse 
du tonus du sphincter inferieur de l’oeso- 
phage27 et Papparition d’ondes secondai­
res au niveau du corps de l’oesophage.28 
On a pu montrer experimentalement que 
Poesophagite provoque une baisse de 
P amplitude des contractions et une moins 
bonne vidange oesophagienne.16,18 Tous 
ces facteurs vont majorer le reflux et il se 
cree ainsi un cercle vicieux.
Diagnostic
Il repose sur un interrogatoire et un 
examen minutieux, et sur une batterie de 
tests. Cooper et Jeejeebhoy29 ont judi- 
cieusement affirme que ce qu’il faut, e’est 
avoir une vision equilibree se fiant a un 
bon jugement clinique, sans ecarter les 
tests de la fonction oesophagienne, mais 
tout en ne les considerant pas comme 
infaillibles. En effet, le diagnostic doit 
decouler d’un faisceau d ’arguments. 
Parmi les tests, certains sont d’une grande 
sensibilite et d ’une grande precision, 
d ’autres le sont moins. Ils evaluent soit 
le reflux, soit Poesophagite.
• L ’endoscopie permet d ’apprecier et 
de classer une oesophagite et de pratiquer 
des biopsies. Elle explore egalement 
l’estomac et le duodenum a la recherche 
d’une pathologie associee.30
• La pH-metrie oesophagienne de 24 
heures, decrite initialement par Johnson 
et DeMeester,1 a une sensibilite et une 
specificite de 90%.31 C’est actuellement 
le maitre-test pour evaluer le reflux.
• La manometrie oesophagienne 
donne des informations sur la longueur, 
le tonus et le fonctionnement du sphinc­
ter inferieur de l’oesophage: on peut ainsi 
affirmer l’incompetence du sphincter. 
Elle permet egalement de qualifier et de 
quantifier les contractions oesopha- 
giennes. Cependant, ce test seul (comme 
d’ailleurs tous les autres) n ’est pas suffi- 
sant pour poser une indication.29
• La scin tigraphie oesophago- 
gastrique peut etre utile dans la recher­
che d’anomalies morphologiques et fonc- 
tionnelles associees au reflux gastro- 
oesophagien. Elle peut eventuellement 
reveler un reflux actif. Ce test permet ega­
lement de la vidange gastrique. En defi­
nitive, Pindication premiere de la scinti­
graphie oesophagienne au cours du reflux 
gastro-oesophagien est la recherche des 
desordres moteurs associes.32
• Le transit baryte oesophago-gastro- 
duodenal fournit des details d ’ordre ana- 
tomique et fonctionnel sur l’oesophage, 
renseigne sur l’estomac et le duodenum. 
Ce n’est toutefois pas un bon test de 
reflux.
Traitement medical
Le traitement poursuit trois objectifs: 
la d im inution du reflux  gastro- 
oesophagien en quantite, frequence et 
duree; la baisse du potentiel agressif du 
liquide reflue: acide chlorhydrique, pep­
sine, bile et enzymes pancreatiques; et la 
restauration des mecanismes antireflux: 
sphincter inferieur de l’oesophage et fac­
teurs anatomiques.
Dans un premier temps, on soumet le 
patient essentiellement a des mesures 
hygieno-dietetiques: cure d ’amaigrisse- 
ment; elevation de la tete du lit pendant 
le sommeil; eviter le port d ’habits trop 
serres; modifier le regime alimentaire: evi­
ter les exces a table, les aliments gras, le 
chocolat, le cafe, le the, la menthe et les 
aliments connus du patient lui-meme 
comme causes du reflux  gastro- 
oesophagien; eviter Palcool et le tabac; 
proscrire les medicaments provoquant ou 
majorant le reflux gastro-oesophagien: 
progesterone, theophylline, anticholiner- 
gique, diazepam, morphine;21 corriger 
les situations de stress et d’instabilite emo- 
tionnelle si possible, ou tout au moins les 
reconnaltre.9
On associe a ces mesures, l’administra- 
tion d’anti-acides et de P acide alginique 
avant et apres les repas et avant le cou- 
cher. Ce traitement sera poursuivi de 3 a 
6 mois avant de poser une indication ope- 
ratoire. Chez les patients obeses, il fau- 
dra etre patient et poursuivre le traitement 
medical pendant au moins 1 an .33
Neanmoins, malgre cette approche the- 
rapeutique, environ 25% des patients pre- 
senteront quand meme une persistance ou 
une aggravation des symptomes. Il faut 
alors poursuivre les investigations tout en 
administrant certains medicaments aux 
indications bien particulieres. Ainsi, pour 
ameliorer la vidange oesophagienne, on 
utilisera volontiers le betanechol;20 le 
metoclopramide ou bien le domperi- 
done.34-37 Les antagonistes des recepteurs 
H2 (cimetidine et ranitidine) seront utili­
ses pour combattre une hypersecretion 
gastrique acide. De plus, le reflux gastro-
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oesophagien pourra etre ameliore par le 
metoclopramide et le domperidone qui 
accelerent la vidange gastrique.17,38,39
Toutefois, 10% a 20% des patients ne 
repondront pas au traitement medical. II 
est alors legitime de proposer au patient 
un traitement chirurgical dont il faudra 
discuter les avantages et les inconvenients. 
Le but du chirurgien sera de choisir les 
bons candidats chirurgicaux capables de 
subir sans risques de mortalite Tinterven- 
tion. De plus, il devra s’assurer du choix 
judicieux de la technique chirurgicale, 
compte tenu des donnees sur la compe­
tence du sphincter inferieur, la vidange de 
l’oesophage et de l’estomac, de la pre­
sence ou non d’une stenose peptique ou 
d’un oesophage court.
Traitement chirurgical
Principes d ’une reparation ideate du 
reflux gastro-oesophagien
Objectifs therapeutiques.—Il s’agit 
d ’obtenir une continence cardiale ade­
quate en restaurant la competence du 
sphincter inferieur de l’oesophage et une 
longueur suffisante d’oesophage abdomi­
nal. Ainsi, on laissera un segment oeso­
phagien sous-diaphragmatique suffisam- 
ment long pour subir les pressions 
intra-abdominales positives.5,29,40 Il fau­
dra, de plus, proceder a un rapproche­
ment des piliers du diaphragme.
Les facteurs impliques dans la realisa­
tion d ’une valvuloplastie (Fig. 1).— 
Toutes les valvuloplasties realisent une 
reconstruction de Tangle de His (Fig. 1: 
1). Selon le cas, on procedera a une libe­
ration des vaisseaux courts de l’estomac 
afin de permettre la rotation du fundus 
(Fig. 1: 2). L’etendue de fundus mobilise 
depend, d ’une part, du type de fundopli- 
cature (totale ou partielle) et, d’autre part, 
de la longueur d ’oesophage entoure de 
fundus (Fig. 1: 3, 4 et 5). Selon le cas, le 
nerf vague est inclus ou exclus de la fun- 
doplicature. On doit menager entre le 
fundus et Testomac un espace suffisam- 
ment lache pour ne pas provoquer de 
dysphagie. Le fundus plicature doit etre 
fixe a 1’oesophage meme afin d’eviter un 
glissement vers l’estomac (Fig. 1: 6). 
Meme si initialement on a utilise les deux 
parois anterieure et posterieure du fun­
dus et que Tutilisation de la face poste­
rieure seule est aussi possible, les techni­
ques actuelles de fundoplicature utilisent 
essentiellement la paroi anterieure (Fig. 
1: 7).
Prevention des complications chirurgi- 
cales.—Lorsqu’on effectue une fundopli­
cature, la reparation ne doit etre ni trop 
serree, ni trop lache. Trop serree, elle peut 
etre la source de dysphagie, d ’impossibi- 
lite de vomir ou d ’eructer; trop lache, elle 
laisse un sphincter inferieur de l’oeso- 
phage incompetent. Il faut eviter de pro­
ceder a une reparation trop longue, car 
la encore, on peut voir apparaitre une 
impossibility d’eructer ou de vomir, et 
done un syndrome de “ gas bloating” . 
Une fundoplicature doit etre stable, e’est- 
a-dire qu’elle doit pouvoir se maintenir 
sans tension sous le diaphragme, sinon on 
risque d’observer une protrusion dans le 
thorax. La fermeture des piliers du diaph­
ragme ne doit pas etre trop serree afin 
d’eviter la dysphagie, une obstruction a 
la vidange de Toesophage et une dilata­
tion de celui-ci. La reussite du traitement 
chirurgical du reflux gastro-oesophagien 
exige un estomac qui se vide normale- 
ment. Il faudra done controler medicale- 
ment ou chirurgicalement toute maladie 
ulcereuse contemporaine. Il faut preser­
ver T integrity des nerfs vagues afin de ne 
pas compromettre la vidange gastrique. 
Tout reflux biliaire doit etre corrige afin 
notamment de prevenir une gastrite 
biliaire. On doit mobiliser suffisamment 
Toesophage abdominal afin que la fun­
doplicature se fasse autour de Toesophage 
distal et non autour de Testomac proxi­
mal. Dans ce dernier cas, on risque de 
voir apparaitre le phenomene dit du 
“ telescopage” .41 On evitera d’abandon- 
ner la fundoplicature dans le thorax. 
Cette attitude expose au developpement 
d’ulcere gastrique et de gastrite dans la 
poche intra-thoracique avec les risques de 
perforation et d ’hemorragie.42 Afin de 
permettre une meilleure mobilisation du 
fundus et de rendre la fundoplicature plus 
lache, on pensera a lier quelques vaisseaux 
courts, entre autres quand on effectue une 
fundoplicature de Nissen.
Dans tous les cas, il s’agit, la, d’une 
pathologie initialement benigne dont la 
correction peut se faire avec un minimum 
de morbidity et ne doit entrainer aucune 
mortalite.
Mode de fonctionnement 
des valvuloplasties
Des hypotheses explicatives et des tra- 
vaux experimentaux on ete consacres a ce 
sujet. Dans les valvuloplasties, le cardia 
est replace dans T abdomen et sera plus 
ou moins entoure du fundus (selon le type 
d’intervention), ce qui restaure la compe­
tence du sphincter inferieur de Toeso­
phage. Dans Tabdomen, les fibres mus- 
culaires oesophagiennes longitudinales 
sont stimulees et accroissent leur tension 
sous l’effet de la pression abdominale 
positive.40,41 L’enveloppe fundique 
autour de Toesophage se comporte 
comme un ballonnet qui se gonflerait sous 
l’effet de la pression intra-gastrique et 
viendrait comprimer Toesophage. Ce der­
nier mecanisme serait comparable a celui 
d ’un clapet.43 Dans la fundoplicature 
totale de Nissen et Toperation de Belsey, 
le tonus musculaire de Tenveloppe fun­
dique vient augmenter celui de Toeso­
phage.44 La fundoplicature ameliore le 
rapport tension appliquee-force de ferme­
ture du sphincter inferieur de Toesophage 
en agissant au niveau des fibres muscu- 
laires de la couche circulaire.45 Ces deux 
derniers mecanismes sont d ’autant plus 
accentues que la circonference oesopha- 
gienne entouree du fundus est plus impor- 
tante. Ceci explique que la competence du 
sphincter inferieur de Toesophage est 
mieux restauree apres une fundoplicature 
totale de Nissen.44
Les techniques de correction chirurgicale
Nous allons decrire les techniques de 
Belsey, de Hill et de Nissen. Ces trois pre­
cedes possedent en commun les modali- 
tes techniques suivantes: mobilisation 
adequate de Toesophage, restauration 
d’un segment intra-abdominal de Toeso­
phage, fundoplicature totale ou partielle 
afin d’augmenter la competence du 
sphincter inferieur de Toesophage, rap­
prochement posterieur des piliers du 
diaphragme afin de corriger ou de preve­
nir une hernie.
La voie d ’abord.—L’abord abdominal 
est obligatoire pour Toperation de Hill. 
Cette voie abdominale peut egalement 
etre utilisee pour effectuer une fundopli­
cature de Nissen. On doit pratiquer une 
thoracotomie pour realiser Toperation de 
Belsey-Mark IV. On peut tout aussi bien 
pratiquer une fundoplicature de Nissen 
lors d’une thoracotomie et cette voie est 
privilegiee par certains. Toutefois, la voie 
thoracique sera voluntiers utilisee pour 
pratiquer une fundoplicature sur un oeso­
phage “ difficile” : oesophagite marquee 
(raccourcissement), recidive, autres 
lesions oesophagiennes ou alors en cas 
d’obesite du patient ou de pathologie tho­
racique associee et a traiter dans le meme 
temps. Cette voie thoracique permet 
d’apprecier de visu les lesions oesopha­
giennes et, en outre, de proceder a une 
meilleure mobilisation de Toesophage et 
d’effectuer une reparation sans tension.
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FIG. 1—Facteurs impliques dans la con­
struction d’une valvuloplastie: 1 = reconstruc­
tion de Tangle de His, 2 = liberation ou non 
des vaisseaux courts, 3 = quantile de fundus 
disponible pour la fundoplicature, 4 = lon­
gueur d'oesophage entoure par le fundus, 5 = 
degre d’enroulement de Testomac autour de 
Toesophage: fundoplicature totale et fun­
doplicature partielle, 6 = fixation de Ten­
veloppe fundique a Toesophage, 7 = utilisa­
tion de la paroi anterieure du fundus pour 
confectionner la valve fundique.
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Les techniques
• L ’operation de Belsey-Mark IV .46 
La voie d’abord est une thoracotomie 
gauche, habituellement a travers le 6e 
espace intercostal. L’oesophage est mobi­
lise jusqu’au niveau de la crosse aortique. 
La partie superieure du petit epiploon est 
incisee. On procede a l’ablation de la 
graisse recouvrant le cardia afin de favo- 
riser ulterieurement l’apparition d’adhe- 
rences avec le fundus plicature. Les nerfs 
vagues sont liberes de l’oesophage abdo­
minal afin de leur faire adopter une posi­
tion posterieure et d ’etre a l’abri des 
points de suture de la fundoplicature. Une 
plicature utilisant le fundus gastrique est 
executee autour de l’oesophage sur une 
circonference de 270° et sur une hauteur 
d’environ 4 a 5 cm,29 mais laissant le 
cote postero-droit de I’oesophage libre. 
Le nerf vague droit se trouve ainsi en 
dehors de la plicature. On fixe le fundus 
a 1’oesophage abdominal a l’aide de 
points en U horizontaux disposes en deux 
rangees de trois points chacune. Les 
points de la rangee superieure chargent le 
bord de la partie tendineuse du dia- 
phragme. Les sutures doivent charger la 
musculeuse oesophagienne sans pour 
autant interesser la muqueuse.42 Les 
piliers sont rapproches en arriere de 
l’oesophage de fason a admettre un 
index. L’oesophage est reintegre en posi­
tion abdominale, sans tension, avant le 
serrage des noeuds.
• L ’operation de Hill.47,48 L’abord 
sera abdominal. L’oesophage abdominal 
est mobilise apres division du petit epi­
ploon et section de la membrane phreno- 
oesophagienne. On mobilise la grande 
courbure et cela peut necessiter eventuel- 
lement la ligature d’un ou deux vaisseaux 
courts. S’il y a une hernie hiatale, elle est 
reduite. Le ligament arque median est 
repere: c’est la partie antero-inferieure de 
l’orifice aortique du diaphragme. On dis- 
seque aussi le fascia pre-aortique et 
l’arcade fibreuse. Le bord inferieur du 
ligament arque est libere par dissection. 
II est situe juste au-dessus du tronc coe- 
liaque. On placera une lame en-dessous 
du ligament arque afin de proteger le 
tronc coeliaque et l’aorte. Un tube de 
Levin no 18 est introduit dans l’oesophage 
qui permettra d’apprecier la fermeture du 
hiatus et d’eviter une plicature du cardia. 
Les piliers du diaphragme sont alors fixes
FIG. 2—Fundoplicature totale de Nissen.
entre eux, en arriere de l’oesophage, par 
deux ou trois points en X au fil non resor­
bable. Cette fermeture des piliers doit 
autoriser le passage de l’oesophage con- 
tenant le tube de Levin et de l’index. On 
suture la berge interne du petit epiploon 
incise, les bords anterieur et posterieur de 
la petite courbure de l’estomac au liga­
ment arque (quatre points suffisent en 
general). On suture egalement la partie 
posterieure du ligament phreno- 
oesophagien (que l’on fait passer a gau­
che de l’oesophage) au fascia pre- 
aortique. La tension ainsi appliquee sur 
le cardia s’exerce sur le sphincter inferieur 
de l’oesophage, accentue Tangle de His 
et cree un effet de valve. Hill recommande 
de “ calibrer” le cardia en plaqant des 
points de suture entre, d ’une part, la par- 
tie du cardia maintenant situee en avant 
de Toesophage et la jonction gastro- 
oesophagienne et, d ’autre part, entre la 
partie du cardia maintenant a droite de 
la petite courbure et le ligament arque. 
Cette “ calibration” doit permettre a 
l’index du chirurgien d’invaginer la paroi 
gastrique a cote du tube de Levin.47
• La fundoplicature totale de Nissen 
(Fig. 2). Decrite en 1956 par Nissen,49 
elle a ete modifiee en 1971 par Rossetti 
et Allgower.50 Nous decrirons la techni­
que modifiee de Rossetti. La voie d ’abord 
est thoracique ou abdominale. On pro­
cede a une section du ligament triangu- 
laire gauche du foie qui est recline. Deux 
ou trois vaisseaux courts peuvent etre lies 
au niveau de la grande courbure. L ’esto­
mac est attire vers le bas et le peritoine 
parietal est incise au niveau de sa reflexion 
pres du hiatus. La membrane phreno- 
oesophagienne est sectionnee. Le peri­
toine pre-oesophagien est ouvert et la 
graisse peri-cardiale est enlevee, permet- 
tant de decouvrir les fibres musculaires 
longitudinales de Toesophage. On pro­
cede a une liberation aux doigts des atta­
ches posterieures de Toesophage jusqu’a 
permettre le passage de deux a trois doigts 
derriere Torgane. On fait passer un lacs 
en caoutchouc autour du cardia afin d’en 
faciliter la traction en bas et en avant. Le 
vague posterieur est habituellement bien 
en arriere de Toesophage et reste en 
dehors de la fundoplicature.
Le vague anterieur est a droite, sur la 
face anterieure de Toesophage, et on doit 
en reperer egalement le rameau hepatique. 
Ces derniers elements seront inclus dans 
la fundoplicature et devront continuer 
leur trajet et apparattre a la partie infe- 
rieure du repli fundique. L’operateur 
demande a Tanesthesiste d’introduire 
dans Toesophage une bougie de Hurst no 
50 ou 52 Fr. Les piliers du diaphragme 
sont rapproches en arriere de Toesophage, 
mais les fils ne sont pas noues. Ensuite, 
coiffee de la paroi anterieure du fundus, 
un doigt de 1’operateur la fait passer en 
arriere de Toesophage et ressortir sur le
bord droit de celui-ci ou elle sera saisie 
a l’aide de deux pinces d ’Allis. On fait 
passer un autre pli de la paroi anterieure 
du fundus en avant de Toesophage. On 
fixe entre eux les deux plis anterieur et 
posterieur avec cinq ou six points extra- 
muqueux au fil non resorbable chargeant 
egalement la musculeuse de la face ante­
rieure de Toesophage. On cree ainsi un 
manchon d’une hauteur de 3 cm environ 
autour de Toesophage abdominal, assez 
lache cependant pour permettre le passage 
d’un doigt. On procede au serrage des 
noeuds assurant la fermeture des piliers 
du diaphragme. Cette fermeture doit per­
mettre le passage de deux doigts. La bou­
gie est retiree et remplacee par une sonde 
de Levin no 18.
Les complications
Les complications peroperatoires.— 
Ces complications ne sont pas frequen- 
tes. Les perforations peuvent etre obser­
v e s  sur Toesophage ou sur le manchon 
gastrique.41,51 Lorsqu’on les decouvre 
pendant Tintervention, on peut les fermer 
par apposition de la paroi gastrique. 
Neanmoins, elles peuvent etre gravissi- 
mes. L ’hemorragie n ’est pas excep- 
tionnelle et est en rapport avec la ri- 
chesse vasculaire de la jonction  
gastro-oesophagienne.42 L ’incidence des 
lacerations de la rate est de 5% a 
7%.41,52 Ces blessures peuvent survenir 
lors de la mobilisation du fundus ou de 
Toesophage, elles peuvent etre dues aux 
ecarteurs. La fundoplicature de Nissen 
(qui utilise davantage de fundus) semble 
exposer plus que les autres procedes a ces 
blessures de la rate. L’instrumentation 
moderne utilisant les retracteurs du 
sternum  et de la region sous- 
diaphragmatique, la lumiere frontale a 
fibre optique et les instruments longs per- 
mettent de realiser avec confort ce type 
de chirurgie.
Complications postoperatoires.—La 
dysphagie demeure la plus frequente de 
ces complications. Sa frequence, de 
l’ordre de 50%, diminue a mesure qu’on 
s’eloigne de la date de Tinterven- 
tion.44,51,52 Cette dysphagie retient plu- 
sieurs etiologies. Elle peut relever d’une 
imperfection technique (rapprochement 
excessif des piliers du diaphragme, man­
chon fundique trop serre ou trop long), 
d ’un oedeme52 ou de la meconnaissance 
d’un etat dyskinetique oesophagien pre- 
existant.51 De toute fapon, on observe 
une impossibility de la relaxation com­
plete apres reparation.41 La dysphagie 
est plus frequente apres une fundoplica­
ture totale de Nissen.42
Le “gas bloat syn d ro m e’’ (ou 
syndrome post-fundoplicature), decrit ini- 
tialement par Woodward,43 correspond a 
une satiete precoce; a une sensation de 
plenitude au niveau de Tepigastre et de
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Fhypochondre gauche; a une difficulty, 
voire une impossibility d’eructer, accom- 
pagnee d ’une accentuation des borboryg- 
mes intestinaux et d’une flatulence. II se 
voit essentiellement apres une fundopli- 
cature de Nissen. Woodward43 a d’abord 
estime sa frequence a 20%, puis finale- 
ment a 11 % ;53 Rossetti et Allgower50 
trouvent ce syndrome chez 10% de leurs 
590 patients; d’autres auteurs (Beau­
champ G: Etude retrospective comparent 
le Nissen et le Collis-Nissen. Non pu- 
blie),42 enfin, le rencontrent encore 
autour de ce dernier chiffre. L’explication 
de cette anomalie n’est pas univoque. 
Toutefois, on constate que la confection 
d’une valve trop serree ou trop longue 
peut en etre la cause. La valve formerait 
un clapet qui empecherait F evacuation de 
Fair vers l’oesophage. L ’amputation 
fonctionnelle du fundus dans la fundo- 
plicature pourrait etre a l’origine d’ano- 
malies de vidange gastrique qui provoque- 
raient le “ gas bloat syndrome” . Une 
autre cause a ete decouverte par DeMees- 
ter et collaborateurs31 qui ont identifie 
des sujets “ avaleurs d’air” et presentant 
un reflux en orthostatisme lors de la pH- 
metrie prolongee. L’air avale permettrait 
de lutter contre les effets du reflux. Ces 
patients seraient predisposes a presenter 
un “ gas bloat syndrome” du fait de la 
moins bonne evacuation de Fair, notam- 
ment apres fundoplicature totale.31’44'54
Une vagotomie accidentelle peut surve- 
nir lors de la dissection de Foesophage 
distal. La cause peut en etre une section, 
une elongation ou une prise d’un nerf 
dans un noeud. Chez certains patients, 
cela provoque une stase et une distension 
gastrique;42 chez d ’autres, on peut obser­
ver une diarrhee.41 Siewert et Blum41 
l’observent chez 3% de leurs patients. II 
semble que la frequence des vagotomies 
accidentelles soit plus grande avec l’abord 
abdominal.44
Enfin, on peut observer une persistance 
ou une recidive du reflux. Orringer, et 
collaborateurs55 trouvent pour [’opera­
tion de Belsey, sur 892 patients, un taux 
de recidive de 12% a plus de 3 ans et de 
15% a 10 ans et plus. Avec la fundopli­
cature de Nissen, Polk52 trouve un taux 
de 4.5% de recidive symptomatique ou 
anatomique avec un suivi postoperatoire 
de 5 ans. En 1977, Hill47 donnait un taux 
de recidive de 0.89% pour sa technique. 
II faut remarquer que, en general, les reci- 
dives anatomiques sont moins frequentes 
que les recidives symptomatiques.
Resultats
Evaluation endoscopique.—La gueri- 
son endoscopique d’une oesophagite est 
obtenue au bout de 10 a 12 semaines.41 
Le premier controle endoscopique sera 
effectue au bout de 3 mois. Un autre con­
trole le sera demande 1 an plus tard. La 
recidive du reflux gastro-oesophagien
serait rare lorsque le resultat a 1 an est 
bon.56
Evaluation fonctionnelle. —L’evalua­
tion par le pH-metrie de 24 heures mon- 
tre une superiority de la fundoplicature 
de Nissen sur les autres techniques. Une 
etude de DeMeester et collaborateurs44 
revele une correction du reflux a 100% 
avec la fundoplicature de Nissen, 73% 
avec celle de Hill et 46% pour celle de Bel­
sey. L’operation de Nissen est la plus per- 
formante aussi quant a l’augmentation de 
la pression du sphincter inferieur de 
Foesophage.44 La fundoplicature res- 
taure la pression du sphincter a des 
valeurs egales ou superieures aux valeurs 
preoperatoires. Sur le plan clinique, on 
recherche la disparition du reflux. Les 
bons resultats sont de l’ordre de 90% avec 
la fundoplicature de Nissen (Beauchamp 
G: Etude retrospective comparent le Nis­
sen et le Collis-Nissen. Non pu­
blic).41'50'52 Hill et collaborateurs48 ont 
rapport 97% de bons resultats avec leur 
technique. Skinner et Belsey46 font etat 
de 85% de bons resultats avec la fundo­
plicature partielle de Belsey.
De nouvelles attitudes se degagent 
maintenant dans le suivi des patients ope­
ras pour reflux gastro-oesophagien. Tous 
les patients devraient etre suivis metho- 
diquement pour une periode d’au moins 
5 ans pour s’assurer des resultats a long 
terme. Tous ces patients devraient etre 
soumis a des examens objectifs de con­
trole comme la cineradiologie de Foeso­
phage, Fendoscopie, la manometrie. La 
pH-metrie prolongee serait le test de plus 
fiable; cependant, compte tenu des diffi- 
cultes de la technique et des couts, il ne 
faudrait pas en faire une evaluation de 
routine chez les patients qui vont bien. 
L’etude de Negre et collaborateurs57 
montre bien que les resultats postopera- 
toires a long terme ne sont pas toujours 
aussi parfaits que semblent le repeter cer­
tains auteurs qui proposent leur propre 
technique de reparation.
Conclusions
L’affinement des methodes d’investi- 
gation a permis une meilleure connais- 
sance de la physiopathologie du reflux 
gastro-oesophagien, un diagnostic plus 
precis et des indications plus pertinentes. 
Le traitement du reflux non complique est 
d ’abord medical. L’echec du traitement 
medical legitime le recours a la chirurgie. 
En matiere de traitement chirurgical, les 
valvuloplasties, qui regroupent les opera­
tions de Belsey, de Hill et de Nissen, ont 
fait la preuve de leur efficacite quant a 
la correction du reflux. La technique de 
Nissen s’est averee la plus performante. 
Toutefois, une certaine morbidity accom- 
pagne cette chirurgie, morbidity que 
davantage de rigueur dans le geste et les 
indications pourrait amoindrir.
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If fibroids require treatment, hysterec­
tomy is usually the therapy of choice. 
Myomectomy is best reserved for 
women who wish to preserve their 
uterus and have a single large fibroid 
tumour; it is not normally recommended 
for either abnormal uterine bleeding or 
infertility. The blood supply of leiomyomas 
is from the periphery and is such that 
degeneration frequently ensues. 
Degeneration, in particular the acute 
degeneration that may occur in pregnancy, 
is rarely an indication for operation.
Myomectomy has been associated 
with considerable blood loss intraopera- 
tively and prolonged morbidity postoper- 
atively. The former can be avoided by 
limiting the uterine circulation during 
surgery with a uterine tourniquet 
and vascular clamps. Atraumatic intra- 
capsular removal of the tumour and 
perfect hemostasis will minimize the latter.
On consictere gen6ralement I'hysterecto- 
mie comme le traitement approprie pour 
soigner les personnes atteintes de 
fibromyomes. On a principalement 
recours a la myomectomie pour les fem­
mes qui d^sirent garder leur uterus et qui 
sont atteintes d’une seule grosse tumeur 
fibreuse; il n'est generalement pas 
recommande d'utiliser la myomectomie pour 
des saignements ut6rins anormaux ou pour 
les cas de sterilite. L'apport sanguin du 
leiomyome s'effectue au niveau de leur 
Peripherie, et cela peut frGquemment 
entrainer leur deg£nerescence. Celle-ci, 
et particuliferement la d£gen£rescence 
aigue qui peut se manifester chez une 
femme enceinte, ne constitue pas un 
signe que la femme doit etre operee.
On associe souvent la myomectomie d 
une perte de sang considerable lors de 
l’op6ration, et £ une morbidity postopera- 
toire prolongee. Cette perte de sang 
excessive lors de I'op6ration peut etre
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evitee en limitant la circulation uterine 
pendant la chirurgie en utilisant un tour­
niquet et des pinces vasculaires. Afin de 
prevoir une morbidity postoperatoire 
excessive, on doit s'assurer d'enlever 
avec soin la tumeur capsulde atraumati- 
que et s'assurer d'une parfaite hemos- 
tase en utilisant des techniques 
chirurgicales soignees.
Uterine fibroids are the most common 
tumours found in women. It is important 
that general surgeons be aware of the 
nature of these tumours and of the 
symptoms they may produce and are cog­
nizant of recommended therapy. This 
appreciation will affect therapeutic 
recommendations, particularly those for 
hysterectomy. A myomectomy may be 
indicated not only per se but also to gain 
access to the pelvis during difficult 
abdominal or pelvic operations, such as 
abdominoperineal operation in the 
presence of a large fibroid.
Development
Fibroids are benign smooth-muscle-cell 
tumours (leiomyomas). The individual 
uterine tumour develops from the 
proliferation of a single parent cell1 
whose growth is stimulated by estrogen. 
Some patients with fibroids have 
increased estrogen secretion, but most do 
not, even though there may be increased 
estrogen activity in the tumour itself. This 
heightened activity is apparently due to 
an increased number of estrogen recep­
tors in the tumour2 and a change in local 
enzymatic activity.3
As the fibroid enlarges it displaces the 
adjacent musculature, compressing it into 
a thick homogeneous layer called the 
pseudocapsule, which forms a dense wall 
around the fibroid. Its presence on cut 
section is pathognomonic. By dissection 
within this capsule the fibroid can be 
removed with the certain knowledge that 
adjacent structures are not injured.
Pathological Changes in Fibroids
Degeneration
The blood vessels supplying the fibroid
are in the capsule, thus it is nourished 
from the periphery, and as the centre of 
the tumour is approached the blood sup­
ply is diminished. Degeneration is recog­
nized as a normal phenomenon, chang­
ing only in degree and not in itself an 
indication for operative intervention. It 
becomes especially marked as the fibroids 
enlarge, the most dramatic example being 
the red degeneration of pregnancy. A 
minority of fibroids increase rapidly in 
size during pregnancy,4 thus outgrowing 
the already marginal blood supply and so 
acute degeneration occurs.
Malignant Change
Fibrosarcoma may be the malignant 
transformation of a benign fibroid or a 
new growth in the uterine wall; opinion 
favours the latter.5 Malignant change in 
fibroids is rare. Buttram and Reiter6 
found three leiomyosarcomas amongst 
1815 operative specimens. The incidence 
is considerably less, however, as the 
majority of fibroids are not removed. 
Should a fibrosarcoma develop, the prog­
nosis is guarded, especially when the 
tumour is discovered in a postmenopausal 
woman.7 The most common presenting 
symptom of leiomyosarcoma is abnormal 
vaginal bleeding. A perceived enlarging 
pelvic mass is an unusual presentation.
Symptoms
There are few symptoms diagnostic of 
fibroids, the patient is usually unaware of 
their presence and removal is generally 
not necessary for continued well-being. If 
symptoms do develop they are due to one 
or more of the following: a pelvic mass, 
menstrual disturbance or infertility.
Pelvic Mass
It is not often that fibroids cause 
women discomfort because of their size. 
The physician usually discovers the mass 
on routine examination for an unrelated 
complaint. The woman may, however, 
palpate the mass herself and bring it to 
her physician’s attention. How large 
should an asymptomatic fibroid be before 
it should be removed? The traditional
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answer is equivalent to 14 weeks’ gesta­
tion or larger (15 cm in greatest diameter). 
The reason for removal in such instances 
is the fear of malignant change and the 
difficulty of palpating the uterine append­
ages, thus making diagnosis of cancer of 
the ovary difficult. When discovered at 
laparotomy for an unrelated complaint, 
removal is rarely prudent, and small 
asymptomatic fibroids should not be 
■removed.
Menstrual Disturbance
Although disturbance of menstrual 
function is frequently associated with 
uterine fibroids, cause and effect are 
difficult to establish. Various explana­
tions have been offered to explain the 
heavy menstrual flow, including (a) 
impeded uterine venous blood flow,8 (b) 
interference with the contractility of the 
uterine wall9 and (c) an increased 
endometrial surface area.10 None is com­
pletely convincing, and it may be that the 
menorrhagia is caused by a hormonal dis­
turbance resulting in dysfunctional uter­
ine bleeding. This same hormonal distur­
bance may be associated with fibroid 
development. Menorrhagia is not always 
relieved when fibroids are removed and 
the results of myomectomy, for this rea­
son, are unpredictable and often disap­
pointing.11
What of other menstrual dysfunction? 
Bleeding between periods may be due to 
submucous fibroid, but a pregnancy 
threatening to abort or endometrial 
cancer (particularly in older patients) 
should be considered. Secondary dys­
menorrhea is uncommon and thought to 
be caused by excess production of 
prostaglandins from the large endometrial 
surface. Dysmenorrhea is an infrequent 
indication for myomectomy.
Infertility
Infertility has become a questionable 
indication for myomectomy.12 Although 
patients with fibroids tend to be older and 
less fertile, most patients with fibroids 
conceive with ease.13 If they do not, an 
infertility investigation will, in most 
instances, reveal other causes. This is sub­
stantiated by the indifferent results that 
follow myomectomy done for infertility 
alone (17%).12 The published results14 of 
myomectomy for infertility do not differ 
greatly from “ treatment independent 
pregnancy rates” and may be lower.
A particularly difficult situation arises 
when fibroids are discovered in patients 
who have had pelvic inflammatory dis­
ease. Myomectomy combined with tubal 
surgery, in the hopes of enhancing fertil­
ity, has not been successful. In a large ser­
ies from Jamaica15 there were no intrau­
terine pregnancies after this procedure,
and a report from Nigeria16 is equally 
discouraging.
Treatment
Alternatives to Myomectomy
Except when fertility or the uterus must 
be preserved, hysterectomy is most often 
the treatment of choice. Menorrhagia will 
certainly be cured; the fibroid mass will 
not recur; hysterectomy is generally tech­
nically easier than myomectomy and 
postoperative complications are less fre­
quent. Therefore, if the patient’s family 
is complete and there is no cultural or 
individual desire to preserve the uterus, 
hysterectomy should be recommended.
In recent years there have been isolated 
reports on hormone treatment for 
fibroids.17 An analogue of gonado­
tropin-releasing hormone will create a 
medical menopause, reducing the size of 
the myoma. Unfortunately, the side 
effects are relatively severe and there are 
no long-term studies of such therapy.
Contraindications
Myomectomy should not be done dur­
ing pregnancy, either for treatment of 
acute degeneration or incidentally at the 
time of cesarean section. Red degenera­
tion, which may be acute and associated 
with severe abdominal pain and local 
peritoneal signs, will almost always 
resolve with conservative management. 
Surgery may result in abortion or prema­
ture delivery and frequently intraopera­
tive or postoperative hemorrhage, which 
may require hysterectomy to control the 
situation.18 The case against myomec­
tomy immediately after cesarean section 
is equally strong. The age of the woman 
and the number of fibroids influence the 
choice of procedure. Myomectomy is 
favoured in the young, but large numbers 
of fibroids are a contraindication. 
Malone19 reported that when multiple 
myomectomies were done, 26% of the 
women required hysterectomy later.
Surgical Technique
Hemostasis
It is generally accepted that the blood 
supply to the uterus should be secured 
before myomectomy.20-22 This is not 
necessary with small subserosal fibroids, 
but in these cases myomectomy is rarely 
performed. Control of the blood supply 
limits blood loss and also permits care­
ful surgical technique in an effort to pre­
vent adhesions postoperatively. A theo­
retical objection is the possibility of 
ensuing vascular damage,6 but this risk 
has been discounted.23
If a tourniquet is to be used, the first 
step is to dissect the bladder from the 
lower segment of the uterus, which is 
encircled by a red rubber catheter. The 
catheter is pulled up tight and grasped 
with a Kocher clamp, thus occluding the 
uterine vessels. The remaining blood sup­
ply to the uterus comes from the ovarian 
vessels, which are controlled with 
Satinsky vascular clamps placed over the 
vessels (without disturbing the 
peritoneum).
Incision
The uterine incision should be vertical 
and placed as low as possible on the 
anterior uterine surface. It is in the least 
vascular portion of the uterus and from 
it secondary tunnelling incisions can be 
made to reach other fibroids. It is also an 
incision that can be extraperitonealized 
with the bladder flap. These advantages 
limit blood loss and help prevent adhe­
sions postoperatively.
Although subject to controversy, the 
classic approach to fibroids on the 
posterior wall of the uterus is from the 
anterior surface, through the endometrial 
cavity.22 This approach allows simul­
taneous removal of submucous fibroids 
and also avoids incising the posterior uter­
ine wall where adhesions of the adnexa 
and small intestine are most likely to 
occur. On the other hand, adhesions may 
form in the uterine cavity6 and there is 
the fear of uterine rupture in a subsequent 
pregnancy, a factor that is now largely 
discounted.
Myomectomy
First one must find the plane between 
the fibroid and its capsule. This is most 
readily achieved by cutting boldly into the 
fibroid (nearly bisecting it) and then exert­
ing traction on each half with a tenacu­
lum. The plane is usually obvious, and 
magnification techniques are not nor­
mally required. Dissection of the fibroid 
from its wall is now done atraumatically, 
with ease. Nutrient arteries from the cap­
sule are ligated separately. The wound is 
closed with a single layer of interrupted 
0 polyglycolic acid sutures, tied beneath 
the serosa, which in turn is approximated 
with a 5-0 polyglycolic acid Lembert 
suture. Perfect hemostasis is ensured after 
the tourniquet and the ovarian artery 
clamps are released. The bladder is now 
elevated and sutured in place to cover the 
incision on the anterior uterine wall. It 
has recently been suggested that the use 
of the operating laser would reduce tis­
sue trauma and blood loss during 
myomectomy.24 Intraperitoneal adminis­
tration of Dextran is thought to help pre­
vent adhesions; therefore a final step is
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the instillation of 200 mL of 10% Dex- 
tran into the peritoneal cavity.
Vaginal Myomectomy
No description of myomectomy is com­
plete without mention of vaginal 
myomectomy. Even gynecologists who 
believe that there are few indications for 
abdominal myomectomy acknowledge 
the place of its vaginal counterpart.25 
The clinical situation in which this oper­
ation is indicated is one in which a fibroid 
has prolapsed through the cervical os. The 
tumour, which can be large, is attached 
to the endometrial surface by a pedicle. 
The patient may have bled heavily from 
the ulcerated, infected fibroid. Immedi­
ate abdominal hysterectomy has been 
traditionally discouraged for fear of 
postoperative peritonitis and an increased 
risk of injury to ureters and bladder.20 
Vaginal myomectomy on the other hand 
is straightforward. Before myomectomy, 
an attempt is made to sound the uterine 
cavity. This avoids mistaking a chronic 
uterine inversion for a prolapsed fibroid. 
The pedicle can be suture-ligated or sim­
ply twisted and cut. Blood supply to the 
fibroid is poor and hemorrhage postoper- 
atively seldom a problem. The results of 
vaginal myomectomy are excellent with 
both febrile morbidity and hospital stay 
being less than those after abdominal hys­
terectomy, for a comparable case.26
Summary
Myomectomy should be done only for 
a tumour of considerable size in a patient 
who desires to retain her uterus. It is 
sometimes indicated for menstrual abnor­
malities, but the success of the procedure 
is unpredictable. Likewise, infertility is a 
rare indication for myomectomy, for the 
results are poor. The technique of myo­
mectomy includes meticulous hemostasis.
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SESAP V Question
Items 195-197
The lettered headings below are followed by a list of numbered phrases or statements. For each number select one of 
the following:
A if the numbered item is associated with (A) only,
B if the numbered item is associated with (B) only,
C if the numbered item is associated with both (A) and (B),
D if the numbered item is associated with neither (A) nor (B).
(A) Staphylococcus epidermidis
(B) Candida albicans
(C) Both
(D) Neither
195. Common cause of nosocomial infections in intensive care units
196. Important pathogen in long-term central venous catheterization for total parenteral nutrition (TPN)
197. Treated with vancomycin
For the critique of Items 195 to 197 see page 204.
(Reproduced by permission from SESAP V Syllabus; Surgical Education and Self-Assessment Program No. 5. For enrol­
ment in the Surgical Education and Self-Assessment Program No. 5, please apply to the American College of Surgeons, 
55 East Erie St., Chicago, IL 60611.)
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CANADIAN ASSOCIATION OF GENERAL SURGEONS
Symposium on Surgical Manpower 
in the Smaller Community
F r a n k  W . T u r n e r , m b , c h  b , m s c , f r c s c , f a c s
1. Introduction
Since its foundation 9 years ago, the 
Canadian Association of General Sur­
geons (CAGS) has attempted to address 
the problems of all general surgeons, not 
simply those living in the larger conurba­
tions. In trying to define future man­
power and training requirements, the 
question arose as to just what the general 
surgeon in smaller communities was 
expected to do. Numerous attempts have 
been made to define the scope of general 
surgery and it was considered important
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to document the variety and number of 
procedures actually carried out by sur­
geons living in smaller communities, often 
relatively remote from multispecialty 
hospitals. The Committee on Manpower, 
Practice and Economics of the associa­
tion therefore designed a questionnaire to 
be sent to such surgeons; in addition to 
the basic questions regarding procedures 
done, the questionnaire included queries 
relating to hospital facilities, workload, 
professional relations and educational 
requirements. The task of putting this 
information together was undertaken by 
Dr. F.G. Inglis and his report forms the 
basis of this symposium. Excerpts from 
the report are contained in the paper 
by Dr. Inglis beginning of page 166.
Following Dr. Inglis’s report, Dr. 
Leonard Rivers compares the advantages 
and disadvantages of practice in a smaller 
and relatively remote community. Dr. 
Rivers practised in a teaching hospital in
Edmonton before moving to Fort Mc- 
Murray and is ideally suited to make this 
comparison. Dr. Edward O ’Brien also 
moved from an academic environment in 
Montreal to Salmon Arm, BC, where he 
has practised for many years; he discusses 
the training and continuing medical edu­
cation requirements of the surgeon in this 
type of practice who frequently needs far 
more expertise in orthopedics, gynecology 
and urology than that offered in the usual 
residency program.
The question is often raised as to the 
future of the general surgeon in smaller 
communities. Dr. Barry Cutler addresses 
this subject on the basis of his experience 
and with the knowledge that he has some 
strongly held opinions on the matter. 
Finally, Dr. Richard Railton, President 
of the Canadian Association of General 
Surgeons, comments on the relevance of 
this organization to the community 
surgeon.
BOOK REVIEWS
ADVANCES IN GASTROINTESTINAL 
SURGERY. From the Forty-seventh 
Annual Continuation Course in Surgery, 
University of Minnesota Medical School, 
Minneapolis. Edited by John S. Najarian 
and John P. Delaney. 640 pp. Illust. Year 
Book Medical Publishers, Inc., Chicago, 
1984. Price not stated. ISBN 0-8151-6336-3.
There is a profusion of publications reporting 
the proceedings of conferences, workshops and 
courses. Although some are essential reading, 
few are widely read. It seems logical to take 
a successful postgraduate course and transpose 
it into a book so that a much wider audience 
might benefit. Unfortunately, this rarely 
works. Advances in Gastrointestinal Surgery 
is perhaps the ultimate example of this regret­
table failure. It is a faithful reproduction of 
part of the 47th Annual Continuation Course 
in Surgery, conducted by the University of 
Minnesota Medical School. This widely
acclaimed course enjoys a deservedly high repu­
tation. It attracts a distinguished panel of lec­
turers and a large audience that is enthusiastic 
in its praise. Yet the book is disappointing. 1 
believe this is mainly because the editors have 
too faithfully reproduced the speakers’ texts 
and discussions. Since the art of speaking is 
entirely different from the art of writing, an 
excellent lecture may make a poor book chap­
ter. The variation in style and personalized 
messages so necessary in a course make for dis­
jointed, unconvincing and at times frustrating 
reading.
The editors note in their preface that the dis­
cussions were printed essentially as they were 
given. It is perhaps because of this deliberate 
lack of editing that these same sections of the 
book fail to prove either controversial or enter­
taining.
As the book covers only selected topics in 
gastrointestinal surgery there are some glaring 
omissions. All aspects of hepatobiliary and
pancreatic surgery are omitted and even gas­
tric cancer has been excluded, yet the book 
includes three chapters on the surgery of mor­
bid obesity.
The true value of this excellent course does 
not come through in the book. It is certainly 
less expensive than a trip to Minneapolis and 
so deserves a place in every medical library 
where it can be consulted by residents looking 
for material for rounds not readily found in 
standard texts.
M.M. Cohen, md, frcsc
Member,
Editorial Board.
Professor of Surgery,
University of Toronto,
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600 University Ave.,
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2. The Canadian Association 
of General Surgeons’ Questionnaire: 
Results and Observations
The Canadian Association of General 
Surgeons distributed a questionnaire to 
members located in communities of 
40 000 population or less. The objective 
was to establish a minimal referral base 
of general surgeons, to identify the scope 
of procedures performed and the ade­
quacy of training for serving smaller 
communities and to gain knowledge of 
the need for other specialists and the 
activity of the general practitioner- 
surgeons in smaller centres.
A review of 92 replies indicated that, 
in general, these surgeons are very satis­
fied with the hospital and laboratory 
facilities, and perform a broad range of 
operative procedures for which there is 
abundant operating time. In communities 
of 10 000 to 20 000 there appears to 
be a need for extra training in obstetric, 
gynecologic and orthopedic procedures. 
Most of the larger communities have an 
adequate number of ether surgical 
specialists with the exception of neu­
rosurgeons. Of the respondents, 80%  
practised on a referral basis only with an 
average of 10 referring general practi­
tioners; 2 4 %  were in competition with 
general practitioner-surgeons, but most 
indicated that this is a diminishing 
problem. It appears that practice in small 
communities provides a very rewarding 
and professionally challenging surgical 
career.
L'Association canadienne des chirurgiens 
generaux a distribue un questionnaire 6
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ses membres qui pratiquent dans des 
agglomerations de 40 000 habitants ou 
moins. L'objectif etait d'etablir une base 
de reference des chirurgiens generaux, 
d'identifier I'etendue des interventions 
pratiquees et la pertinence de la forma­
tion chirurgicale pour desservir les peti- 
tes communautes, et d'acquerir des 
connaissances sur les besoins en specia- 
listes d'autres disciplines et sur les acti- 
vites des chirurgiens-praticiens generaux 
dans les petits centres.
L'etude des 92 reponses recues indi- 
que que, en general, ces chirurgiens sont 
tres satisfaits des hopitaux et des servi­
ces de laboratoire dont its disposent, et 
qu'ils pratiquent un vaste eventail 
d'interventions chirurgicales pour iesquei- 
les ils disposent d'amplement de temps. 
Dans les communautes de 10 000 a 
20 000 habitants, il semble exister un 
besoin pour davantage de formation en 
chirurgie obstetrique, gynecologique et 
orthopedique. La plupart des villes plus 
importantes possedent un nombre suffi- 
sant de chirurgiens specialistes, a 
I'exception des neurochirurgiens. Parmi 
ceux qui ont repondu, 8 0 %  ont une pra­
tique de consultation avec en moyenne 
10 praticiens generaux comme source de 
malades; 24%  sont en competition avec 
des medecins-chirurgiens quoique la plu­
part indiquent que ce probleme soit en 
voie de disparition. II semble que la prati­
que dans les petits centres procure une 
carriere chirurgicale d la fois tres grati- 
fiante et stimulante au plan profes- 
sionnel.
The Canadian Association of General 
Surgeons instituted a study to identify the 
scope of surgical practice in smaller Cana­
dian communities. A questionnaire 
designed by the Manpower Economics 
and Practice Committee was sent to mem­
bers of the association who practise in 
municipalities with a population of not 
more than 40 000. Of the 300 question­
naires sent out, 104 were returned; 12 
were eliminated because they came from 
surgeons practising in communities with
more than 40 000 people. Thus, the final 
sample is based on 92 replies. The follow­
ing findings and observations are excerpts 
from the committee’s report presented in 
February 1985 to the executive of the 
Canadian Association of General Sur­
geons.
In general, the committee’s findings 
reflect three problems:
1. The fear o f the general practitioner 
that the presence of a surgeon undermines 
his competence (“ didn’t you take the full 
course in medical school?” was an 
apocryphal question by Premier Tommy 
Douglas to a physician in northern 
Saskatchewan who stated he didn’t do 
surgery).
2. The fear that a surgeon will engage 
in family practice if he is not busy 
enough. This is a real concern and, from 
the comments of the respondents, it takes 
a fair bit of single-mindedness for the sur­
geon to let the community know that sur­
gery will only be done on a referral basis. 
Once that has been established, the 
problems usually resolve.
3. The problem of communities with 
two clinics, one of which has a qualified 
surgeon. This creates competition and 
sometimes inconveniences patients requir­
ing surgery. In this situation the surgeon 
would be advised to establish a solo 
practice.
The comments of respondents to the 
questionnaire were important and gener­
ally indicated a tendency towards the 
acceptance of specialists in smaller com­
munities. This trend will be further aug­
mented by the infusion of graduates of 
current family practice residency pro­
grams, in which the physician receives lit­
tle practical surgical training.
Workload
Not all respondents indicated whether 
their workload was optimal, adequate or 
too heavy. Only 7 of the 92 indicated that 
their workload was too heavy. A review 
of the annual operative load revealed 
somewhat surprising figures. One surgeon
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stated that he did a total of 1700 opera­
tions, which included 500 endoscopies. 
Eleven respondents did more than 1000 
operations. When these questionnaires 
were reviewed in detail, they revealed 
that, with one exception, each surgeon 
was practising with others in the commu­
nity and, in general, the communities, 
although ranging in population from 10 
000 and 20 000, had a drawing popula­
tion of 30 000 up to more than 40 000 
and, in one case in northern Quebec, 
exceeded 100 000. Only 2 of the 11 sur­
geons indicated that they were overly busy 
(i.e., were doing more than they wanted 
to do) and none of them did general prac­
tice. Also, there was an abundance of 
general practitioners in the area and either 
the communities were in isolation or they 
were in highly populated areas such as 
southwestern Ontario. Taking the group 
as a whole, the average number of oper­
ations was 618/yr (range from 35 to 
1700).
In response to the question on time 
spent in nonoperative work, consultations 
averaged 10 h/wk, scheduled office visits 
14 h/wk, night calls (between 2000 hours 
and 0800 hours) approximately 4 h/wk, 
and night operations during the same 
period approximately 2/wk. Other duties, 
such as resuscitation of trauma patients 
or work in the intensive care unit, took 
up a maximum of 4 h/wk and a minimum 
of 2 patients a year. Other nonoperative 
duties included administration (8 h/wk), 
endoscopy (10 h/wk) and meetings and 
committee work (approximately 5 h/wk).
Operative Procedures
Operations were reviewed in commu­
nities of 10 000 or less, 10 000 to 20 000, 
20 000 to 30 000 and 30 000 to 40 000. 
Some surgeons were asked to check off 
the frequency of operations, others sim­
ply noted that the operation was per­
formed in their centre. Thus, in formulat­
ing the summary of these answers, it was 
possible only to show what procedures are 
done, with some indication of the rela­
tive frequency (Table I).
The range of surgery practised in the 
smaller communities seems to be more 
broadly based than in the communities of 
30 000 and over. It should be remembered 
that these findings represent relatively 
small numbers. On reviewing the ques­
tionnaires, one gains the impression of 
general trends. It would appear that in 
communities of 40 000, the surgeon con­
fines himself more and more to gastroin­
testinal surgery and surgery that is more 
commonly part of the general surgery 
program in the teaching centres through­
out Canada. At the other end of the scale, 
surgeons are expected to provide expert 
services for which they were not originally 
trained, but to which it appears they can 
readily adapt (i.e., gynecologic and 
obstetric surgery). This should be taken 
into consideration by program directors. 
It is anticipated that, as the general sur­
geons in the larger centres retire, they will 
be replaced by younger graduates but, as 
general surgeons proliferate into the 
smaller communities, it is expected that 
fewer general practitioners will do intra­
abdominal surgery, so the requirements 
for this career choice should be modified 
in training programs to meet the antici­
pated demand.
Questions in the questionnaire regard­
ing the management of specific injuries 
were not well answered, but they gave the 
impression that all patients with neurosur­
gical complications were immediately 
referred. Those with more serious multi­
ple injuries were resuscitated and sent to 
the nearest centre. It was encouraging to 
note that several surgeons indicated that 
they had applied the advanced trauma life 
support (ATLS) protocol (American Col­
lege of Surgeons) before referring patients 
to central areas. A recurring comment 
was that whenever head injuries were 
involved, patients were referred because 
of the lack of neurosurgical expertise in 
the local situations. This was also the case 
when qualified orthopedic consultation 
was not available. Otherwise, plastic and 
abdominal surgery was managed locally.
Burns were usually either handled 
locally, if a plastic surgeon or a general
surgeon with a special interest in the area 
was available, or the patient was referred 
after resuscitation. Some surgeons indi­
cated an interest in treating burns. For 
instance, one respondent in Alberta 
stated, “ I treat burns up to 20% to 30% 
in adults and up to 10% to 15% in chil­
dren. There is a problem with nursing 
care if I treat major burns.” From Brit­
ish C olum bia, another surgeon 
responded, “ Resuscitate and transfer to 
a Burn Unit if greater than 30% to 40% 
total body surface or complicated by 
respiratory or other problems.”
Cancer surgery is certainly carried out 
in the smaller centres as indicated by the 
response concerning the percentage of 
surgical operations that dealt with cancer. 
Twenty-eight respondents indicated that 
less than 10% of their operations were 
involved with cancer, 52 estimated that 
10% to 20% of operations were per­
formed for malignant disease and 10 esti­
mated greater than 20%. Two did not 
answer this question.
Endoscopy performed by surgeons has 
been a controversial issue in terms of sur­
gical training, and to establish the role of 
this problem in smaller communities, we 
asked surgeons to state whether they did 
endoscopy: 83 did, 6 did not and 3 
did not respond. Some performed up to 
500 endoscopies annually. The average 
was 75. Specifically, surgeons did 95 
esophagogastroscopies, 60 colonoscopies 
and 57 flexible sigmoidoscopies per year 
on the average. Surgeons practising in the 
communities of 40 000 people or less per­
formed an average of 42 endoscopic 
retrograde cholangiopancreatographies, 
21 bronchoscopies and 48 cystoscopies 
annually.
Summary
In general, the replies to the question­
naire were very positive, indicating that 
practice in the smaller communities was 
rewarding from the surgical standpoint 
and that facilities were adequate for the 
surgeons to do things they were trained 
to do. There were relatively few com­
plaints concerning the lack of equipment. 
Hospital facilities were generally consi­
dered most satisfactory, but there was the 
occasional complaint that frozen-section 
facilities were not always available. A let­
ter from a surgeon who practised in com­
munities of 40 000 in both Alberta and 
currently in British Columbia provided a 
balanced perspective:
In the size of communities that I have prac­
tised in, there is no doubt that the full spec­
trum of...general surgical expertise is required. 
Any general surgeon coming out into this size 
of community would be expected to have con­
fidence in endoscopy, both upper and lower, 
but not in highly specialized endoscopy, such 
as ERCP and endoscopic sphincterotomy...he 
must be able to perform standard thyroid sur-
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gery, but salivary gland surgery would proba­
bly be optional because the volume is 
small. Major neck surgery...would be sent 
away to head and neck specialists in a tertiary 
referral centre.
One would be expected to perform all the 
normal G.I. operations but not liver resections 
and the degree of pancreatic surgery would 
depend largely on experience, but...most peo­
ple facing the prospect of a Whipple resection 
would prefer to refer such a patient to a ter­
tiary referral centre . . . Also I think that most 
people in this size of community would tend 
to refer adrenal tumors and generally complex 
endocrine problems . . . There would, of 
course, be the usual necessity to do varicose 
veins, hernias and minor anorectal problems, 
including much neglected hemorrhoidal band­
ings and cryosurgery . . . Most general sur­
geons in the smaller community will do limited 
vascular surgery such as aortic resection, 
femoropopliteal bypass and profundoplasty, 
but would not get involved in mesenteric revas­
cularization, renal artery stenosis and carotid 
and cerebral problems and certainly no cardiac 
or thoracic aortic problems . . .
In communities like . . . and . . . one has 
enough orthopedic, plastic surgery and urolog­
ical back-up that only a limited expertise in 
these areas is necessary . . .  I feel that the 
general surgical training as learned within the 
residency programs as they stand today is a 
very satisfactory training for a surgeon work­
ing in this size of community as he will get the 
opportunity to practise his full spectrum of 
skills but to be selective in sending away com­
plex problems to the tertiary referral centre.
Perhaps the spirit of practice in a 
smaller community is best reflected by the 
comments of an Ontario community 
surgeon:
We do a wide range of procedures. We are not 
confined like so many teaching hospital sur­
geons. What we do is done competently and 
safely. We feel we have excellent facilities for 
the type of surgery we do. We could support 
a full-time neurologist. However, a full-time 
gynecologist would severely cut into our ‘bread 
and butter’.
A respondent from British Columbia 
reflected an expected change in the pat­
tern of practice:
The scope of practice has been unlimited, but 
in the recent 2 or 3 years, patients’ expecta­
tions, ease of transportation and readily close 
availability of orthopedists have continued to 
change the pattern of practice substantially.
And, from Nova Scotia,
I am mostly concerned that new graduates keep 
sending many patients to tertiary care hospi­
tals when they could easily be looked after in 
our hospital — don’t they realize that we 
trained at the ‘Great Halls of Learning’ also?
Despite the occasional plaintive com­
ment, it appears that general surgeons 
practising in communities o f 40 000 or less 
have very satisfying and professionally 
challenging careers.
L e o n a r d  F . R i v e r s , m d , f r c s c , f a c s
3. The Advantages and Disadvantages
of Practising Surgery in a Small Community
The advantages of practice in a commu­
nity encompassing a population of about 
35 000 include readily available beds 
and operating rooms, a relative diversity 
of surgical problems, increased job satis­
faction and solid community support 
through service clubs and other volun­
teer organizations.
Disadvantages in some situations can 
include lack of investigational facilities 
and of internists for consultation. A lack 
of surgical assistants, anesthetists and 
intensive-care-unit support are other 
potential negative factors. The quest for 
continuing medical education requires 
definite resolve, and practice finesse 
must be well honed.
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Les avantages d'une pratique chirurgicale 
dans une agglomeration d'environ 
35 000 habitants incluent la facilite 
d'acces aux lits d'hopitaux et aux salles 
operatoires, une diversity relative des 
problemes chirurgicaux, une grande 
satisfaction au travail et un solide sou 
tien communautaire de la part des clubs 
sociaux et autres organismes de volon- 
taires.
Les inconvenients dans certaines situa­
tions peuvent inclure un manque d'equi- 
pements pour les examens et i'absence 
d'internistes pour les consultations. 
L'absence d'assistants de chirurgie, 
d'anesthesistes et d'unite de soins inten- 
sifs sont d'autres facteurs negatifs possi­
bles. La poursuite d'une formation 
medicale continue exige de la determina­
tion: la finesse dans la pratique doit etre 
bien aiguisee.
In 1979 my family and I moved from 
Edmonton, where I had practised in a 
550-bed metropolitan hospital, to the 
northern city of Fort McMurray, Alta. At 
the time, the construction of a new 
regional hospital was almost complete. 
My comments reflect the experiences we 
have had as a result o f this move.
Fort McMurray, a city o f 35 000 with 
an additional drawing population of 
about 2000, is located 450 km northeast 
of Edmonton.
With an average age o f less than 25 
years, 50% of the population in school 
and 800 births per year, the inhabitants, 
who work principally in the mining, sepa­
ration and upgrading of tar sand into syn­
thetic crude oil, can best be described as 
enthusiastic and productive.
Fort McMurray Regional Hospital, 
although built to accommodate 300 
patients, has only 150 beds at present. 
Departments were formed from the major 
services of family practice, medicine, 
obstetrics and gynecology, surgery and 
anesthesia when the new facility was ini­
tially occupied. The services of pediatrics, 
radiology, pathology and psychiatry have 
since been added as fellowship-qualified 
physicians have been recruited to the area. 
In 1979 there were 12 physicians on staff, 
this number has increased to 40. The 
department of surgery comprises two 
general surgeons, one orthopedic surgeon 
and four general-practitioner surgeons.
Advantages of Practice in This Setting
The greatest advantage to such a prac-
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tice is the availability of beds and oper­
ating rooms. Urgent cases can be admit­
ted within 48 hours and waiting lists for 
elective surgery are almost always less 
than 4 weeks. Utilization rounds, 
although they are required occasionally, 
are pleasantly infrequent. This utopic sit­
uation we all realize is temporary, and will 
gradually be eroded as more surgical sub­
specialists are recruited to the area.
The need to perform many different 
types of surgery in a host of subspecialty 
areas, I regard only partly as an advan­
tage. It is not unusual for a general sur­
geon in this environment to address, 
according to his or her training, interest 
and skill, problems relating to the special­
ties of orthopedics, obstetrics and gyne­
cology, plastic, thoracic and vascular sur­
gery, and urology, in addition to the 
traditional areas of abdominal, breast, 
head and neck and, to a varying extent, 
pediatric surgery. Obviously no one sur­
geon could hope to provide in-depth 
definitive coverage of the areas just men­
tioned. Referral to a subspecialty surgeon 
in a metropolitan centre must be consi­
dered in every case. Critical assessment 
of my capabilities, compared with those 
of a subspecialist less than 2 hours away, 
is mandatory in all circumstances. One 
must be ruthlessly honest, for on the other 
side of the coin looms the possibility of 
providing your patient with less than 
optimal care and the legal liability 
associated therewith. You will recognize 
that many of the subspecialty areas men­
tioned have a substantial litigation 
potential.
Job satisfaction, paramount to a happy 
practice, is more readily achieved in the 
setting of a small community. The general 
surgeon is regarded as a cornerstone of 
surgical and trauma care. The provision 
of elective and, on many occasions, life­
saving surgical skills to a peripheral popu­
lation is indeed gratifying. These patients 
would otherwise be inconvenienced and 
financially imposed upon when required 
to seek care in an often-impersonal, 
metropolitan environment. Another 
advantage is the relief of many of the 
daily frustrations associated with 
metropolitan practice.
Surgical practice in the small commu­
nity calls for close cooperation with our 
administrative colleagues, which is 
required for the management of our facil­
ities. In my experience, because both 
groups are fewer in number, the issues 
seem to be addressed with more dispatch 
than in larger hospitals.
Because there is usually only one hospi­
tal in a small community, a near monop­
oly exists for donated funds raised by 
service clubs and others. These consider­
able donations are responsible for the 
acquisition of innumerable pieces of 
equipment and even assist in the institu­
tion of some new services. In a metropoli­
tan environment such funds usually are 
gobbled up by high-profile institutions 
such as university hospitals and cancer 
clinics that provide high-profile services 
(e.g., coronary artery surgery, transplan­
tation).
Teaching housestaff, although not a 
regular activity in my present situation, 
is sometimes required and I have found 
the experience always stimulating and 
rewarding, a statement I could not make 
while involved in a metropolitan practice. 
Candidates coming to this smaller centre 
do so electively, are well motivated, ener­
getic and have a desire to be close to the 
action.
Disadvantages
Continuing medical education requires 
definite resolve. In the past the arrange­
ments for physician coverage, family and 
pets presented particular difficulty in 
small communities. Adequate coverage 
by another surgeon may be impossible. 
Now these problems have been partially 
overcome by the introduction of telecon­
ferencing and video cassette programming 
for continuing medical education. Regu­
lar clinical surgical rounds by a depart­
ment small in numbers is difficult, and 
peer fellowship and information transfer 
were the most negative aspects associated 
with our relocation to a small city prac­
tice. Initially the telephone provided a 
substitute but gradually our needs in this 
area are being met as more surgical 
specialists are being recruited.
Practice finesse, the art of relating to 
your referring physicians, important in 
any practice, must be handled with kid 
gloves in a smaller centre. My experience 
is that family practitioners respect and 
readily accept specialists provided they 
don’t infringe on family practice. That 
means the surgeon must establish a prac­
tice by referral only from the outset. If 
such a stand cannot be supported, then 
probably surgical specialists are not 
required in the area. Surgeons who prac­
tise family medicine must develop their 
surgery from that practice. It is difficult 
to maintain a practice by referral only. 
Your secretary must be your closest ally 
in dealing politely but firmly with the 
myriad attempts to secure appointments. 
Referring physicians will be reassured 
when they receive a completion of care 
letter that reads: ’’Dear Dr. Smith, I 
return to your care Mrs. ...” . Equally 
critical I believe are practice groups in 
which specialists are associated with other 
specialists and preferably surgeons with 
surgeons. Multidisciplinary clinics involv­
ing family practitioners and specialists 
have many problems, not the least of 
which is the alignment of the specialists 
with one general practitioner. In such a 
situation other family practitioners may 
refer their patients out of the local
environment rather than risk losing cases 
to the opposition!
Investigational facilities are certainly 
limited in the small community. In 
Alberta, regionalization of health care by 
the provincial government has led to the 
establishment of extensive investigational 
facilities in regional hospitals. The lack 
of computed tomography in investigating 
acute head trauma and in other situations 
is particularly noteworthy. This and other 
investigational requirements necessitating 
transfer to a large centre will be mostly 
filled during the next decade.
The lack of internists in some smaller 
communities occasionally poses problems 
for surgeons who, with family practi­
tioners, become responsible for total 
m anagem ent of patien ts with 
emphysema, asthma, angina pectoris, 
hypertension and diabetes mellitus. 
Although this may be gratifying, input by 
an internist in such situations would be 
desirable.
Sometimes surgical assistants are 
difficult to find unless a reciprocal 
arrangement can be made with another 
surgeon. Even this is not ideal for it dou­
bles the time spent by each surgeon in the 
operating room. Family practitioners also 
are often reluctant to be separated from 
their busy offices. In our hospital, full­
time emergency physicians regularly assist 
during their off hours. I often think this 
would be a useful activity for retired phy­
sicians and surgeons living in a small com­
munity. The problem doesn’t exist when 
housestaff are available.
General surgical practice is eroded by 
each new subspecialist arriving in the 
community. Although this provides more 
and varied services, it may lead to a ques­
tion of the viability of a referred general 
surgical practice. The training require­
ments of general surgeons practising in 
smaller communities must address this 
problem.
Anesthetic capability and coverage, 
intensive-care-unit support, operating- 
room facilities and staffing — all poten­
tial restrictive obstacles — have presented 
no problem in our setting.
Comment
I have addressed many aspects of clin­
ical practice in a small community, but 
the most critical requirements dictating 
success or failure of practice in this set­
ting relate to factors that support the 
spouse and family, such as the provision 
of education, the availability of cultural 
activities, shopping, religion, extended 
family and social contacts and recreation.
Many variables apply to practice in a 
smaller city, but so, too, do they apply 
to practice in metropolitan areas. For me 
the advantages of practice in a facility 
such as Fort McMurray Regional Hos­
pital far outweigh the disadvantages.
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4. Training and Continuing Medical Education 
Requirements for Practice in the Small Community
The author considers the training require­
ments of a general surgeon who will be 
the only surgical specialist in a small 
community. Apart from the usual heavy 
gastrointestinal content, the surgeon's 
training should include 1 year of fracture 
and trauma training, the care of head in­
juries and urologic injuries, and, the 
management of abdominal gynecologic 
problems and the technique of cesarean 
section. Attendance at smaller regional 
surgical meetings, participation in the 
Surgical Education and Self-assessment 
Program (SESAP) of the American Col­
lege of Surgeons and other continuing 
education programs are also essential in 
maintaining standards.
L'auteur envisage les besoins de forma­
tion medicate pour un chirurgien general 
destine a devenir I'unique specialiste de 
la chirurgie dans une petite communaute. 
En plus de la forte concentration 
habituelle en chirurgie gastrointestinale, 
la formation du chirurgien devrait com- 
prendre une annee dans les soins des 
fractures et traumatismes, les lesions 
craniennes et urologiques et le traitement 
des probl&mes gynecologiques 
abdominaux ainsi que le technique de 
c£sarienne. La presence a de petites 
reunions rggionales de chirurgie, la par­
ticipation au programme d'auto- 
evaluation et d'education chirurgicale 
(Surgical Education and Self-Assessment 
Program ou SESAP) de I'American Col­
lege of Surgeons de meme que d'autres 
programmes de formation mgdicale con­
tinue sont aussi essentiels au maintien 
de standards eleves.
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Although surgical manpower is not in 
short supply, there is a problem of dis­
tribution that is common to all of medi­
cine. There are now 7558 funded post­
graduate training positions in Canada, 
mostly in specialty training programs 
which turn out 2200 to 2300 new physi­
cians a year. It is therefore unlikely that 
there will be a shortage of general sur­
geons in the forseeable future. The 
problem of maldistribution must be 
solved. Young surgeons should be 
encouraged to practise in smaller commu­
nities, where there is a clear need for them 
and where general surgical practice can 
be very satisfying.
I have been asked to consider and to 
discuss the training of a community sur­
geon. The Canadian Association of 
General Surgeons’ study of 1985 looked 
at towns with a population of 40 000 or 
less. Most towns of this size in Canada 
have an adequate supply of surgical 
specialists. Such a town near my location 
has three orthopedic surgeons, three 
ophthalmologists, two obstetrician- 
gynecologists, one otolaryngologist, one 
urologist and three general surgeons. 
General surgeons here are primarily 
abdominal surgeons.
I shall consider the training required by 
the general surgeon in a community where 
he or she is the only surgical specialist 
available. The suggestions are my own, 
supplemented by ideas solicited from my 
general practitioner colleagues as they 
apply to the current situation. I have sur­
veyed my own practice since 1974 and 
have found that 25% consisted of frac­
tures and other limb trauma, and elective 
limb surgery other than varicose veins. 
Before 1974, when there were few ortho­
pedic surgeons in the interior of British 
Columbia, fractures and other limb 
trauma constituted 35% to 40% of my 
practice. Gynecologic problems and cesa­
rean sections make up 15% of the 
practice.
The training of the general surgeon 
should be as broad as possible for as long 
as possible. It should start with a rotat­
ing internship. You learn a great deal 
from your fellow trainees at this level, and 
a broad base in all major medical dis­
ciplines is important to the future sur­
geon. The most serious gap in present 
general surgical training is in the area of 
fractures and limb trauma. Another lies 
in the lack of exposure to gynecologic sur­
gery and cesarean sections, all of which 
are important in a small community prac­
tice. Training in these areas should be at 
a senior level, after 2 years of surgical 
training. Any trainee expressing an inten­
tion of practising in a small or isolated 
community would benefit from as much 
as a year on a fracture service.
I am not familiar with every training 
program in the country, but I would plead 
that the care of fractures, gynecologic sur­
gery and cesarean sections be included in 
training programs. The care of urologic 
emergencies and of acute head injuries 
must also be taught. I would say that such 
training is more important for a commu­
nity surgeon than training in endoscopy.
Continuing medical education is a 
major consideration, especially important 
for the surgeon living away from a teach­
ing centre. With the plethora of oppor­
tunities, there is no excuse for not keep­
ing up to date. Continuing education, 
however, is an attitude of mind, not ease 
of access. It begins at home. In our com­
munity, we have a journal club that meets 
monthly. It is amazing how much can be 
learned from colleagues in this way. A 
good hospital library also is important. 
In British Columbia, we are fortunate in 
having a provincial medical library serv­
ice run by the College of Physicians and 
Surgeons of British Columbia. The librar­
ian visits each hospital annually and sug­
gests purchases to update the library. 
They will search the literature for you and 
provide reprints, up to 100 pages free each 
year. Another home activity that I recom­
mend is participation in the American 
College of Surgeons’ Surgical Education 
and Self-Assessment Program (SESAP). 
It is most useful, shows you your weak­
nesses and will keep you sharp for the
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inevitable future appearance of recertifi­
cation examinations.
I like to get away to meetings and find 
that I prefer smaller ones, like those of 
the British Columbia Surgical Society. 
The one big meeting I attend is the Ameri­
can College of Surgeons Clinical Con­
gress. Postgraduate courses at these meet­
ings are usually excellent and have a 
considerable basic science content, which 
I find important. Three or 4-day surgical 
review courses, such as those run by the 
University of Toronto, are also excellent.
The new videotape clinics are often well 
done and we place these in the hospital 
library where they are available to all.
Continuing education is a personal 
responsibility. As you know, the Ameri­
can Board of Surgery now certifies suc­
cessful candidates for only 10 years, 
requiring re-examination at that time. The 
Canadian Association of General Sur­
geons should take the lead in this field and 
urge the Royal College of Physicians and 
Surgeons of Canada to introduce recer­
tification. In the meantime we should
require our members to participate in the 
SESAP program. We should be the sur­
gical leaders in this country. If we aren’t, 
governments or other agencies will be.
In summary, I make a plea for the 
general training of general surgeons. 
Community surgeons must be trained to 
manage fractures and other limb trauma, 
abdominal gynecology, cesarean sections, 
emergency urologic problems and head 
injuries. Continuing education begins at 
home. Postgraduate courses and smaller 
regional meetings are recommended.
Barry  K. Cu t l e r , m d , fr c sc , facs
5. Is There a Future 
for the Community General Surgeon?
The author attempts to assess the fac­
tors affecting the future of surgery in 
Canadian communities with a population 
of 10 000 to 30 000. Five problems are 
identified: (a) unrealistic patient expecta­
tions, (b) government cutbacks causing 
reduced equipment budgets, (c) difficulty 
in getting competent, modern 
anesthesia from well-trained general 
practitioners, (d) undergraduate and 
postgraduate training focus and (e) politi­
cal enlargement of medical schools and 
reduced funding for health care.
The proposed solutions are as follows: 
realistic patient expectations should be 
possible through authoritarian advertising 
compaigns; residency training should be 
keyed to community surgery; community 
health care standards can be promoted 
and maintained by creating a link 
between the community surgeon 
(specialist) and the tertiary hospital of 
his choice. This can be accomplished by 
creating a new class of staff appoint­
ment in the tertiary hospital, the "refer­
ring consultant" (i.e., the community 
surgeon).
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L'auteur a tente d'evaluer les facteurs 
qui vont influencer le futur de la chirurgie 
dans les agglomerations canadiennes de 
10 000 6 30 000 habitants. Cinq proble- 
mes sont identifies: a) les attentes irrea- 
listes des patients, b) les coupures 
gouvernementales sur les budgets 
d'equipements, c) les difficultes de recru- 
ter des praticiens generaux bien entrai- 
nes capables d'assurer avec soin un 
service d'anesthesie moderne et de 
bonne qualite, d) la specialisation de la 
formation au niveau universitaire et gra- 
due, et e) la decision politique d'augmen- 
ter le nombre d'etudiants en medecine 
tout en reduisant les fonds consacres 
aux soins de sant£.
Les solutions proposees sont les sui- 
vantes: les attentes des patients pour- 
ront etre rendues realistes par la mise 
sur pied par les organismes appropries, 
de campagnes d'information; la resi­
dence devrait etre orientee vers la chirur­
gie communautaire; les standards de 
soins de sante communautaires peuvent 
etre am6liores et ensuite maintenus par 
la creation de liens entre le chirurgien 
communautaire (specialiste) et I'hopital 
tertiaire de son choix. Ceci pourrait etre 
realise en errant une nouvelle classe de 
medecins affilies aux hopitaux tertiaires, 
celle des "consultants exterieurs" (e'est 
a dire les chirurgiens communautaires).
Is there a future for the community 
general surgeon? I say no, not if present 
trends are allowed to continue. By com­
munity I mean a population centre of 
10 000 to 30 000, more than 30 minutes 
by road from a tertiary care centre. There 
are fewer than 200 such communities in 
this country and in many the shift of peo­
ple toward the large cities is reducing their 
population. In each of those 200 commu­
nities reside between one and four gen­
eral surgeons. When you remember that 
the present membership of the Canadian 
Association of General Surgeons is about 
1000, it is obvious that these community 
surgeons deserve the attention of our 
organization.
The Problems
I have identified five specific problems 
that must be resolved.
1. Patients have expectations that are 
unrealistic. These are fed by the media 
and reinforced by massive medicolegal 
settlements. On television and in maga­
zines they can see replacement of almost 
every body part and they realize that they 
can have input into the decisions as to 
where and how they are treated. Their 
attitude is that they pay for the service so 
they should get the best of care. This atti­
tude shouldn’t surprise us because it 
parallels that of the National Health Serv­
ice in Great Britain. Unfortunately, our 
society has finite resources and we can’t 
afford “ the best” care for everyone, 
meaning that priorities must be set.
2. Government cutbacks have reduced 
equipment budgets everywhere. Equip­
ment for procedures such as image inten­
sification computed tomography and 
nuclear isotope scanning is not available 
in every community hospital and unfor­
tunately much publicity has been given to 
the idea that such equipment is essential 
for surgical practice in 1985.
3. In contrast, competent, careful and 
up-to-date anesthesia is essential to 
modern surgery and I rank it highly as a
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problem in the small community because 
I believe there is a crisis in the making. 
Unfortunately medicolegal settlements, 
increased training requirements and 
escalating insurance premiums are mak­
ing this area increasingly unattractive to 
family physicians who form the backbone 
of anesthesia in the smaller community. 
The protective, isolationist attitude of cer­
tified anesthetists does not help this 
problem.
4. Undergraduate training programs 
are not directed toward community sur­
gical practice, for which the training must 
be broadly based and adaptable to the 
locality where the surgeon is to practise. 
Surveys such as Dr. Inglis has carried out 
are needed to study accurately the work­
load on the spot and to make appropri­
ate adjustments to fit the needs.
With respect to postgraduate training 
or continuing medical education, how 
does the bewildered community surgeon 
handle the three-ring circus that goes on 
at most major surgical meetings? How 
does he choose which sessions to attend? 
For example, we are trained as general 
surgeons, now mostly gastrointestinal; 
when we attend a meeting we want to hear 
the papers that will bring us up to date 
in that area, but next week we might have 
to perform a tendon repair, a breast 
reduction , an arthroscopy or an 
obstructed obesity bypass, so that papers 
on those subjects would also be valuable 
to us. If the sessions overlap, how do we 
decide which to attend? Effectively, we 
set our own limits or out patients and 
general practitioner colleagues set them 
for us.
5. Governments are flooding the med­
ical schools with students on the one hand 
and cutting back funding on the other. 
Recent graduates are frightened away 
from practice in smaller communities 
because they may never be able to get 
back into the urban setting. Ideal general
surgeon-population ratios are now quoted 
as 1:17 000 but such figures are totally 
meaningless unless we have a better defi­
nition of what that surgeon’s practice 
encompasses — and I suspect that may 
vary from community to community.
The Solutions
Should we resist the trend by defining 
our limits of practice in the smaller com­
munity and sticking to them or should we 
instead urge governments to purchase 
more helicopters and abandon the field 
to the general practitioner and the tertiary 
care hospital?
1 suggest to you the former solution 
rather than the latter but with perhaps a 
different twist. I challenge you that there 
will always be a need for certified sur­
geons in small communities.
How then can we solve the problems 
we have identified?
• Patients’ expectations could be made 
more realistic by a judicious advertising 
campaign, especially if it came from 
provincial medical associations and from 
the Royal College. There is ample evi­
dence of the benefit of such campaigns 
in the “ second-opinion” campaign of the 
American College of Surgeons which 
resulted in a reduction of unnecessary sur­
gery in the United States.
• 1 have already alluded to ways of 
making the training of community sur­
geons more meaningful. It must be more 
broadly based and yet it must not be per­
ceived as being second-class qualification.
The easiest solution of all is that of con­
tinuing medical education or postgradu­
ate training. The organizers of meetings 
must involve people who are working in 
smaller centres and find out from them 
what is relevant, and must keep asking 
until they get meaningful answers.
• Governments must be convinced that
better use of health-care dollars can be 
made to keep the community hospital 
system (in which they already have a huge 
investment) alive and healthy. There must 
also be evidence that the standards of care 
are maintained. How do we do this — 
and solve the problem of anesthetists? I 
propose that a new class of hospital staff 
appointment be created — the “ referring 
consultant” — and that the surgeons be 
brought back into the tertiary care 
centres. Every community surgeon would 
choose the tertiary hospital he liked to 
refer to, and would have privileges in that 
institution, to admit and ideally to treat 
his patients. Commensurate with these 
privileges would be responsibilities — 
attending rounds, making presentations, 
serving on some hospital committees and 
maintaining records, just like every other 
staff appointment. Thus, if the commu­
nity surgeon had a patient with a special 
medical or anesthetic problem that had 
a simple surgical solution, such as a her­
nia with emphysema or a blood dyscra- 
sia, the surgeon might choose to carry out 
the operation in the tertiary centre where 
the support facilities are available. Also, 
a patient who had previously been oper­
ated on in a community hospital and who 
required a complex operation would be 
better served by having his community 
surgeon assisting (involved) in that proce­
dure. How better to influence the stan­
dards of care than to have the commu­
nity surgeon involved and subtly soaking 
up the methods as they are developed in 
the training centres. The benefits to all 
specialties would be far-reaching.
This solution would not be easy — 
scheduling of operations and office hours 
would be more complex, travel time and 
costs would be greater, but the end result 
I firmly believe is that the community 
hospitals would be constantly rejuvenated 
and that the patient would be the better 
for it.
BOOK REVIEWS 
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CURRENT CONCEPTS IN HAND SUR­
GERY. Edited by John A. Boswick, Jr. 287 
pp. lllust. Lea & Febiger, Philadelphia, 
1983. $47. ISBN 0-8121-0881-7.
Is this book a useful addition to the library of 
the experienced hand surgeon or of those train­
ing for a career involving hand surgery? It is 
essentially a compilation of papers presented 
at the 9th annual Rocky Mountain Interna­
tional Seminar on Hand Surgery. Twenty-three 
of the 38 chapters are written by visiting 
faculty, while the remaining 15 are authored 
by Denver hand surgeons. Each chapter reflects 
the experience and writing skills of its author, 
thus quality is inconsistent. A broad range of 
topics is covered, many in a very sketchy man­
ner with inadequate figures and references.
Some of the authors have written similar, more 
thorough chapters elsewhere. There are, 
however, several things that can be learned, 
especially in the chapter on hand infections.
This book, which makes relatively light read­
ing, is not a must for your bookshelf.
Carolyn L. Kerrigan, md, frcsc
Assistant Professor of Surgery,
McGill University,
Royal Victoria Hospital,
Montreal, PQ,
H3A 1A1
THE MULTIPLY INJURED PATIENT  
WITH COMPLEX FRACTURES. Marvin 
H. Meyers. 423 pp. lllust. Lea & Febiger, 
P hiladelphia, 1984. $81.25. ISBN  
0-8121-0882-5.
This book is clear, concise and didactic in all 
of the subjects it exposes. The chapters per­
taining to systems in which the orthopedist is 
only occasionally involved are practical and a 
pleasure to read. Of particular interest are the 
chapters on the adult respiratory distress syn­
drome and on urologic assessment of the mul­
tiply injured patient.
The author provides enough guidelines to 
manage adequately the patient in the acute 
phase until the orthopedist can be called to take 
care of these systems and further complica­
tions.
The chapters concerned with orthopedics 
give enough detail to allow the resident and the 
young orthopedist to make rational decisions 
for the treatment of complex problems. The 
more frequent problems are: open fractures 
grades 1 to III, pelvic fractures, ipsilateral, 
femoral and tibial fractures and segmental frac­
tures of femur and tibia, ligament injuries with 
lower extremity fractures, head injury and mul­
tiple fractures.
continued on page 203
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6. The Canadian Association of General Surgeons 
and the Community Surgeon
The relationship between the Canadian 
Association of General Surgeons and the 
community surgeon is a symbiotic one. 
Despite the controversy about medical 
costs and the oversupply of physicians, 
there is and will continue to be an 
increased need for general surgeons in 
Canada. Highly trained general surgeons 
are needed in medium-sized and smaller 
communities where the bulk of general 
surgery is done. The Canadian Associa­
tion of General Surgeons sponsors 
research in education that will affect sur­
gical knowledge and the training and 
future of community surgeons.
L'Association canadienne des chirurgiens 
generaux et le chirurgien communautaire 
ont I'un pour I'autre un rapport symbio- 
tique. En depit du debat qui a cours con- 
cernant les couts des soins medicaux et 
le surplus de medecins, il existe et il con­
tinues d'exister un besoin croissant de 
chirurgiens generaux au Canada. Des 
chirurgiens generaux possedant une 
solide formation sont requis dans les 
agglomeration de petite et moyenne 
tailles ou la majeure partie de la chirurgie 
generate est pratiquee. L'Association 
canadienne des chirurgiens generaux 
soutient la recherche dans le domaine de 
I'education touchant les connaissances 
chirurgicales, ainsi que la formation et le 
futur des chirurugiens communautaires.
Does the community surgeon need the 
Canadian Association of General Sur­
geons?
The association’s board meeting 
agenda this year shows that the creation
Presented as part o f a symposium on surgi­
cal manpower in the smaller community at 
the 54th annual meeting o f the Royal Col­
lege o f  Physicians and Surgeons of 
Canada, by the Royal College in coopera­
tion with the Canadian Association o f  
General Surgeons, Vancouver, BC, Sept.
11, 1985
Accepted for publication Nov. 1, 1985
Reprint requests to: Dr. R.H. Railton, 
Medical Arts Building, 165 Plymouth Rd., 
Welland, Ont. L3B 3E1
of a general surgery task force has been 
discussed especially to look into the 
danger of fragmentation of general sur­
gery by special-interest groups. A com­
mittee on community surgery has been set 
up. State-of-the-art advice has been 
sought and is given, for example this year 
on antibiotic prophylaxis in colorectal 
surgery.
The Canadian Association of General 
Surgeons has taken off like a house on 
fire and now has over 1000 members, 
making it the largest surgical association 
in Canada. The first clinical meeting held 
at the Royal York Hotel in Toronto 
enjoyed a good turnout of community as 
well as academic surgeons, with Profes­
sor Goligher as the highlight speaker. 
Program committees worked diligently, 
with the consequence that general sur­
geons are coming back to the Royal Col­
lege meetings in increasing numbers. The 
Canadian Association of General Sur­
geons’s program is now regarded as an 
important part of continuing medical 
education, as well as a chance for mem­
bers to see old friends and find out what 
is really going on in the communities and 
the medical schools. Increased commit­
tee activity has increased expenses and 
forced a re-examination of our involve­
ment with the Royal College. The possi­
bility of making use of the Royal College 
of Surgeons’ expense allowances is being 
considered. Better budgeting procedures 
and increased use of teleconferencing 
have all helped. This has allowed us to 
keep our dues extremely low.
Our interest in continuing medical edu­
cation for the community surgeon 
encouraged us to become involved with 
SurgSat (video taped continuing medical 
education for surgeons). The spin off has 
improved our membership and financial 
situation and the programs have been of 
value to residents as well as to the prac­
tising surgeon.
The community surgeon has often felt 
alienated from the Royal College of Phy­
sicians and Surgeons, considering it to be 
the forum of the academic surgeon. He 
has fallen into the trap of the old “ town- 
gown” antipathy. A membership poll, 
however, clearly showed that the majority
of members wish to hold the annual meet­
ing in conjunction with that of the Royal 
College. This relationship is improving 
steadily with effort and better communi­
cation. It continues to be monitored and 
may be changed.
Efforts to maintain a bilingual associ­
ation have been made from the start and 
have ensured enthusiastic support from 
French-speaking surgeons, with input to 
all committees. Community surgeons are 
represented on the Advisory Council and 
on the Executive.
The Canadian Association of General 
Surgeons has been and is sponsoring 
research in education that will affect sur­
gical knowledge and training and the 
future community surgeon. Accumulated 
data on the surgical needs of the commu­
nity are already influencing the training 
of general surgeons that many felt was 
becoming too restricted. The association 
has vigorously promoted endoscopy as an 
integral part of general surgery. It is now 
mandatory in surgical training programs. 
The annual course in endoscopy is 
increasing in popularity and is dedicated 
to making all interested community sur­
geons proficient in endoscopy.
Our association has provided surgical 
tariff committees with information use­
ful to them in discussions with their 
provincial organizations. Manpower 
studies are ongoing and are typical of the 
increased medical-political activity that 
will be required in the future.
Gradually the Canadian Association of 
General Surgeons is accumulating data on 
surgical practice and should be a resource 
for such information. We have heard 
from Dr.Jnglis about the results of our 
questionnaire sent to surgeons in smaller 
communities. A previous study by Dr. 
MacKenzie,1 a general practitioner and 
economist from Kingston, showed that 
the average general surgeon is much older 
than the other surgical specialists. We are 
joining the Royal College in the joint 
Royal College/Canadian Medical Associ­
ation (CMA) project on peer validation, 
which is a cross-check on the CMA Phy­
sician Resource Data Bank.
The CMA Special Committee on Med­
ical Manpower reported to its General
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Council on Aug. 15, 1985 (unpublished 
data). The report was referred back 
without action, and opinions will be 
sought from this association, as well as 
others. The committee in its report 
became involved with control on physi­
cians entering general practice and was 
opposed by the Canadian Association of 
Internes and Residents and other groups. 
One “ non-problem” identified was that 
a general surgeon may not be competent 
to deliver primary care, and the report 
suggested changes in licensure to prevent 
this.
The Federal/Provincial Advisory Com­
mittee on Health Manpower was direct­
ed by the Conference of Deputy Ministers 
of Health to undertake a short-term study 
on medical manpower in Canada in late 
1982. Their report2 was released in mid- 
July 1985. It stated that physician man­
power supply requirements, distribution 
and costs are a concern. In the 20 years 
from 1961 to 1980, the physician supply 
more than doubled, while the population 
increased by one third. The physician to 
population ratio increased from 1:1004 to 
1:643. The committee used the Southam 
medical data base which has been criti­
cized by the CMA committee and the 
Canadian Association of Internes and 
Residents, but it was the best medical 
manpower data bank available at the 
time. The Hall Report3 and other man­
power studies4 have all suggested a phy­
sician oversupply. Strategies to reduce this 
oversupply are recommended, such as 
cutting down medical school enrolment 
and physician immigration, but the 
recommendation is to increase surgical 
training. Shortages in surgical and labora­
tory specialties are predicted by the year 
2000. Some of the recommendations are
impractical but in spite of all the rhetor­
ic from ministries of health about the 
oversupply of physicians and the stated 
intent to reduce the number of specialists, 
a shortage of surgeons is predicted. Some 
of the numbers in the report are of in­
terest (Table I).
What does all of this mean? Despite the 
controversy about medical care costs and 
the oversupply of physicians, there is and 
will continue to be an increased need for 
general surgeons in Canada. This is of 
great importance to program directors.
Trunkey and Blaisdell5 in the July 
1985 Bulletin o f the American College o f  
Surgeons cried out against a return to the 
“ barber surgeon” who cuts when and 
where he is told. They promote the con­
cept of the broadly trained general sur­
geon who can provide global and com­
prehensive surgical care. Surgeons should 
be constantly reminded that they have 
advanced from barber surgery to the 
present state of excellence through the 
introduction of scientific principles. 
Canadian Association of General Sur­
geons’ committees have struggled for 
years over a good definition of general 
surgery and have at last come up with 
such a statement. With a background in 
anatomy, physiology and pathology, such 
highly trained general surgeons are 
needed in medium-sized and smaller com­
munities where the bulk of general sur­
gery is done.
Frank Turner, who organized this sym­
posium, has sometimes questioned the 
relevance of the Canadian Association of 
General Surgeons to the community sur­
geon, citing the proliferation of societies 
offering useful continuing medical edu­
cation. He has been like the boy who 
pointed out that the Emperor wasn’t
wearing any clothes and has made all of 
us consider our raison d ’etre. I think 
today’s panel has helped answer the ques­
tion, “ Do community surgeons need the 
Canadian Association of General Sur­
geons?” Of course they do. More impor­
tantly, the association needs the commu­
nity surgeon.
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Table I—Features of Interest From the Report2 of the Federal/Provincial Advisory Committee on
Health Manpower
1. General surgeon supply -  December 1980:
Canada 2106 New Brunswick 57
British Columbia 253 Nova Scotia 94
Alberta 154 Prince Edward Island 10
Saskatchewan 70 Newfoundland 29
Manitoba 94 Yukon Territories 4
Ontario 741
Quebec 600
2. Annual average inflow from 1979 to 1982 -  70 per year.
3. In 1980 the number of general surgeons who had graduated from Canadian medical schools between 
1942 and 1961 was 1246 and it is assumed that these surgeons will retire or die by the year 2000.
4. Outflow annually 
(1981-1990)
Retired or dead 56.3
Moved 20.8
Returned to training 
(1991-2000)
11.0
Retired or dead 68.3
Moved 17.1
Returned to training 11.0
5. Target 1980 is 1971 general surgeons. This gave a surgeon to population ratio of 1:12 292.
6. The age-sex adjusted increase in requirements for 1981 to 2000 is 640.6.
7. The female productivity adjustment is 55.8 and by the year 2000 target is 2667.4.
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Dosage adjustment should be made in renal insufficiency.
PIPRACIL* is a monosodium compound containing 1.98 milliequivalents (45.5 mgl of Na -+- per gram based on 
vial content which includes the U.S.P. allowed average. The calculated value, based on molecular weight is 1.85 
mEq/g (42.55 mg). Periodic electrolyte determinations should be made in patients w ith  low potassium reserves 
and the possibility of hypokalemia should be kept in mind w ith  patients who have potentially low potassium 
reserves, receiving cytotoxic therapy or diuretics. Electrolyte and cardiac status should also be monitored during 
prolonged-treatment in patients w ith  impaired cardiac function.
Prior to treatment, patients w ith  gonorrhea should also be evaluated for syphilis. Specimens for darkfield 
examination should be obtained from patients w ith  any suspected primary lesions, and serologic tests should be 
performed. In all cases where concomitant syphilis is suspected, monthly serological tests should be made for a 
minimum of 4 months.
The use of penicillins (ampicillin, amoxicillin) has been associated w ith  morbilli form rashes in some cases of 
infectious mononucleosis. PIPRACIL* should be used w ith caution in the treatment of patients w ith  infectious 
mononucleosis.
Drug Interactions: The mixing of PIPRACIL* w ith  an aminoglycoside in vitro can result in substantial inactivation 
of the aminoglycosides.
Usage During Pregnancy or Lactation: Safety of PIPRACIL* use in pregnant women has not been determined. 
Because animal reproduction studies are not always predictive of human response, this drug should be used 
during pregnancy only if clearly needed. It has been found to cross the placenta in rats. Caution should be 
exercised when PIPRACIL* is administered to nursing mothers. It is excreted in low concentrations in milk. 
Pediatric Use: Dosages for children under the age of 12 have not been established.
ADVERSE REACTIONS: PIPRACIL* is generally well tolerated. The most common adverse reactions have been 
local in nature, following intravenous or intramuscular injection. The following adverse reactions may occur:
Local R eactions-ln  clinical trials thrombophlebitis was noted in 3.8% of patients. Pain, erythema, and/or 
induration at the injection site in 1.9% of patients. Less frequent reactions: ecchymosis, deep vein thrombosis 
and hematomas. Hypersensitivity Reactions-Rash was noted in 1.9% of patients. Drug fever 2.1%. Less 
frequent findings: Pruritus, vesicular eruptions, positive Coombs tests. Gastrointestinal-Diarrhea and loose 
stools were noted in 2.8% of patients. Less frequent reactions: vomiting, nausea, bloody diarrhea. 
Hepatic-Increases in liver enzymes (LDH, SGOT, SGPT), hyperbilirubinemia. Rarely, cholestatic hepatitis. 
Renal-Elevations of creatinine or BUN. Central Nervous System-Headache, dizziness, fatigue Hemic and 
Lymphatic-Reversible leukopenia, thrombocytopenia and/or eosinophilia, bleeding and decreases in prothrombin 
time have been reported. Reversible leukopenia (neutropenia) is more apt to occur in patients receiving prolonged 
therapy at high dosages or in association w ith  drugs known to cause this reaction. Serum Electrolytes-lndividualt 
w ith  liver disease or individuals receiving cytotoxic therapy or diuretics, were reported rarely to demonstrate a 
decrease in serum potassium concentrations w ith  high doses of PIPRACIL*. Musculo-Skeletal-Rarely, prolonged 
muscle relaxation. Other-Superinfection, including candidiasis.
ADMINISTRATION
Intramuscular: When indicated by clinical and bacteriological findings, intramuscular adminstration of 6 to 8 g 
daily of PIPRACIL* in divided doses, may be utilized for initiation of therapy and this route may be considered for 
maintenance therapy after clinical and bacteriologic improvement has been obtained w ith intravenous piperacillin 
sodium treatment. Administration should not exceed 2 g per injection at any one site. This route has been used 
primarily in the treatment of patients w ith  uncomplicated gonorrhea and urinary tract infections.
Adults and Children More Than 12 Years of Age: The reconstituted solution is given by deep intramuscular 
injection. The preferred site of injection is the upper outer quadrant of the buttock li.e. gluteus maximus). Also 
may be given in the mid-lateral muscles of the thigh. The deltoid area should be used only if well developed, and 
then only w ith  caution to avoid radial nerve injury. Intramuscular injection should not be made into the lower or 
mid-third of the upper arm.
Intravenous: The intravenous route should be used in the treatment of serious infections.
Direct Intravenous (Bolus) Injection: The vials should be reconstituted w ith  5 mL of suitable diluent listed below 
and the resulting solution should be injected slowly over a period of 3 to 5 minutes to help avoid vein irritation. 
Intravenous Infusion: A dilution of at least 15 mL per gram is recommended to reduce potential for vein 
irritation. The reconstituted and diluted solution may be administered by interm ittent or continuous drip.
Intermittent infusion should be administered over a period of about 30 minutes. During intermittent infusion it is 
desirable to discontinue the primary intravenous solution. Any unused portion must be discarded. For continuous 
infusion the solution may be administered over a longer period of time 
RECONSTITUTION
For Intramuscular Use: Solutions for Reconstitution: Sterile Water for injection, or if required Bacteriostatic 
Water for Injection, Lidocaine HC1 0.5 or 1% (without epinephrmel-For Intramuscular Use Only.
For Intravenous Use: Solutions for Reconstitution: Sterile Water for Injection, or if required, Bacteriostatic Water 
for Injection. Either parabens or benzyl alcohol. Lidocaine HC1 is contraindicated in patients w ith  a known history 
of hypersensitivity to local anesthetics of the amide type.
RECONSTITUTION TABLE
Product Size
Volume of Diluent 
to be added
Approximate Available 
Volume
Approximate Average 
Concentration
Vials 2 g 4.0 mL 5.0 mL 1 g/2.5 mL
3 g 6.0 mL 7.5 mL 1 g/2.5 mL
4g 7.8 mL 10.0 mL 1 g/2.5 mL
Infusion Bottles
3 g 15 mL 17 mL
4g 20 mL 23 mL
The prepared solution may be further diluted to the desired volume w ith any of the solutions for intravenous 
infusion listed below.
The contents of the 3 and 4 g infusion bottles should be diluted to at least 15 mL per gram.
The appropriate quantity of reconstituted solution may be added to an intravenous bottle or bag containing any 
of the solutions for intravenous infusion listed below.
Solutions for Intravenous Infusion:
Intravenous Solutions:
5% Dextrose in Water (DWV).
0.9% Sodium Chloride (Normal Saline) (NS). 
Dextrose 5% and 0.9% Sodium Chloride (D&NS) 
Lactated Ringer's Injection, U.S.P.
Dextran 6% in 0.9% Sodium Chloride
Intravenous Admixtures:
Normal Saline I +  KCL 40 mEq.)
5% Dextrose/Water |D,W) ( +  KCL 40 mEq).
5% Dextrose/Normal Saline (Dr.NS) ( +  KCL 40 mEq). 
Ringer's Injection, U.S.P. I +  KCL 40 mEq).
Lactated Ringer's Injection, U.S.P. I +  KCL 40 mEq).
STABILITY OF SOLUTIONS: PIPRACIL* is stable in both glass and plastic containers when reconstituted w ith  
recommended diluents and further diluted w ith  the indicated intravenous solution and intravenous admixtures. 
Stability studies have demonstrated chemical stability (pH, potency and clarityl through 24 hours at room tern 
perature and up to 72 hours refrigerated. Appropriate consideration of aseptic technique, however, recommends 
discarding unused portions after storage for 24 hours at room temperature or 48 hours refrigerated If used as a 
multi dose container, the vials must be reconstituted only w ith the bacteriostatic diluents noted above 
INCOMPATIBILITY: Because of chemical instability, PIPRACIL* should not be used for intravenous 
administration w ith solutions containing sodium bicarbonate.
PIPRACIL* should not be added to blood products, protein hydrolysates or amino acids.
When PIPRACIL* is given concurrently w ith  aminoglycosides, it is recommended that both drugs be used in full 
therapeutic doses, but administered separately. PIPRACIL* should not be mixed w ith an aminoglycoside in a 
syringe or infusion bottle, since this can result in inactivation to the aminoglycoside.
DOSAGE FORMS: PIPRACIL* (sterile, lyophilized piperacillin sodium) is available in vials containing amounts of 
piperacillin sodium equivalent to 2, 3 and 4 grams of piperacillin. Available in boxes of 12 vials.
Product Numbers: 2 g/vial-3879 48 3 g/via l-3882 49 4 g/vial-3880 50
Available in 100 mL size infusion ("piggyback") bottles, containing sterile, freeze-dried piperacillin sodium powder 
equivalent to 3 and 4 grams of piperacillin. Boxes of 12 infusion bottles.
Product Numbers: 3 g/bottles-3882 41 4 g/bottles-3880-42.
Pipercillin Sensitivity Discs impregnated w ith  100 j/g  of piperacillin are also available.
Storage: PIPRACIL'vials and infusion bottles should be stored at controlled room temperatures of 15 30°C 
(59-86°F).
Pipercillin Sensitivity Discs should be refrigerated upon receipt. Product Monograph available on request.
DOSAGE AND ADMINISTRATION: PIPRACIL* may be administered by the intramuscular route or intravenously 
by injection or infusion. Dosage and route of administration should be determined by the severity of the infection 
and condition of the patient. The usual dosage for serious infections is 3 to 4 grams given every 4 to 6 hours as a 
20 to 30 minute infusion administered intravenously. The maximum daily dose usually administered to adults is 
24 g/day, although higher doses have been used.
__________  DOSAGE
Type of Infection Usual Total Daily Dosage Frequency of Administration
Serious infections such as septicemia, nosocomial 12-18 gl.V. Every 4 to 6 hours
pneumonia, intra-abdominal infections, aerobic (200-300 mg/kgl
and anaerobic gynecologic infections, and skin
soft-tissue infections.
Complicated urinary tract infections. 8-16 g I.V. (125 200 mq/kql Every 6 to 8 hours
Uncomplicated urinary tract infections and most 6-8 g I.M. or I.V. Every 6 to 12 hours
community-acquired pneumonia. 1100-125 mg/kgl
Uncomplicated gonococcal urethritis. 2 g I.M .* Single dose
*0ne gram of probenecid given orally 1/2 hour prior to injection.
Dosage in Renal Impairment
Creatinine Clearance 
mL/min.
Urinary Tract Infection Urinary Tract Infection 
(uncomplicated) (complicated)
Serious Systemic 
Infection
> 4 0 No dosage adjustment necessary
20-40 No dosage adjustment necessary 9 g/day 3 g every 8 hrs. 12 g/day 4 g every 8 hrs.
< 2 0 6 g/day 3 g every 12 hrs. 6 g/day 3 g every 12 hrs. 8 g/day 4 g every 12 hrs.
Patients on 
Hemodialysis*
'Hemodialysis removes 30-50% of piperacillin in 4 hours; 
1 g additional dose should be administered following 
each dialysis period.
6 g/day 2 g every 8 hrs.
For patients w ith renal failure and hepatic insufficiency, measurement of serum levels of PIPRACIL* w ill provide 
additional guidance for adjusting dosage.
Infants and Children-Dosages m infants and children under 12 years of age have not been established.
The average duration of PIPRACIL* treatment is from 7 to 10 days, except for gynecologic infections, in which 
it is from 3 to 10 days; the duration should be guided by the patient's clinical and bacteriological progress. For 
most acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes 
asymptomatic. Therapy for Group A beta-hemolytic streptococcal infections should be maintained for at least 10 
days to reduce the risk of rheumatic fever of glomerulonephritis.
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Reoperation After Failed Esophagomyotomy
for Achalasia
Of 49  patients with achalasia treated 
surgically between 1 9 7 5  and 1985 , 12 
(8 women, 4  men) had undergone trans­
thoracic esophagom yotom y previously. 
Four had had concom itant upper gas­
trointestinal surgery. All 12 patients 
complained of dysphagia; other sym p­
toms included regurgitation, nocturnal 
aspiration, heartburn, chest pain, vomit­
ing, upper gastrointestinal bleeding and 
weight loss. The average time from ini­
tial operation to onset of sym ptom s was 
9 months. Preoperative investigations 
and operative findings identified the 
cause of dysphagia as inadequate or 
healed esophagom yotom y with persis­
tent or recurrent achalasia (eight 
patients — two had partially disrupted fun- 
doplications contributing to their dyspha­
gia), hiatus hernia with reflux esophagitis 
causing esophageal spasm  or peptic 
esophageal stricture (two patients) and 
incorrect initial d iagnosis and treatment 
(two patients). Treatment, with the aid 
of intraoperative manometry, included 
repeat Heller m yotom y (five patients),
Hill antireflux repair (four patients), 
takedown of N issen fundoplication and 
extension of m yotom y (two patients).
The average follow-up w a s 16 months. 
Eight patients had good results, two 
required further operation and one under­
went multiple dilatations postoperatively.
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The causes of recurrent dysphagia fol­
low ing surgery for achalasia are diverse 
and patients require individualized inves­
tigation and treatment. Remedial surgery 
for achalasia can correct postoperative 
dysphagia but results are less successfu l 
than those following an adequate initial 
operation.
De 4 9  patients souffrant d 'achalasie qui 
ont ete operes entre 1 9 7 5  et 1985 , 12 
(8 femmes et 4  hommes) avaient prece- 
demment subi une oesophago-m yotom ie 
transthoracique. Quatre avaient eu une 
chirurgie des voies gastro-intestinales 
superieures. Les 12  patients se plai- 
gnaient de dysphagie et autres sympto- 
mes dont regurgitation, aspiration noc­
turne, brulure d 'estom ac, douleur 
thoracique, vomissement, saignement 
gastro-intestinal haut et perte de poids. 
Les examens preoperatoires et les obser­
vations a I'operation ont identifie com me 
cause de dysphagie, une oesophagom yo- 
tomie inadequate ou cicatrisee avec acha- 
lasie persistante ou recidivante (huit 
patients dont deux avaient comme fac- 
teur contribuant & la dysphagie, un 
derangement de fundoplicature), une her- 
nie hiatale avec reflux oesophagien cau- 
sant un spasm e oesophagien ou un retre- 
cissement oesophagien (deux patients), 
et un diagnostic initial et un traitement 
errone (deux patients). Le traitement 
avec manometrie operatoire a compris 
une seconde myotomie de Heller (cinq 
patients), une correction antireflux de Hill 
(quatre patients), defaire une fundoplica­
ture de N issen et une extension de m yo­
tomie (deux patients). La periode 
d 'observation postoperatoire est de 16 
mois. Huit patients montrent de bons 
resultats, deux ont necessity une nou- 
velle operation et un a subi de multiples 
dilatations postoperatoires. Les causes 
de dysphagie recidivante apres une ope­
ration pour achalasie sont variees et elles 
exigent des exam ens et un traitement
individualises. Les operations destinees a 
corriger I'achalasie  sont susceptibles 
d'ameliorer la dysphagie postoperatoire 
mais elles y arrivent m oins frequemment 
que lors d 'u n e  operation primaire reussie.
Controversy surrounds the current 
management of patients with achalasia of 
the esophagus. Pneumatic dilatation of 
the lower esophageal sphincter or modi­
fied Heller esophagomyotomy are the two 
primary therapeutic modalities.1,2 Physi­
cians who favour myotomy as the treat­
ment of choice disagree on its extent3-5 
and the need for a concomitant hiatal her­
nia repair.5,6 Since there is no standard 
operative technique, results of individual 
series are difficult to compare. Most ser­
ies report excellent or good results from 
myotomy in 90% to 95% of cases.3,7 
However, complications do occur, result­
ing in persistent, recurrent or new sym­
ptoms. Knowledge of the physiology of 
normal esophageal function as well as the 
pathophysiology of the disease process 
are prerequisites for a proper operative 
approach. When reoperation is necessary 
this is even more important because the 
cause of the patient’s symptoms may be 
entirely different from that of the origi­
nal motility disorder. We reviewed our 
experience with reoperative surgery after 
failed Heller esophagomyotomy at the 
Virginia Mason Medical Center in Seattle.
Patients and Methods
Between 1975 and 1985, 49 patients 
with achalasia were assessed and treated 
surgically. Of these, 12 (8 women, 4 men) 
had previously undergone a transthoracic 
esophagomyotomy elsewhere. The mean 
age was 38.6 years (ranging from 17 to 
62 years). The mean time to recurrence 
of symptoms postoperatively was 9 
months (ranging from 3 to 24 months), 
and the mean time to remedial surgery 
was 24 months (ranging from 3 to 48
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months). Four patients had undergone 
concomitant upper gastrointestinal proce­
dures (two Nissen fundoplications and 
two pyloroplasties). Before reoperation 
all patients underwent upper gastrointes­
tinal roentgenography, endoscopy, 
esophageal manometry (also performed 
intraoperatively), pH reflux testing and 
esophageal radionuclide scintigraphy. 
Preoperatively and intraoperatively every 
effort was made to define the reason for 
the failure of the previous operation. The 
reoperative technique was tailored to cor­
rect the specific cause of failure of the ini­
tial procedure.
Results
All patients complained of recurrent or 
persistent dysphagia to both solids and 
liquids. Aspiration recurred as the main 
symptom in three patients. Regurgitation 
occurred in three others, two of whom 
also had heartburn as a new symptom. 
Chest pain, protracted vomiting, weight 
loss and upper gastrointestinal hemor­
rhage with hematemesis were present in 
one patient each.
The causes for failed operation were 
classified as unsuccessful myotomy (eight 
patients), complication of myotomy (two 
patients) and incorrect primary therapy 
(two patients). Myotomy was unsuccess­
ful in four patients because it was not 
extended far enough distally to divide the 
sphincter adequately. In two patients the 
myotomy had healed completely with scar 
tissue. In one patient intact muscle fibres 
were identified at the base of the previ­
ous myotomy. In one patient the 
myotomy was not carried far enough 
proximally (Fig. 1).
Complications of the myotomy took 
the form of gastroesophageal reflux. In 
one of the two patients the myotomy was 
extended too far distally to the anterior 
gastric wall, causing ulcerative esophagi­
tis and a peptic esophageal stricture. The 
other patient had a large hiatus hernia 
postoperatively with secondary eso­
phageal spasm (Fig. 2). This was not 
present at the time of the original 
esophagomyotomy.
Incorrect primary therapy resulted in 
development of gastroesophageal reflux 
in two patients. A patient with a 
Schatzki’s ring misdiagnosed as achala­
sia, had severe chronic ulcerative esopha­
gitis with peptic esophageal stricture after 
myotomy. The other patient underwent 
myotomy for a short distal esophageal 
stricture rather than achalasia. This 
patient also suffered chronic gastro­
esophageal reflux with a recurrent 
stricture.
Remedial operations were individual­
ized. Manometry was used intraopera­
tively to determine the pressure and length 
of the lower esophageal sphincter. Oper­
ative procedures included repeat Heller 
myotomy (four patients), antireflux 
operation (posterior fixation sphincter 
calibration—Hill procedure) with dilata­
tion of a peptic stricture (four patients), 
takedown Nissen fundoplication plus 
repeat Heller myotomy (two patients), 
repeat Heller myotomy plus reconstitu­
tion of the gastroesophageal flap valve 
(two patients). Following repeat myotomy 
in two patients, the cardia was found to 
be incompetent by palpation, and 
manometry carried out intraoperatively 
revealed that the sphincter muscle had 
been completely divided. Therefore a flap 
valveplasty was performed at the gas­
troesophageal junction. Through a gas- 
trotomy, musculomucosal sutures were 
placed in the stomach so that a fold of 
muscularis and mucosa overlapped the 
gastroesophageal junction. The intraoper­
ative measurements of lower esophageal 
sphincter pressure before and after 
remedial operation are shown in Fig. 3 
and Table I. The length of the sphincter 
in the first three groups was reduced from 
2.5 cm to between 0.9 and 1.5 cm. The 
length of the sphincter in the Hill 
antireflux repair group was increased 
from 2.0 cm to 4.0 cm (Fig. 4).
Good results were obtained in nine 
patients (75%), who had only minimal 
dysphagia and no gastroesophageal 
reflux. The result was fair in one patient 
(8%) who continued to have dysphagia 
requiring intermittent dilatation. Two 
patients (17%) had a poor result and 
required a subsequent operation for relief 
of dysphagia.
Discussion
Persistent or recurrent dysphagia fol­
lowing a Heller esophagomyotomy for 
achalasia is particularly distressing for 
patients who have undergone surgery 
expecting relief of this symptom. It is 
equally disturbing for the surgeon who 
has performed what he expects to be a 
curative operation. Recurrent or persis­
tent symptoms after a myotomy indicate 
that the operation has been inadequate 
whereas new symptoms (i.e. hemateme­
sis) indicate complications of the 
myotomy. In this series and others8-9 
symptoms recurred within 9 months of a 
failed operation. However, a remedial 
operation is delayed an average of 2 years 
and occasionally as long as 4 years 
because the patient and physician are 
reluctant to go ahead with further surgery 
for what they believe is the same original 
problem. Although dysphagia was 
present in all of our patients, the reasons 
for its recurrence were multiple and 
included continued cardiospasm, peptic 
esophageal stricture and secondary 
esophageal spasm. Some patients com­
plained of regurgitation, heartburn, chest
Fig. lb
Fig. lc
FIG. 1—(a) Preoperative esophagogram. 
Inadequate length of myotomy proximally with 
persistent achalasia and development of 
megaesophagus, (b) Intraoperative manome­
try identifies peak pressure in lower esophageal 
sphincter of 100 mm Hg over 4 cm. (c) Post­
operative esophagogram. Esophagus is less 
dilated and there is no delay in transit of 
barium.
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pain and hematemesis which were new 
symptoms and were more troublesome 
than their dysphagia.
These difficult problems require the full 
armamentarium of modern diagnostic 
tests to identify the type of motility dis­
order as well as the reason for failure of 
the previous operation. Remedial surgery 
is then individualized to correct the 
problem identified. This operation is tech­
nically more demanding than the original 
procedure because of intense scarring that 
occurs both in the mediastinum and the 
upper abdomen. The anatomy must be 
redefined before undertaking repair, but 
dissection of the scar tissue often results 
in attenuation of the remaining normal 
tissue, compounding the difficulty of the 
operation.
Our classification of indications for 
reoperation is similar to that of others.8’9 
A clear distinction is made between
FIG. 2—Iatrogenic hiatal hernia after Heller 
esophagomyotomy caused by overzealous hia­
tal dissection. Hill antireflux repair was used.
FIG. 3—Intraoperative lower esophageal 
sphincter pressures before (white bars) and 
after (hatched bars) remedial operation.
patients having an unsuccessful myotomy 
with continued achalasia and patients 
having a complication of the myotomy 
causing gastroesophageal reflux. The 
third group — patients having incorrect 
primary therapy — has not previously 
been described.
Myotomy may be unsuccessful for var­
ious reasons. Imperfect technique results 
in an inadequate length of myotomy 
either proximally or distally, or in in­
adequate depth. Nonrelaxing lower 
esophageal sphincter muscle remains and 
symptoms persist or recur soon after 
operation. This was the reason for 
remedial surgery in five patients. If the 
muscularis is not dissected away from the 
submucosa for approximately 50% of the 
esophageal circumference, the myotomy 
may heal together rapidly, resulting in 
early recurrence of symptoms.9'10 This 
was the cause of failure in two patients 
in this series. Patients presenting with a 
megaesophagus have poorer results fol­
lowing myotomy than if they had been 
operated on earlier.11 Fekete and 
associates8 reoperated on 10 patients 
with megaesophagus who had unsuccess­
ful Heller myotomies. Eight required 
resection with colon interposition and two 
had repeat myotomy. One of our patients 
also had a megaesophagus (Fig. 1). Thick­
ened circular muscle fibres were found 
at the apex of the myotomy, indicating 
inadequate proximal length of myotomy. 
Following extension of the myotomy, the 
patient was symptom-free and her upper 
gastrointestinal roentgenogram showed 
reduction in size of the esophagus. Inter­
stitial or periesophageal fibrosis and 
esophageal cancer have been de­
scribed8,10 as causes of unsuccessful 
myotomy. We did not encounter these 
problems in our series.
Complications of Heller myotomy 
occur when it is carried too far distally. 
The gastroesophageal junction becomes 
incompetent and reflux occurs. Due to 
disordered or absent motility in the body 
of the esophagus in achalasia, prolonged 
contact of acid with the esophageal 
mucosa causes severe esophagitis. Over- 
zealous hiatal dissection, resulting in an 
iatrogenic hiatus hernia may also cause 
reflux esophagitis. The myotomy must be 
performed without mobilizing the gas­
troesophageal junction. If the phreno-
T a b l e  1- M e a n  M e a s u r e m e n t s  ( ± S E M )  o f  L o w e r  E s o p h a g e a l  S p h i n c t e r  
P r e s s u r e  B e f o r e  a n d  A f t e r  R e m e d ia l  O p e r a t i o n
L o w e r  e s o p h a g e a l  s p h i n c t e r  p r e s s u r e ,  m m  H g
R e m e d ia l  p r o c e d u r e B e f o r e  o p e r a t i o n A f t e r  o p e r a t i o n
H e l l e r  m y o t o m y 3 6 . 0  ±  4 . 0 1 2 .5  ±  3 . 0
H e l l e r  m y o t o m y  +
f l a p  v a l v e p l a s t y 4 0 . 0  ±  3 . 0 8 .5  ±  1 .8
T a k e d o w n  N i s s e n  
f u n d o p l i c a t i o n  +
H e l l e r  m y o t o m y 2 7 .5  ±  2 .7 9 .0  ±  1 .2
H il l  a n t i r e f l u x  r e p a ir 6 . 5  ±  1 .8 3 6 .0  ±  3 . 2
esophageal bundles are damaged during 
operation, the gastroesophageal junction 
is free to migrate into the mediastinum. 
Each of these complications occurred in 
our series. Inadequate hemostasis at the 
myotomy site causing periesophageal 
fibrosis has been described as a cause of 
failure.12 This was not identified in our 
series.
The primary therapy was incorrect in 
two patients in this series. One had a 
Schatzki’s ring and the other peptic 
esophageal stricture at the time of 
myotomy. The condition of each was mis­
diagnosed as being achalasia, and 
myotomy caused subsequent development 
of severe reflux esophagitis. These dis­
turbing complications developed because 
the preoperative investigation was inade­
quate or interpretation of the findings of 
preoperative studies was incorrect.
The controversy continues with respect 
to the length of the esophagomyotomy3-5 
and the necessity for concomitant 
antireflux surgery.5,6 We use manometric 
pressure measurements intraoperatively 
as an adjuvant to surgery in patients with 
esophageal motility disorders.13 The 
technique allows us the luxury of an 
objective intraoperative assessment of the 
length of the myotomy necessary and 
eliminates the need for concomitant hia­
tal hernia repair. In repeat operations 
when there may be uncertainty about the 
extent of the previous myotomy, this 
measurement is invaluable. We, and 
others, believe that the addition of a rou­
tine antireflux repair is not only unneces­
sary but inadvisable because it replaces 
the physiologic obstruction of the lower 
esophageal sphincter with an anatomic 
obstruction composed of an antireflux 
repair.9 In two patients we found that a 
fundoplication augmented lower eso­
phageal sphincter pressure to the point at 
which the dysmotile esophagus could not 
propel swallowed bolus through the 
sphincter. Ellis and Gibb9 reported simi­
lar cases in which myotomy plus fun­
doplication resulted in com plete 
esophageal obstruction  because 
esophageal peristalsis was inadequate to 
overcome the obstruction caused by the 
fundoplication.
Recently we reoperated on two patients 
in whom the gastroesophageal junction 
was palpably incompetent following
FTG. 4—Length of lower esophageal sphinc­
ter before (white bars) and after (hatched bars) 
remedial operation.
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repeat myotomy. A gastroesophageal flap 
valveplasty was performed to prevent 
reflux. Both patients had no dysphagia 
and no clinical or radiologic evidence of 
reflux postoperatively. This technique 
was devised with cadaver dissections. The 
valve prevents reflux of gastric acid but 
does not increase lower esophageal 
sphincter pressure and is therefore ideal 
in achalasia. This technique is now being 
evaluated at a number of institutions.
Our results (75% good, 8% fair, 17% 
poor) are similar to those in other series 
of remedial surgery for achalasia.8,9’12 It 
is apparent that reoperation does not 
achieve as good results as after effect­
ive primary therapy.3'7 Therefore it is 
important to perform an adequate 
myotomy initially and yet not be so 
aggressive as to cause gastroesophageal 
reflux.
We conclude that the best treatment for
patients with achalasia should be to pre­
vent symptom recurrence by adequate 
primary therapy. In our hands, intraoper­
ative manometry has been invaluable in 
this respect. When symptoms do recur, 
intensive investigations are necessary to 
determine the cause of the failure. 
Individualized remedial surgery is 
required to correct the problem. In these 
difficult cases intraoperative manometry 
to determine both the sphincter pressure 
and length is critical in obtaining a good 
postoperative result.
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Endobronchial Carbon-Dioxide Laser Therapy
<V -
Twenty-four patients underwent single 
and multiple carbon-dioxide laser treat­
ments for endobronchial lesions at the 
Mount Sinai Hospital in Toronto. Fifteen 
had malignant disease, 2 had benign 
tumours and 7 had benign strictures. 
Rigid bronchoscopy with Venturi ventila­
tion was used in all. with the C02 laser 
therapy directed down the open end of 
the bronchoscope. In the majority of 
cases laser therapy was combined with 
mechanical debridement, consisting of 
removal with biopsy forceps and use of 
the end of the rigid bronchoscope to 
"core out" the tumour mass. Assess­
ments were made subjectively by the 
patient and objectively by bronchoscopic 
examination and post-treatment roent­
genography. Worthwhile improvement
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was noted in patients who had proximal 
malignant lesions and those with benign 
lesions at all levels. Overall there was an 
effective improvement in 18 of the 24 
patients.
Au Mount-Sinai Hospital de Toronto, 24 
patients souffrant de lesions endobron- 
chiques ont subi un ou plusieurs traite- 
ments au laser de bioxyde de carbone. 
Quinze etaient atteints de cancer, 2 de 
tumeurs benignes et 7 de retrecissement 
benins. Dans tous les cas, on a utilise un 
bronchoscope rigide avec ventilation de 
Venturi; le rayon laser au C 02 a ete 
dirige a travers I'orifice du bronchos­
cope. Dans la majorite des cas le traite- 
ment laser a ete associe a un debride­
ment mecanique a I'aide de forceps de 
biopsie et a I'utilisation de I'extremite du 
bronchoscope rigide pour enlever le 
coeur de la masse tumorale. Des appre­
ciations subjectives ont ete faites par le 
patient, et des evaluations objectives ont 
ete realisees par bronchoscopie et radio- 
graphie post therapeutiques. Une amelio­
ration notable a ete observee chez des 
patients porteurs de lesions malignes 
proximales et ceux qui avaient des 
lesions benignes a tous les niveaux.
Dans I'ensemble, on a enregistre une 
bonne amelioration chez 18 des 24 
patients.
The application of laser technology to the 
tracheobronchial tree has continued to 
expand and has added an exciting new 
dimension to bronchology and thoracic 
surgery. Endoscopic application began in 
1973 with the use of carbon-dioxide 
(C02) laser therapy to ablate benign 
neoplasms such as tracheobronchial 
papillomas and, later, to palliate malig­
nant obstruction of the major airways.1’2 
Today, relief of airway obstruction from 
tracheobronchial tumours has become a 
common indication for laser bron­
choscopy. Our initial experience was with 
the C 0 2 laser; our more recent 
experience with the neodymium-yttrium 
aluminum garnet (NdiYAG) laser will be 
presented at a future date.
The primary indication for laser ther­
apy is to alleviate symptoms of malignant 
disease; to relieve obstruction and control 
hemoptysis. The laser removes endoscop- 
ically visible tumour from airways by 
directing energy at the tumour mass, 
causing vaporization. Therapy is deli­
vered under the direct vision of the 
endoscopist.
Patients and Methods
Over the last 18 months, 24 patients 
have undergone 50 C02 laser therapies at 
the Mount Sinai Hospital in Toronto; 13 
patients received a single treatment, 6 
underwent two treatments and 1 patient
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each received three, four, five, six and 
seven treatments. For those receiving 
more than one treatment, the frequency 
ranged from 2 days to 6 months (mean 
8 weeks). The patients ranged in age from 
31 to 84 years (mean 58 years).
The majority of the lesions were 
malignant—primary bronchogenic carci­
noma (nine patients), secondary carci­
noma of the bronchus (two), primary car­
cinoma of the trachea (three) and 
secondary carcinoma of the trachea (one 
patient) (Table I). Of nine benign lesions, 
seven were strictures: secondary to pos­
tresection granulation tissue (two), 
tracheal scarring after tracheal resection 
(three), lye burn (one) and tuberculous 
bronchostenosis (one) (Table II). The two 
remaining patients had obstructing lesions 
of a major airway due to a benign 
fibropapilloma and a carcinoid (Table 
III).
In all instances ventilation was given by 
rigid bronchoscope, using the Venturi 
ventilation technique and intravenous 
anesthesia with muscle relaxants and
sodium pentobarbital. Air oximetry was 
routine. The concentration of oxygen 
at the delivery point, at the end of 
the bronchoscope, was kept at or below 
35% to prevent laser-induced com­
bustion.
Malignant Lesions (Table I)
Fifteen patients underwent therapy for 
malignant lesions. The average age of the 
group was 62 years. Before the laser ther­
apy, several patients had received various 
other treatments such as surgery, exter­
nal radiotherapy, chemotherapy and 
endoscopy with the mechanical re­
moval of obstructing tumour. Single 
laser treatments were given in nine 
patients, and in the remaining patients the 
number of treatments varied from two to 
seven. With multiple treatments, the 
intervals between treatments varied 
between 1 week and 5 months.
One patient underwent tracheal resec­
tion after airway palliation by laser ther­
apy preoperatively, and another has been
maintained with repeated laser therapies 
for invasive and occlusive disease in his 
proximal trachea, secondary to a medul­
lary carcinoma of the thyroid. The others 
died, at intervals ranging from 1 week to 
4 months after therapy, of either 
metastatic disease or extension of local 
disease.
Benign Stricture (Table II)
Of seven patients having benign stric­
tures, five had airway resections and 
postoperative stenoses or occlusive granu­
lomas. The number of laser treatments 
varied between one and four, with inter­
vals of 2 days to 2.5 months. Laser ther­
apy was ineffective in treating a lye stric­
ture in the distal pharnyx, which was 
eventually surgically bypassed. The 
chronic stenoses produced by the tuber­
culous stricture and the stitch granulomas 
after resection did well after the laser 
treatments. In the three with acute 
stenoses after tracheobronchial resection 
with circumferential narrowing, the laser
Tab le 1— Endob ronch ia l Carbon-D ioxide Lase r The rap y  fo r  M a lig n a n t Les ions
P a tie n t
no. Sex
Age,
V
S ite  of 
o b s tru c tio n D iagnos is
P rev ious
th e ra p y
No. o f la se r 
t re a tm e n ts In te rv a ls R e su lt F o llo w u p
1 M 4 0 P ro x im a l trachea Ca th y ro id S u rg e ry , D X T 5 3 - 4  mo E ffe c t iv e
In te rm it te n t  la se r th e ra p ie s
2 M 60 R m a in  b ronchus Ca lung — 1
- E ffe c t iv e D ied  (4  mo) w ith  m e ta s ta se s
3 M 57 R m a in  b ronchus Ca lung D X T , c hem o the rap y 1
- In e ffe c t iv e D ied  (1 mo) of lo ca l d isease
4 F 75 R, L m a in  b ronchi Ca lung - 1 - E ffe c t iv e D ied (1 w k )  o f o th e r  causes
5 F 4 5 L m a in  b ronchus Le iom yosa rcom a  C hem o the rap y 6 1 - 5 mo
E ffe c t iv e D ied  of m e ta s ta s e s
6 M 51 D is ta l tra chea Ca tra chea - 1
- E ffe c t iv e U n d e rw e n t tra c h e a l re sec tio n
7 M 75 Carina, R main bronchus Ca tra c h ea D X T , endoscopy 1 - E ffe c t iv e
D ied (1 mo)
8 M 51 R m a in  b ronchus Ca lung
- 2 2 w k E ffe c t iv e D ied (1 mo)
9 F 8 4 D is ta l R b ronchus Ca th y ro id
- 1 - In e ffe c t iv e D ied  (1 mo)
10 M 55 Carina, R, L main bronchi Ca lung D X T , endoscopy 2 1 w k E ffe c t iv e
D ied  (1 mo)
11 M 61 R, L m a in  b ronchi Ca lung D X T , chem o the rap y 3 1 mo E ffe c t iv e
D ied o f m e ta s ta s e s
12 M 71 P ro x im a l tra chea Ca tra c h ea D X T 7 1 -2 mo E ffe c t iv e
D ied o f lo ca l d isease
13 M 68 L m a in  b ronchus Ca lung D X T , c h em o the rap y 1
- In e f f e c t iv e D ied  o f lo ca l d isease
14 F 8 2 R m a in  b ronchus Ca lung - 1 - In e ffe c t iv e D ied  w ith in  1 mo
15 F 60 R, L m a in  b ronchi Ca lung C h em o the rap y 1 - In e ffe c t iv e
D ied w it h in  1 mo
R *  r ig h t, L -  le f t ,  Ca - ca rc inom a, D X T  -  e x te rn a l rad io th e rap y .
Tab le  I I— Endob ronch ia l Carbon-D ioxide Lase r T h e ra p y  fo r  Ben ign S tr ic tu re s
P a tie n t
no. Sex
Age,
y r
S ite  of 
o b s tru c tio n D iagnos is
P rev ious
th e ra p y
No. of la se r 
tre a tm e n ts In te rv a ls R e su lt Fo llow-up
1 F 31 P h a ryn x Lye s t r ic tu re D ila ta t io n s 3 1 mo In e ffe c t iv e S u rg ic a lly  b ypassed
2 F 38 L m a in  b ronchus Tb s t r ic tu re D ila ta t io n s 2 1.5  mo E ffe c t iv e W e ll a f te r  18  mo
3 F 4 0 D is ta l R b ronchus S titc h  g ranu lom a R e se c tive  su rg e ry 2 6  mo E ffe c t iv e W e ll
4 M 8 0 R m a in  b ronchus G ranu lom a S leeve  resec tio n 1 - E ffe c t iv e W e ll
5 F 62 P ro x im a l tra c h ea T ra ch e a l s te no s is T ra ch e a l resec tio n 2 2 w k E ffe c t iv e H e lp fu l b u t needed T- tube
6 F 4 9 P ro x im a l tra c h ea T ra ch e a l s te no s is T ra ch e a l resec tio n 4 2 d
2 .5  mo
E ffe c t iv e H e lp fu l b u t needed T- tube
7 F 36 L m a in  b ronchus Bronchia l s tenos is L e ft lung 
tra n s p la n ta t io n
2 1.5 mo E ffe c t iv e H e lp fu l b u t needed end o ­
b ro n c h ia l p ro s th es is
Tb  = tube rcu lous .
Tab le  I ll- E n d o b ro n c h ia l Carbon-D ioxide Lase r T h e ra p y  fo r  Ben ign T u m o u rs
P a tie n t
no. Sex
Age, S ite  of 
y r  o b s tru c tio n D iagnos is
P rev ious
th e ra p y
No. of la se r 
t re a tm e n ts In te rv a ls  R e su lt Fo llow-up
1 M 3 9  L m a in  b ronchus C arc ino id
_ 1 -  E ffe c t iv e U n d e rw e n t re sec tio n
2 M 60 D is ta l L b ronchus F ib ropap illom a 1 -  E ffe c t iv e
H e lp fu l b u t needed fu r th e r  
YAG  la s e r  th e ra p y
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therapy was effective in the short term, 
but eventually these patients required per­
manent endobronchial or endotracheal 
prostheses.
Benign Tumours (Table III)
Two patients, aged 39 and 60 years, 
constituted this group. A carcinoid of the 
left main bronchus produced an obstruc­
tion, that was effectively relieved by one 
laser treatment; subsequently, this patient 
had surgical resection. The other patient 
had a fibropapilloma at the origin of the 
left lower lobe, producing left-lower-lobe 
atelectasis, which was effectively treated 
with one laser treatment. This was help­
ful in the short term, but YAG laser ther­
apy was required distally for eventual 
total ablation.
Results
The results of laser therapy were 
assessed by a combination of pre­
treatment and post-treatment roentgeno­
grams, bronchoscopic assessment of the 
diameter of the airway after therapy, and 
by physical examination and discussion 
with the patient after therapy.
Improvement was marked after 24 laser 
therapies, moderate after 11 and minimal 
after 9. On bronchoscopic assessment, 
laser therapy brought about marked 
improvement in 21 instances, moderate in 
15 and minimal in 4. Objective radiologic 
assessment was difficult unless distal 
atelectasis was present. In the 14 patients 
who were followed up by postoperative 
chest roentgenography because of pre­
treatment atelectasis, the roentgenogram 
suggested a marked improvement in 3 
instances, moderate in 1 and minimal 
in 10.
We found that laser therapy was most 
effective in patients who had chronic 
benign strictures and benign tumours at 
all levels. It had less effect in correcting 
airway obstruction in patients with malig­
nant disease, particularly if the obstruc­
tion was distal to the main-stem bronchi 
or there was significant extrinsic compres­
sion. It was effective in 5 and effective to 
some degree in 10. Overall, we noted a 
moderate to marked improvement in 38
of our 45 recorded assessments. In 7 the 
response was minimal (Table IV).
Complications
The major reported complication of 
laser therapy is hemorrhage due to local 
erosion into an adjacent segmental or 
subsegmental artery. Other reported com­
plications include tracheosophageal 
fistula, endobronchial flash fires, post­
treatment pneumonia and complications 
secondary to the anesthesia. In this ser­
ies, there was only one instance of 
minimal bleeding postoperatively that 
required reintubation for control of the 
airway and tracheal toilet. The bleeding 
resolved spontaneously and required no 
further therapy. In one of our early cases, 
one suction catheter vaporized, but this 
did not happen again once we gained 
more experience. On three occasions 
patients had to be reintubated because of 
bronchospasm, pulmonary edema and 
tracheal stridor in one case each. They 
were all promptly extubated in the recov­
ery room and returned to the ward 
without incident.
Discussion
The use of laser therapy for a variety 
of endobronchial lesions has met with 
general enthusiasm.3'5 From published 
series it is difficult to determine specific 
indications for it, based upon patients’ 
complaints, the location of tumour and 
any concomitant therapy. Most reports 
do not provide sufficient information to 
permit adequate comparisons regarding 
improvement in symptoms and long-term 
efficacy. Our aim was to assess our 
method of delivery for C 0 2 laser therapy 
in patients compromised by airway occlu­
sion, with both benign and malignant 
disease.
Exophytic lesions of the trachea and 
main-stem bronchi are most amenable to 
therapy by laser, and improvement in 
symptoms correlates best with improved 
patency of larger airways. In most 
patients the major portion of the 
endobronchial debulking procedure can 
be performed quickly by physically cor­
ing out the exophytic tumour mass with
the rigid end of the bronchoscope. A large 
biopsy forceps can help accomplish this 
with very little bleeding. The laser can 
then remove any remaining tumour and 
produce hemostasis of the tumour bed. 
The major indication for laser therapy in 
malignant lesions is to lessen or com­
pletely relieve symptoms of obstruction. 
Laser therapy to obstructed lobar or seg­
mental bronchi rarely relieves or reduces 
symptoms unless they are associated with 
a post-obstructive pneumonia. When the 
obstruction is long-standing, laser abla­
tion may fail to establish airway patency. 
Hemoptysis from exophytic lesions can 
usually be well controlled. Laser therapy 
to extrinsic compressive tracheal or bron­
chial lesions is usually of little value. We 
have found this type of therapy most suc­
cessful in patients with proximal malig­
nant lesions, benign lesions of the major 
airways, and benign strictures. The 
benign lesions may require repeat therapy 
so that epithelialization of the laser cut 
can occur between treatments. A severe 
hemorrhage may occur, even in carefully 
selected patients, and is the most serious 
complication of this type of therapy.
When compared to diathermy coagu­
lation, mechanical removal, cryotherapy 
and radioactive seed application, the 
advantages of C 0 2 laser bronchoscopy 
are that it produces moderately good 
hemostasis, it is rapid and it provides a 
precise “ no touch” application with 
minimal tumour manipulation.
The C 0 2 delivery system has certain 
disadvantages that have more recently 
been eliminated with the use of the 
Nd:YAG laser. The C 02 laser cannot be 
projected through fiberoptic material, 
and relies on an articulated arm with deli­
cate reflective surfaces. Delivery, through 
a rigid bronchoscope, limits therapy to 
the more proximal lesions, because dis­
tal and upper-lobe lesions cannot be 
reached. Because of low penetration, 
effective hemostasis is limited to vessels 
the size of terminal arterioles and capil­
laries. Despite these disadvantages, the 
C 02 laser is a precise cutting instrument 
with limited penetration into underlying 
tissue, moderately good hemostasis and 
a great degree of safety when compared 
with the coagulating and penetrating 
effects of the Nd:YAG laser.
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W hen you want an effective antibiotic at all costs.
But not at any price.
During the critical 24 to 48 
hour wait for susceptibility tests, 
you need an antibiotic with a clini­
cally proven spectrum of activity. 
An antibiotic with an excellent rec­
ord of safety. An antibiotic such 
as Cefobid*.
When cost must also be 
considered, Cefobid* remains an 
antibiotic of choice. Its realistic
pricing structure and economical 
twice-a-day dosage make 
Cefobid* cost-effective therapy.12
Cefobid* is an advanced 
cephalosporin proven effective 
against a wide range of infections. 
It is very well tolerated. With a 
unique dual pathway of excretion, 
Cefobid* at usual dosage requires 
no modification of dosage in 
patients with renal impairment.
Cefobid* Effective antibiotic 
therapy you can well afford to use.
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Prescribing Information
Antibiotic For Intravenous or Intramuscular Injection
ACTION
In vitro studies indicate that the bactericidal action of CEFOBID (cefoperazone sodium) 
results from the inhibition of bacterial cell wall synthesis.
INDICATIONS AND CLINICAL USES
CEFOBID (cefoperazone sodium) may be indicated for the treatment of the following 
infections when caused by susceptible strains of the designated microorganisms: 
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, 
Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, Kleb­
siella species (including Klebsiella pneumoniae), Pseudomonas aeruginosa, Escheri­
chia coli, Proteus mirabilis, indole-positive Proteus species and Enterobacterspecies. 
URINARY TRACT INFECTIONS caused by Escherichia coli, Pseudomonas aeruginosa, 
Enterobacter species, Klebsiella species, Enterococcus, Proteus mirabilis, Staphylo­
coccus aureus, Staphylococcus epidermidis and indole-positive Proteus species. 
Due to the nature of the underlying conditions which usually predispose patients 
to Pseudomonas infections of the lowe r respiratory and urinary tracts, a good clini­
cal response accompanied by bacterial eradication may not be achieved despite 
evidence of in vitro sensitivity.
ACUTE BILIARY TRACT INFECTIONS ASSOCIATED WITH CHOLECYSTITIS OR CHO­
LANGITIS caused by Escherichia coli.
SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Strep­
tococcus agalactiae, Escherichia coli and Klebsiella species.
WOUND INFECTIONS (SURGICAL AND TRAUMATIC) caused by Staphylococcus 
aureus, Streptococcus pyogenes and Pseudomonas aeruginosa.
GYNECOLOGICAL INFECTIONS (SUCH AS PELVIC INFLAMMATORY DISEASE AND 
ENDOMETRITIS) caused by Streptococcus agalactiae, Neisseria gonorrhoeae, 
Escherichia coli, Bacteroides species (including Bacteroides fragilis), Peptococcus 
species and Peptostreptococcus species.
Specimens for bacteriologic culture should be obtained prior to therapy in order to iden­
tify the causative organism and to determine its susceptibility to CEFOBID (cefoperazone 
sodium). Therapy may be instituted before results of susceptibility testing are known; 
however, modification of the treatment may be required once these results become 
available.
CONTRAINDICATIONS: CEFOBID (cefoperazone sodium) is contraindicated in patients 
with known allergy to the cephalosporin class of antibiotics.
WARNINGS: Before therapy with CEFOBID (cefoperazone sodium) is instituted, careful 
inquiry should be made to determine whether the patient has had previous hypersensi­
tivity reactions to cephalosporins, penicillins or other drugs. CEFOBID (cefoperazone 
sodium) should be administered with caution to penicillin-sensitive patients or to any 
patient who has demonstrated some form of allergy, particularly to drugs. If an allergic 
reaction to CEFOBID (cefoperazone sodium) occurs, discontinue administration of 
the drug and treat the patient with the usual agents (e.g. epinephrine, antihistamines, 
pressor amines or corticosteroids).
Pseudomembranous colitis has been reported to be associated with the use of 
CEFOBID (cefoperazone sodium). Therefore, in those patients administered CEFOBID 
(cefoperazone sodium) who develop diarrhea, it is important to consider such a 
diagnosis.
Treatment with broad-spectrum antibiotics, including CEFOBID (cefoperazone 
sodium) alters the normal flora of the colon and may permit overgrowth of Clostridia. 
Studies indicate that a toxin produced by Clostridium difficile is one primary cause of 
antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe 
cases should be managed with fluid, electrolyte, and protein supplementation as indica­
ted. When the colitis is not relieved by the discontinuance of CEFOBID (cefoperazone 
sodium) or when it is severe, consideration should be given to the administration of oral 
vancomycin.
PRECAUTIONS
General: The concomitant administration of aminoglycosides and some cephalosporins 
has caused nephrotoxicity. Although transient elevations of BUN and serum creatinine 
have been observed, there is no evidence that CEFOBID (cefoperazone sodium) when 
administered alone causes significant nephrotoxicity. However, the effect of ad­
ministering CEFOBID (cefoperazone sodium) concomitantly with aminoglycosides is not 
known.
CEFOBID (cefoperazone sodium) is excreted in both the bile and urine. In normal 
volunteers, 19 to 41% of the dose is excreted in the urine, the remainder being excreted 
by the hepato-biliary system. The serum half-life of CEFOBID (cefoperazone sodium) is 
usually prolonged and urinary excretion of the drug increased in patients with hepatic 
disease and/or biliary obstruction. Serum concentrations of cefoperazone should be 
monitored in these patients treated with doses in excess of 2 grams daily and dosage 
should be adjusted as necessary.
Because renal excretion is not the main route of elimination of cefoperazone, adult 
patients with renal failure usually require no adjustment in dosage when daily doses of 
2 to 4 grams (1 to 2 grams every 12 hours) are administered. If higher doses of CEFOBID 
(cefoperazone sodium) are used, serum concentrations of cefoperazone should 
be monitored. If there is evidence of accumulation, dosage should be decreased 
accordingly.
In one study in patients with chronic renal failure, the half-life of CEFOBID (cefopera­
zone sodium) was reduced from 4.17 to 1.67 hours during hemodialysis. Thus, dosing 
should be scheduled to follow a dialysis period.
In patients with both hepatic dysfunction and renal impairment, the initial dosage of 
CEFOBID (cefoperazone sodium) should not exceed 1 to 2 grams daily and serum con­
centrations of cefoperazone should be monitored closely.
Vitamin K deficiency has occurred in a few patients treated with CEFOBID 
(cefoperazone sodium). The mechanism is most probably related to the suppression of 
gut flora which normally synthesizes this vitamin. Those at risk include patients with 
poor diet or malabsorption states (e.g. cystic fibrosis) and patients on prolonged intrave­
nous alimentation regimens. Prothrombin time should be monitored in these patients 
and exogenous vitamin K administered as indicated.
A reaction characterized by flushing, sweating, headache, and tachycardia has been 
reported when alcohol is ingested during and as late as the fifth day after CEFOBID 
(cefoperazone sodium) administration. Patients should be cautioned concerning inges­
tion of alcoholic beverages in conjunction with administration of CEFOBID (cefoperazone 
sodium). For patients requiring artificial feeding orally or parenterally, solutions con­
taining ethanol should be avoided.
CEFOBID (cefoperazone sodium) should be administered with caution to individuals 
with a history of gastrointestinal disease, particularly colitis.
Overgrowth of nonsusceptible organisms may occur during prolonged use of 
CEFOBID (cefoperazone sodium). Patients should be observed carefully during treat­
ment. If superinfection occurs, appropriate measures should be taken.
Drug Laboratory Test Interactions
A false-positive reaction for glucose in the urine may occur with Benedict's or Fehling's 
solution.
Pregnancy: The safety of CEFOBID (cefoperazone sodium) in pregnancy has not been 
established. The use of CEFOBID (cefoperazone sodium) in pregnant women requires 
that the likely benefit from the drug be weighed against the possible risk to the mother 
and fetus.
Reproduction studies have been performed in mice, rats and monkeys at doses up to 
10 times the human dose and have revealed no evidence of impaired fertility or teratoge­
nic effects due to cefoperazone sodium. Animal reproduction studies, however, are not 
always predictive of human response.
Nursing Mothers: Cefoperazone is excreted in low concentration (0.4 to 0.9 ^g/mL) in 
human milk. Caution should be exercised when CEFOBID (cefoperazone sodium) is 
administered to a nursing mother.
Children: The safety and efficacy of CEFOBID (cefoperazone sodium) in children have not 
been established.
ADVERSE REACTIONS
Hypersensitivity: Maculopapular rash, urticaria, pruritis, eosinophilia, drug fever. 
Hematology — Decreases in hemoglobin and/or hematocrit have occurred. Slight 
decreases in neutrophil count have been reported, and reversible neutropenia may occur 
with prolonged administration. Transient eosinophilia has occurred. Hypoprothrombi- 
nemia has been observed. Some individuals have developed positive direct Coombs’ test 
during treatment.
Liver — Transient elevations in SGOT, SGFT and alkaline phosphatase levels have been 
noted. One patient with a history of liver disease developed significantly elevated liver 
function enzymes during therapy with CEFOBID (cefoperazone sodium). Clinical signs 
and symptoms of nonspecific hepatitis accompanied these increases. After CEFOBID 
(cefoperazone sodium) therapy was discontinued, the patient’s enzymes returned to pre­
treatment levels and the symptomatology resolved.
Kidney — Transient elevations of blood urea nitrogen and serum creatinine have been 
noted.
Gastrointestinal — Altered bowel habits (loose stools or diarrhea) have been reported. 
Most of these events have been mild or moderate, but some have been severe. In all 
cases, these symptoms responded to symptomatic therapy or ceased when 
cefoperazone therapy was stopped. Nausea and vomiting have been reported rarely.
Pseudomembranous colitis has been reported rarely in patients administered 
CEFOBID (cefoperazone sodium). Symptoms of pseudomembranous colitis can appear 
during or for several weeks subsequent to antibiotic therapy.
Disulfiram-like Reaction
Disulfiram-like reactions have been reported when alcohol was ingested during and as 
late as the fifth day after CEFOBID (cefoperazone sodium) administration.
Central Nervous System — Headache and dizziness occur rarely.
Local Reactions — CEFOBID (cefoperazone sodium) is well tolerated following intra­
muscular administration. Occasionally, transient pain may follow administration by this 
route. When CEFOBID (cefoperazone sodium) is administered by the intravenous route, 
some patients develop phlebitis at the site of administration.
Other — Diaphoresis/chills
SYMPTOMS AND TREATMENT OF OVERDOSAGE 
Since no case of overdosage has been reported to date with CEFOBID (cefoperazone 
sodium), no specific information on symptoms or treatment of overdosage is available. 
Treatment should be symptomatic.
Hemodialysis is not effective in the removal of cefoperazone.
DOSAGE AND ADMINISTRATION
Dosage
CEFOBID (cefoperazone sodium) may be administered intravenously or intramuscularly.
Dosage and route of administration should be determined by severity of infection, 
susceptibility of the causative organism, and condition of the patient.
Adult
The recommended daily dose of CEFOBID (cefoperazone sodium) is 2 to 9 grams ad­
ministered in equally divided doses every 8 to 12 hours (See table below). The usual 
duration of treatment is 7 to 14 days.
Adult Dosage
Type of infection Daily Dose Frequency and Route
Mild to moderately severe 2 to 4 grams 1 to 2 grams
infections such as pneumonia, every 12 hours
acute urinary tract infection, |.m . or I.V.
wound infection
Severe infections or infections 4 to 8 grams
caused by less sensitive
organisms
2 to 4 grams 
every 12 hours 
I.V.
Infections commonly requiring 9 grams 3 grams every
antibiotics in higher dosage 8 hours I.V.
(e.g. septicemia and life threatening 
infections)
The maximum adult daily dose should not exceed 9 grams.
For infections caused by Streptococcus pyogenes, therapy should he continued for 
at least 10 days.
Impaired Renal Function
Because renal excretion is not the main route of elimination of cefoperazone, adult 
patients with renal failure usually require no adjustment in dosage when daily doses of 
2 to 4 grams (1 to 2 grams every 12 hours) of CEFOBID (cefoperazone sodium) are admin­
istered. If higher doses of CEFOBID (cefoperazone sodium) are used, serum concentra­
tions of cefoperazone should be monitored. If there is evidence of accumulation, dosage 
should be decreased accordingly. For patients whose glomerular filtration rate is less 
than 18 mL/min orwhose serum creatinine level is greaterthan 3.5 mg/dL, the maximum 
CEFOBID (cefoperazone sodium) dosage should be 4 grams per day.
In patients undergoing hemodialysis, dosing should be scheduled to follow a dialysis 
period.
Hepatic Disease and Biliary Obstruction
The serum half-life of cefoperazone is increased 2 to 4 fold in patients with hepatic 
disease and/or biliary obstruction. Serum concentrations of cefoperazone should be 
monitored in patients treated with doses in excess of 2 grams daily and dosage should 
be adjusted as necessary.
Hepatic Dysfunction and Renal Impairment
In patients with both hepatic dysfunction and concomitant renal impairment, the initial 
dosage of CEFOBID (cefoperazone sodium) should not exceed 1 to 2 grams daily and 
serum concentrations of cefoperazone should be closely monitored.
Children
The safety and efficacy of CEFOBID (cefoperazone sodium) in children have not been 
established.
ADMINISTRATION
Intramuscular:
CEFOBID (cefoperazone sodium) should be administered by deep intramuscular 
injection into a large muscle mass such as the gluteus maximus or anterior thigh. The 
maximum dose of CEFOBID (cefoperazone sodium) should be two (2) grams. 
Intravenous:
Direct Intravenous (bolus) injection: The reconstituted solution should be injected 
slowly over a period of no less than three (3) minutes. The maximum dose of 
CEFOBID (cefoperazone sodium) should be two (2) grams.
Intermittent Intravenous Infusion: The reconstituted solution may be infused over a 
period of 15 minutes to 1 hour through the tubing of an administration set while any 
of the intravenous solutions (See Solutions for I.V. Infusion) are being infused. During 
infusion of the solution containing CEFOBID (cefoperazone sodium), it is desirable to 
temporarily discontinue administration of the other solution.
Continuous Intravenous Infusion: CEFOBID (cefoperazone sodium) may also be 
administered over a longer period of time.
Note: If therapy with CEFOBID (cefoperazone sodium) is carried out in combination 
with an aminoglycoside antibiotic, each should be administered at different sites 
because of a physical incompatibility. An aminoglycoside should not be mixed with 
CEFOBID (cefoperazone sodium) in the same container.
PHARMACEUTICAL INFORMATION
CHEMISTRY 
Trade Name: CEFOBID
Proper Name: Cefoperazone sodium 
Chemical Name:
Sodium (6R,7R)-7- [ (R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2- 
(p-hydroxyphenyl) acetamido] -3[ [ (1-methyl-1H-tetrazol-5-yl)thio ] methyl]-8-oxo- 
5-thia-1- azabicyclo[4.2.0] oct-2-ene-2-carboxylate
c2h 5- -CONHCHCONH
Molecular Formula: C2sHx N,0,S;,Na Molecular Weight: 667.65 
Description:
Cefoperazone sodium is a white powder, soluble in water, sparingly soluble in methanol, 
poorly soluble in ethanol, and insoluble in ethyl ether, acetone, chloroform, or n-hexane. 
Composition:
CEFOBID vials contain cefoperazone sodium (expressed in terms of free acid). The 
sodium content of each gram of CEFOBID is approximately 34 mg (1.5 mEq sodium ion). 
The pH of a 25% (w/v) solution is 4.5 to 6.5 and the solution is colorless to straw yellow 
depending on the concentration.
RECONSTITUTION
For Intramuscular Use:
Solution for Reconstitution
Sterile Water for Injection 
or, if required
Bacteriostatic Water for Injection
0.5% Lidocaine Hydrochloride Injection
Reconstitute as follows:
Volume to be Approximate Approximate
Vial Size Added to Vial Available Average Concentration
(g)____________ (ndL)__________ Volume (mL)___________ (mg/mL)________
1.0 3.5 4.0 250
2.0 __________ 7 0 ________________ SO__________________250__________
Shake well until dissolved. Solutions should be allowed to stand after reconstitution to 
allow any foaming to dissipate in order to permit visual inspection for complete solubili­
zation. Vigorous and prolonged agitation may be necessary to solubilize CEFOBID 
(cefoperazone sodium).
For Intravenous Use:
Solutions for Reconstitution and Dilution
Sterile Water for Injection 
or, if required
Bacteriostatic Water for Injection 
Reconstitute as follows:
Volume to be Approximate Approximate
Vial Size Added to Vial Available Average Concentration
(g)____________ (mL|___________ Volume (mL)___________ (mg/mL)_______
1 9.5 10.0 100
2 ____________ 19T)_______________ 200_________________ 100__________
Shake well until dissolved. The prepared solution may be further diluted to the desired 
volume with any of the solutions for I.V. infusion listed below.
For direct intravenous (bolus) injection: Reconstitute as directed above 
For intermittent intravenous infusion: Reconstitute as directed above 
For continuous intravenous infusion: Reconstitute with Sterile Water for Injection. The 
reconstituted solution may be added to an appropriate intravenous bottle/bag containing 
any of the solutions for I.V. infusion listed below:
Solution for I.V. Infusion 
5% Dextrose Injection (USP)
5% Dextrose and Lactated Ringer’s Injection 
5% Dextrose and 0.9% Sodium Chloride Injection (USP)
5% Dextrose and 0.2% Sodium Chloride Injection (USP)
10% Dextrose Injection (USP)
Lactated Ringer's Injection (USP)
0.9% Sodium Chloride Injection (USP)
Normosol® M and 5% Dextrose Injection 
Normosol® R 
Stability of Solutions 
Storage:
Reconstituted solutions for intramuscular injection should be used within 24 hours if 
kept at room temperature, or 72 hours if stored under refrigeration (5° C).
Reconstituted solutions for I.V. injection or infusion should be used within 24 hours 
if kept at room temperature, or 72 hours if stored under refrigeration (5° C). 
Incompatibility
CEFOBID (cefoperazone sodium) should not be added to blood products, protein 
hydrolyzates, or amino acids. CEFOBID (cefoperazone sodium) should not be mixed 
together with an aminoglycoside.
DOSAGE FORMS
Availability:
CEFOBID (cefoperazone sodium) is available as a lyophilized powder:
1.0 g vial — cefoperazone 1.0 g as sodium salt
2.0 g vial — cefoperazone 2.0 g as sodium salt 
Storage
CEFOBID (cefoperazone sodium) should be stored protected from light and 
refrigerated (2 to 8° C).
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Pros and Cons of Urgent Exploratory Sternotomy 
After Open Cardiac Surgery
To determine whether it is appropriate to 
perform urgent exploratory sternotomy 
for potentially life-threatening complica­
tions of open-heart procedures, the 
authors reviewed the charts of 100 such 
patients managed by exploratory ster­
notomy between December 1982 and 
December 1984. Group 1 comprised 32 
patients who suffered cardiac arrest (8) 
or had acute profound hypotension 
(24). Group 2 included 68 patients 
with persistent excessive bleeding. Of 
group 1 patients operated because of 
acute profound hypotension, 50% had 
definite evidence of cardiac tamponade.
In the remainder the cause was severe 
myocardial ischemia and left ventricular 
failure. In group 2 an identifiable correc­
table site of bleeding was found in 78%.
Four of the 8 patients with cardiac 
arrest and 20 (83%) of the 24 patients 
with acute profound hypotension sur­
vived and left the hospital, in group 2,
58 (85%) of the 68 survived.
The mean postoperative stay was 
higher in group 1 than group 2 — 20.3 
± 3.08 days versus 14.2 ± 1.23 days 
(p < 0.1). The duration of ventilatory sup­
port in group 1 was also higher — 6.18 
± 1.32 days versus 2.12 ± 0.38 days. 
Postoperativeiy, sputum cultures gave 
positive results in 19% of the patients, 
all of whom had required prolonged ven­
tilatory support. Minor sternal wound 
infections were present in two and major
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in four. There was no sigificant differ­
ence in morbidity of the survivors 
between those who underwent ster­
notomy in the recovery room or in the 
operating room. In the authors' opinion 
patients who undergo exploratory ster­
notomy after cardiac surgery have a 
higher morbidity in terms of infection 
and prolonged hospital stay, but con­
sidering the life-threatening nature of the 
condition requiring the reopening, the 
overall survival rate of 83% justifies its 
use, so consideration should be given to 
this procedure early even if it must be 
performed at the bedside.
Les auteurs ont etudie de facon retro­
spective 100 patients consecutifs qui 
ont subi d'urgence une sternotomie 
exploratrice a la suite de chirurgie cardia- 
que entre decembre 1982 et decembre 
1984. Le groupe 1 comprenait des 32 
patients qui ont ete explores a la suite 
d'un arret cardiaque (8) ou hypotension 
profonde (24). Le groupe 2 com­
prenait 68 patients qui ont ete reou- 
verts a cause de saignement excessif.
Des patients operas pour hypotension 
profonde, 50% presentaient une tam­
ponade cardiaque. Dans les autres cas il 
s’agissait d'ischemie myocardique severe 
avec defaillance du ventricule gauche. 
Dans le deuxieme groupe nous avons 
identifie une source de saignement chez 
78% des patients.
Quatre des 8 patients qui ont eu un 
arret cardiaque et 20 (83%) des 24 
patients avec hypotension severe ont 
surv6cus et ont pu quitter I'hopital. Dans 
le groupe 2, 58 (85%) des 68 des 
patients ont quitte I’hopital en vie.
L'hospitalisation a 6te plus longue 
dans le groupe 2 que dans le groupe 
1—20.3 ± 3.08 jours versus 14.2 ±
1.23 jours (p < 0.1). La duree de la venti­
lation mgcanique dans le groupe 1 etait 
aussi plus elev6e a savoir 6.18 ± 1.23 
jours compare au groupe 2 — 2.12 ±
0.38 jours. Les cultures de s6cr6tions
bronchiques dans les suites postopera- 
toires etaient positives chez 19% des 
patients, toutes etant associees a une 
ventilation mecanique prolongee. Les 
auteurs ont note une infection sternale 
mineure chez deux patients et majeure 
chez quatre patients. Cependant, il n'y 
avait aucune difference significative dans 
la morbidite des survivants dont la poi- 
trine avait et6 reouverte dans la salle de 
reveil versus dans la salle d'operation.
Les auteurs croient que les patients 
subissant une sternotomie exploratrice h 
la suite de chirurgie cardiaque ont une 
morbidity plus elevee en terme d'infec- 
tion et de duree d'hospitalisation. Cepen­
dant ils croient que la survie de 83% 
justifie I'emploie de la sternotomie 
exploratrice d'urgence qui devrait etre 
meme employee dans la salle de reveil si 
necessaire.
Cardiac arrest, excessive postoperative 
bleeding or acute profound hypotension 
after open-heart surgery may necessitate 
an urgent exploratory sternotomy. Some­
times this must be performed in the recov­
ery room or intensive care unit. In an 
effort to assess its efficacy we reviewed 
the charts of 100 consecutive patients who 
had required an urgent exploratory ster­
notomy after open cardiac surgical proce­
dures performed at the University of 
Ottawa Heart Institute, Ottawa Civic 
Hospital.
Table I—Initial Procedure Performed 
on 100 Patients Who Required Urgent 
Exploratory Sternotomy
Operation
No. of 
patients
CABG* 74
Valve replacement 12
CABG + valve replacement 7
CABG + left ventricular
aneurysmectomy 3
Miscellaneous 4
'Aortocoronary bypass grafting.
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Patients and Methods
From December 1982 to December 
1984, 82 men and 18 women ranging in 
age from 38 to 92 years (mean 58 years) 
underwent urgent exploratory ster­
notomy. They represented 5.4% of adults 
who had undergone open-heart opera­
tions during this time.
The primary operative procedure is 
demonstrated in Table I. There were three 
indications for urgent sternotomy: 
cardiac arrest unresponsive to initial mas­
sage or defibrillation, or both (8 patients), 
acute profound hypotension (24 patients) 
and excessive bleeding—over 400 mL an 
hour or 1200 mL in 3 hours (68 patients).
Eighty-one patients were explored in 
the operating room. The condition of the 
other 19 was considered too critical to 
permit their transfer to the operating 
room. Sterile reopening sets kept in the 
recovery and intensive care rooms were 
used. The chest was hastily prepared with 
Proviodine and draped with sterile towels 
and sheets. All except two patients were 
already intubated at the time. These 
two were rapidly intubated. Analgesia 
was provided by intravenously adminis­
tered morphine or fentanyl citrate. 
In all patients the electrocardiogram 
was monitored as was the arterial 
blood, central venous or pulmonary 
artery pressure. Temporary pacing wires 
were used whenever needed. Arterial 
blood gases were monitored for carbon 
dioxide and oxygen pressures and pH, 
and serum electrolyte values, hematocrit,
platelet count, prothrombin, activated 
clotting and partial thromboplastin times 
and fibrinogen levels were determined 
when necessary. All drugs needed for 
resuscitation as well as blood, colloids 
and crystalloids were available in the 
recovery room. Suction apparatus was 
present at the bedside.
Findings
There were two groups of patients. 
Group 1 comprised patients who were 
explored after cardiac arrest and those 
with acute profound hypotension. In the 
eight patients with cardiac arrest no evi­
dence of tamponade was found. Of the 
24 who had acute profound hypotension, 
12 had a pericardial collection causing 
tamponade and opening of the sternal 
incision was associated with a substantial 
improvement in the hemodynamic state. 
In the remainder, the cause of the pro­
found hypotension was left ventricular 
failure following severe myocardial ische­
mia. An intra-aortic balloon was inserted 
in six of the patients. Twenty patients in 
the group had progressive circulatory 
insufficiency and were already receiving 
inotropic drugs. Two had an intra-aortic 
balloon in place and exploratory ster­
notomy was carried out as a last ditch 
measure to exclude a correctable cause of 
the low-output state.
Group 2 was made up of 68 patients 
who had persistent excessive bleeding— 
1276 ± 112mLover 189 ± 16.5 minutes. 
Fifty of these patients had been given
additional protam ine sulfate in tra ­
venously after operation or had received 
fresh-frozen plasma or cryoprecipitate or 
platelets. Two patients were on cell-saver 
equipment.
At surgery, 53 of these 68 patients had 
an identifiable site of bleeding, which was 
a vascular anastomosis in 18, the distal 
marginal graft anastomosis being the 
commonest site. Chest-wall bleeding was 
seen in 13 patients. In each of the eight 
patients who had previously undergone 
bypass grafting of the internal mammary 
artery, the source of bleeding was the bed 
of the artery.
Survival Rate
In Group 1, of the eight patients who 
had a cardiac arrest four survived. 
Twenty (83%) of the 24 patients with 
acute profound hypotension survived and 
left the hospital. In group 2, 58 (85%) of 
the 68 patients left the hospital alive.
Morbidity
The average postoperative hospital stay 
was longer in group 1 than group 2—20.3 
± 3.08 days versus 14.2 ± 1.23 days (p<  
0.1, paired f-test). These figures compare 
with an average postoperative hospital 
stay for patients with a similar operative 
profile at the University of Ottawa Heart 
Institute of 10 days. Table II compares 
the morbidity of patients in the two 
groups.
Forty-four patients were extubated on 
schedule, that is within 24 hours after sur­
gery. The length of ventilatory support in 
group 1 patients was 6.18 ± 1.32 days 
and was 2.12 ± 0.38 days in group 2. The 
morbidity in patients who had extended 
ventilatory support was higher than in the 
others (Table III).
Table IV lists the bacteria identified 
from various sites.
Sternotomy was carried out in the 
recovery room in 13 of the 32 group 1 
patients (group la) and in the operating 
room in the others (group lb). Six 
patients in group la  died, five within 48 
hours. In group lb  one patient died 
within 48 hours. The morbidity and the 
mortality in the two groups are compared 
in Table V.
The differences between the two groups 
were not statistically significant.
Discussion
Exploratory sternotomy soon after 
open-heart surgery is generally required 
for sudden profound hypotension or 
excessive postopera tive  bleeding. 
Whenever possible the procedure is per­
formed after transferring the patient to 
an operating room. However, operating 
rooms are not always readily available,
T a b le  I I - - C o m p a r is o n  o f th e  M o r b id i t y  E x p e r ie n c e d  b y  P a t ie n t s  
in E a c h  G ro u p
G ro u p  1 G ro u p  2 T o ta ls
C o m p lic a t io n (n =  3 2 ) (n -  6 8 ) (hi =  1 0 0 )
In fe c t io n
R e s p ira to ry 5 4 9
S te r n a l w o u n d :
M in o r 0 2 2
M a jo r 3 1 4
R e n a l fa i lu r e 1 2 3
T r a c h e o s to m y 1 2 3
E n c e p h a lo p a th y 1 1 2
C e re b r o v a s c u la r  a c c id e n t 0 1 1
T a b le  I l l - C o m p l ic a t io n s  W ith  R e s p e c t  to  V e n t i la to r y  S u p p o r t  (N -  9 6 ) *
C o m p lic a t io n
R o u t in e  v e n t i la t o r y  
s u p p o r t  (n -  4 4 )
P ro lo n g e d  v e n t i la to r y  
s u p p o r t  (n «  5 2 )
P n e u m o n ia 0 9
S te r n a l  w o u n d  c o m p lic a t io n :
M in o r 2 0
M a jo r 1 3
R e n a l f a i lu r e 0 3
T r a c h e o s to m y 0 3
E n c e p h a lo p a th y 0 2
C e re b r o v a s c u la r  a c c id e n t 0 1
P o s it iv e  c u ltu re
S p u tu m 0 1 9
U r in a r y  t r a c t 1 5
G ro in  w o u n d 2 3
B lo o d 0 5
‘ E x c lu d in g  4  e a r ly  d e a th s .
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and the patient must be disconnected 
from the ventilator and monitoring equip­
ment and transferred out of the recovery 
room. Sometimes the sternotomy must be 
done at the bedside in the recovery room. 
Fairman and Edmunds1 reviewed emer­
gency thoracotomies performed in the 
recovery room after cardiac surgery and 
found an incidence of 3Vo. The 19 
patients in our series operated on in the 
recovery room constitute 0.5 Vo of the 
total number of open-heart procedures 
performed at our institution. These 
patients were too sick to tolerate the 
delays in transporting them from the 
recovery room to an operating room.
There is little published data on emer­
gency sternotomy after open-heart proce­
dures. The incidence would vary in differ­
ent institutions depending on the attitudes 
of the staff, fellows and residents and on 
the accessibility of an operating room to 
such patients. Our low incidence might 
well reflect the immediate proximity of an 
operating room to the cardiac recovery 
room. This operating room is generally 
used for pacemaker insertions and occa­
sionally for open or closed cardiovascu­
lar procedures.
The main concern for patients who 
have to be re-explored is the possible mor­
bidity that may result, especially if the 
usual sterile precautionary measures of an 
operating room are not possible. Our 
study indicates an increase in morbidity 
associated with exploratory sternotomy. 
It is essential, therefore, that centres deal­
ing with open cardiac surgery should take 
extra care so that exploratory sternotomy 
for an avoidable cause is not necessary. 
Our incidence of 3.7Vo for reopenings 
resulting from postoperative bleeding is 
probably not high compared with rates 
from other centres such as the 4.5Vo 
reported by Zurick and associates.2 The 
disturbing fact in our series was that of 
the 68 patients who were opened for 
bleeding, 78Vo had a localized correcta­
ble source of bleeding. This could have 
been avoided by careful attention to 
hemostasis at the time the wound was 
closed. Our study shows that the usual 
sites that are overlooked are the bed of 
the internal mammary artery pedicle after
dissection and the distal anastomotic site 
on the marginal branch of the circumflex 
artery. The latter is usually difficult to 
evaluate as the graft lies posteriorly, and 
assessment of hemostasis requires mobili­
zation of the heart which often causes 
hypotension and may not initially reveal 
the site of bleeding. We have tried to 
overcome this by injecting indocyanine 
green through the graft before perform­
ing the proximal anastomosis to identify 
any sites of leakage from the distal 
anastomosis or the vein.3 In our series 
only a small percentage of patients had 
serious bleeding postoperatively from 
causes that were not surgically correc­
table.
Infection associated with reopening 
after open-heart procedures was more fre­
quent than when reopening was not neces­
sary. Culliford and colleagues4 and 
Engleman’s group5 had the same 
experience. They noticed an increased 
incidence of mediastinitis and mediasti­
nal wound infection in patients who had 
excessive bleeding postoperatively. Cul­
liford reported that 53Vo of the 39 
patients with mediastinitis had blood loss 
in excess of 1250 mL. This is surprising 
because most patients who have bleeding 
postoperatively can be transferred into 
the sterile environment of an operating 
room. Interestingly, when we compared 
our patients who were reopened in the 
recovery room with those who were reo­
pened in the operating room, the differ­
ence in morbidity between the two groups
was not significant. Our indication for 
performing an emergency sternotomy in 
the recovery room is sudden profound 
hypotension that does not respond within 
a few minutes to drugs or closed resusci­
tation. We agree with Fairman and 
Edmunds' that emergency thoracotomy 
should be considered an important 
adjunct of postoperative care after open- 
heart surgery, and nurses and allied med­
ical personnel should be trained in this 
procedure. Appropriate equipment 
should be available and be readily 
located. No patient should be allowed to 
die in an intensive care unit from cardiac 
tamponade, a correctable condition.
Interestingly, only 50Vo of the patients 
who had sternotomy for sudden profound 
hypotension had a documented cardiac 
tamponade. All these patients ultimately 
did well and were discharged from the 
hospital. Most deaths occurred in group 
1 patients in whom the low-output state 
was due to causes other than cardiac tam­
ponade.
Thus, if cardiac tamponade can be 
excluded by a noninvasive means such as 
echocardiography, exploratory ster­
notomy can be avoided in patients who 
will not benefit from it. Unfortunately, 
the average systolic blood pressure in 
these patients was 60 mm Hg and they 
were being given inotropic agents (two 
required intra-aortic balloon pump sup­
port). It is unlikely that this situation 
would lend itself to bedside echocardiog­
raphy. Besides, in the interest of expe-
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dience it might be safer to go ahead with 
an urgent reopening in the recovery room 
rather than lose valuable time obtaining 
an echocardiogram. The highest death 
rate (50%) was among the eight patients 
who had a cardiac arrest and were 
explored after unsuccessful attempts at 
resuscitation. The overall survival of 83% 
is commendable in view of the predicta­
bly low survival rate that would have 
resulted if these patients had not been 
treated surgically. The 15% death rate in 
the group of patients who were explored 
for extensive bleeding was surprising, but 
this can be explained by the fact that 
bleeding is often associated with hypoten­
sion and varying degrees of cardiac tam­
ponade.6 Such a combination of situa­
tions, especially in the presence of an 
ischemic ventricle, is particularly 
threatening.
Conclusions
Patients requiring urgent exploratory 
sternotomy for life-threatening conditions 
such as profound sudden hypotension or 
postoperative bleeding experience sub­
stantial morbidity in terms of infection 
which results in prolonged hospital stay. 
The morbidity is higher in those who have 
profound hypotension than in those with 
excessive bleeding. There is no apprecia­
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ble difference in morbidity between the 
survivors of reopening in the recovery 
room or the operating room. Consider­
ing the life-threatening nature of the con­
dition requiring an emergency ster­
notomy, the overall survival rate of 83% 
justifies its use. Consideration should be 
given to this procedure even if it must be 
done at the bedside.
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Correction
In the March 1986 issue, the article 
“ Aneurysmal bone cyst: a review of 
26 cases” by K.S. Morton contains an 
error. The illustrations for Figs. 7 and 
9 have been reversed. We apologize to 
Dr. Morton and to our readers for any 
confusion generated by this error.
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(infants below 30 days of age), or in pregnant women.
Khrnlngs: Some cases of severe and persistent diarrhea have been reported during or after therapy with 
i Dalacin C Phosphate (clindamycin phosphate). This diarrhea has been occasionally associated with
f blood and mucus in the stools and has at times resulted in acute colitis. When endoscopy has been
performed, some of these cases have shown pseudomembrane formation.
If significant diarrhea occurs during therapy, this drug should be discontinued or, if necessary, 
continued only w ith close observation. Significant diarrhea occurring up to several weeks post-therapy 
should be managed as if antibiotic-associated.
If colitis is suspected, endoscopy is recommended. Mild cases showing minimal mucosal changes may 
respond to simple drug discontinuance. Moderate to severe cases, including those showing ulceration 
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tion as indicated. Corticoid retention enemas and systemic corticoids may be of help in persistent 
cases. Anticholinergics and antiperistaltic agents may worsen the condition. Other causes of colitis 
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Studies indicate a toxin(s) produced by Clostridia (especially Clostridium difficile) may be a principal 
cause of clindamycin and other antibiotic-associated colitis. These studies also indicate that this 
toxigenic Clostridium is usually sensitive in-vitro  to vancomycin. When 125 mg to 500 mg of vanco­
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disappearance of the toxin from faecal samples and a coincidental recovery from the diarrhea 
Is should be noted that serious relapses have occurred up to one month after apparently successful 
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caution in atopic individuals.
Dalacin C Phosphate must be diluted for intravenous administration. (See Dosage and Administration) 
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yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the 
clinical situation.
As w ith  all antibiotics, perform culture and sensitivity studies in conjunction w ith  drug therapy. 
Since abnormalities of liver function tests have been noted occasionally in animals and man, periodic 
liver function tests should be performed during prolonged therapy. Blood counts should also be 
monitored during extended therapy.
Dalacin C Phosphate may be used in anuretic patients. Since the serum half-life of clindamycin in 
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(a) Intramuscular Injections: Of 404 patients treated w ith Dalacin C Phosphate (clindamycin phos­
phate) intramuscularly (w ith a solution containing 150 m g/m l), six (1.5%) demonstrated local 
reactions as follows: Two complained of pain at the injection site, two demonstrated induration at the 
injection site and two developed sterile abscesses
(b) Intravenous Infusions: Of 192 patients treated with Dalacin C Phosphate by intravenous infusion, 
14 (7,3%) demonstrated local reactions. Eleven patients developed superficial thrombophlebitis and 
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Systemic Side Effects: Twenty-eight patients of 596 treated with Dalacin C Phosphate (clindamycin 
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follows:
Number o f Patients
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Cardiac arrest"”  ............................................................................................................................................  1
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side effect of clindamycin phosphate.
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(clindamycin phosphate) were followed w ith clinical laboratorytests, including complete hematology, 
urinalysis and liver and kidney function tests. Some of these tests were abnormal initially and returned 
to normal during therapy with Dalacin C Phosphate, while others were normal initially and became 
abnormal during therapy. Overall evaluation of clinical laboratory values in these patients does not 
indicate that Dalacin C Phosphate therapy has a toxic effect on the hematopoietic, hepatic or renal 
systems. Transient elevations of serum transaminases have occurred in some patients, but other liver 
function tests (alkaline phosphatase, serum bilirubin) have not shown any tendency to increase and 
there have not been clinical signs of drug-induced hepatic toxicity.
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is known. Doses as high as 1200 mg every six hours (4800 mg/day) by infusion for five days have been 
given without adverse effects.
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Excision of Abdominal Wall Tumours and 
Reconstruction With Marlex Mesh
Because metastatic abdominal wall 
tumours are rare and their biologic 
activity is unpredictable, they must be 
managed aggressively (a) for potential 
cure of isolated recurrences and (b) to 
obtain good palliation, as fetid exophytic 
lesions alter the patient’s self-image and 
life-style. An aggressive surgical approach 
often leaves a large abdominal wall defect. 
The authors describe 19 patients (10 men, 
9 women) with these tumours who had their 
abdominal wall reconstructed with Marlex 
mesh. All patients received antibiotics 
preoperatively, but 16 had either mechan­
ically unprepared bowel due to obstruction 
or abdominal contamination from the 
intestine intraoperatively. The commonest 
complication was wound abscess in 10 pa­
tients; it was controlled without removing 
the Marlex mesh. The majority of patients 
had prolonged palliation with greatly re­
duced symptoms, a reasonable quality 
of life and acceptable cosmesis. Potentially 
life-threatening intra-abdominal complica­
tions were reduced. One patient was con­
sidered cured. The authors believe that 
there is a definite role for aggressive 
surgical management of abdominal wall 
metastases and that Marlex mesh may 
be used for reconstruction even when 
there has been peritoneal contamination.
Les tumeurs m§tastatiques de la paroi 
abdominale sont rares et leur activite bio- 
logique est imprevisible. Elies doivent 
done @tre traitees de fapon vigoureuse a) 
pour tenter d'obtenir la gu6rison des reci- 
dives isolees et b) pour obtenir un bon 
resultat palliatif puisque les lesions 
exophytiques fetides affectent le respect 
de soi et le mode de vie des patients.
Une technique chirurgicale agressive 
laisse souvent une large brfeche dans la 
paroi abdominale. Les auteurs decrivent
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les cas de 19 patients (10 hommes et 9 
femmes) porteurs de telles tumeurs qui 
ont eu une reconstruction de la paroi 
abdominale 6 I'aide de la fibre Marlex. 
Seize n'avaient pas eu de preparation 
intestinale a cause d'une obstruction, ou 
ils eurent une contamination abdominale 
d'origine intestinale durant I'intervention. 
Des abces de plaies survenant chez 10 
patients repr6sentent la complication la 
plus frequente; ils purent etre reduits 
sans eniever la fibre Marlex. La majorite 
des patients ben&ficia d'un effet palliatif 
prolonge avec une diminution marquee 
des symptomes, une qualite de vie satis- 
faisante et des resultats cosmetiques 
acceptables. Les complications intra- 
abdominales susceptibles de menacer le 
pronostic vital ont £te reduites. Un 
patient a ete consider^ gueri. Les auteurs 
croient au role d'un traitement chirurgical 
vigoureux dans les cas de cancers metasta- 
tiques de la paroi abdominale et conside­
re d  que la fibre Marlex peut etre utilisee 
pour la reconstruction meme en presence 
de contamination p£ritoneale.
Malignant tumours of the abdominal wall 
are uncommon and usually arise as 
metastases from primary colorectal 
lesions. Soft-tissue tumours such as sar­
comas may occasionally invade or arise 
from the abdominal wall itself. When 
present, abdominal wall tumours may 
ulcerate, become infected or bleed, caus­
ing unsightly painful lesions with a foul­
smelling discharge, often having a 
deleterious effect on the patient’s self- 
image and life-style. Such lesions require 
aggressive surgical treatment that often 
leaves a large defect requiring reconstruc­
tion o f the abdominal wall.
This report describes the results 
obtained in 19 patients with abdominal 
wall metastases or recurrences in whom 
Marlex mesh was used to reconstruct the 
abdominal wall.
Patients and Methods
The patients (10 men, 9 women) in this 
study ranged in age from 39 to 78 years 
(mean 52 years). All but four had under­
gone laparotomy previously for adeno­
carcinoma and 15 had had an associated
bowel resection: right hemicolectomy in 
3, left colon or sigmoid resection in 7 and 
proctocolectomy in 5. Two rv>' _nts had 
large retroperitoneal sarcomas extending 
through the abdominal wall, and a third 
had a colonic adenocarcinoma invading 
abdominal wall at the time o f presenta­
tion. The remaining patient had a breast 
cancer metastasizing to an oophorectomy 
incision.
After resection of the primary tumour, 
patients received adjuvant therapy, when 
indicated, comprising a combination of 
chemotherapy, radiotherapy, immune 
stimulation or radiofrequency hyperther­
mia. All patients subsequently had evi­
dence o f an abdominal wall mass. Most 
complained o f discomfort or pain, three 
having lesions that ulcerated or bled and 
one an infected tumour. Concomitant 
intra-abdominal disease included ureteric 
obstruction (one patient), bleeding 
through stoma or rectum (two) and bowel 
obstruction (seven).
All patients received antibiotics and if 
there was no obstruction mechanical 
bowel preparation was given before they 
underwent radical en-bloc resection of the 
abdominal wall lesion. Three had excision
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A d u lt  r e s p ir a to r y  d is t r e s s  
s y n d ro m e 2
D e ep  v e in  th ro m b o s is 1
S e p t ic e m ia 3
L a te
M a r le x
D e h is c e n c e  o f M a r le x  f ro m  
s y m p h y s is  p u b is 1
O th e r
P u lm o n a r y  e m b o lis m 1
B o w e l o b s t r u c t io n  
( re c u r re n t  tu m o u r) 4
R e c u r r e n t  a b d o m in a l w a l l  tu m o u r 1
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of the abdominal wall lesion alone. The 
abdominal wall was resected in combina­
tion with small bowel in four patients, 
with large bowel in one and with both 
large and small bowel in three patients. 
Six patients underwent resection of invol­
ved bowel and bladder, kidney and ure­
ter. Two patients required resection of a 
segment of abdominal wall, kidney, ure­
ter, head of the pancreas, large and small 
bowel and a segment of liver. All proce­
dures involved removing tumour with ad­
jacent skin, subcutaneous tissue, fascia 
and any associated intraperitoneal tumour 
mass or involved organs. Marlex mesh 
was used to reconstruct the abdominal 
wall in all patients. A single layer of mesh 
was sutured with nonabsorbable mono­
filament nylon to fascial or bone edges. 
Skin could be mobilized in all cases to 
cover the abdominal wall defect.
Results
There was one early death, secondary 
to a surgery-related coagulopathy. 
Postoperative complications are listed in 
Table I. Early complications associated 
with the Marlex mesh included wound 
infections in 10 patients, 3 of whom had 
obstructed bowel at the time of surgery. 
Nine of the 10 had undergone bowel 
resection just before the abdominal wall 
defect was closed with Marlex. All 
infected wounds were treated conserva­
tively with debridement and packing. The
Marlex mesh was not removed. Other 
septic complications included a sub­
cutaneous seroma, a subphrenic abscess 
that was drained through a flank incision 
leaving the Marlex intact and a colonic 
fistula that drained through the Marlex. 
This last patient was reoperated on 2 
months later to close the fistula, but the 
Marlex was not removed. In one patient 
who had a pelvic exenteration with 
abdominal wall replacement, an ileal- 
conduit cutaneous fistula developed 
through the Marlex. The fistula was 
managed locally for 6 months when 
reoperation through the Marlex was per­
formed, removing the conduit and replac­
ing it with a wet colostomy. The only fur­
ther complication in this patient was a 
wound infection, managed by local meas­
ures. Early systemic complications were 
pulmonary embolism, deep vein throm­
bosis and septicemia. The only late com­
plication associated with the use of 
Marlex was detachment of the mesh from 
the symphysis pubis. Conservative 
management resulted in healing by granu­
lation without herniation or any other 
problem. Thirteen of the 19 patients died 
from 1 to 20 months after operation 
(mean 12 months). Six patients are alive 
1 to 20 months after surgery. Several were 
able to return to their homes and jobs. 
All reported a decrease in the amount of 
pain and freedom from foul-smelling 
lesions of the abdominal wall.
Discussion
Recurrent tumour in the abdominal 
wall is unusual. Surgeons tend to avoid 
operation in these patients because of the 
questionable prognosis, the magnitude of 
resection necessary and a concern about 
closing the defect when there is contami­
nation from infected tumour or ob­
structed bowel. Several groups favouring 
an aggressive surgical approach to such 
tumours report a favourable 5-year rate 
(up to 45%),1 good tumour control and 
prolonged palliation.2 However, a 
limited resection of tumour predicates a 
high rate of local recurrence,3 and 
Ravitch has advocated en-bloc removal of 
skin and underlying strictures taking a 
wide margin of normal tissue, and ampu­
tation of adherent organs.1 A major 
problem is repair of the musculofascial 
abdominal wall defect. Several methods 
have been used in an attempt to recon­
struct the normal anatomy. Fascial and 
muscular flaps, musculocutaneous flaps, 
free fascial grafts and free skin grafts 
have all been tried.4 Subsequent hernia­
tion or abdominal wall weakness is com­
mon, as the nerve and vascular supply 
may be damaged during dissection, and 
tissues are less than optimal in these fre­
quently malnourished or elderly patients. 
If subsequent radiotherapy or surgery is 
needed for local recurrence after tissue 
replacement of the abdominal wall, fur-
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ther problems with strength and viability 
arise and so foreign materials have been 
used. Metallic meshes have been tried, but 
they are heavy, prone to cause infection, 
demonstrate a poor healing capacity and 
tend to late fragmentation.
Mar lex, a knitted polypropylene mesh 
exhibits many of the ideal characteristics 
necessary for use in full-thickness 
abdominal wall replacement.5,6 With a 
uniform molecular structure it has a low 
propensity for bacterial trapping and, 
thus, a high resistance to infection. It 
stimulates little foreign-body reaction. 
Marlex has a high tensile strength in two 
directions and does not degrade. In situ, 
fibroblasts rapidly incorporate into the 
mesh spaces and seal off the peritoneal 
cavity. Within 6 weeks of insertion a 4- 
to 5-mm layer of fibrous tissue through 
the mesh has been measured.7 Healthy 
granulation tissue overlying the mesh 
allows skin grafting as necessary. 
Ledesma and colleagues1 studied 22 
patients with abdominal wall recurrences; 
14 underwent radical en-bloc resection 
of the tumour mass and abdominal 
wall reconstruction with Marlex. As in 
our group, Marlex was placed even when 
the peritoneal cavity was contaminated. 
There was no wound dehiscence, suture­
line necrosis or small-bowel fistulas 
related to the plastic mesh. One patient 
had a chronic staphylococcal infection 
associated with detachment of the mesh,
and a large hernia. Other groups8 found 
no increase in the rate of wound infection 
when Marlex was incorporated in the 
closure. Antibiotics should be given 
prophylactically if contamination is a 
concern. When infection occurs, treat­
ment with antibiotics and local wound 
care usually suffice.
Summary and Conclusions
Our results with en-bloc resection of 
abdominal wall tumours and reconstruc­
tion of the full-thickness abdominal wall 
defect with Marlex are encouraging. Six 
of our 19 patients are alive 1 to 24 months 
postoperatively (mean survival 12 
months). Recently more patients have 
undergone resection as we have been 
encouraged by our early results. In the 
m ajority of patients we achieved 
prolonged palliation with freedom from 
pain or pressure sensation and potential 
intra-abdominal catastrophes from 
obstructed bowel or the urinary system. 
Cosmesis was improved as patients no 
longer had to deal with foul-smelling, 
unsightly abdominal wall tumours. Even 
when there was intestinal contamination 
the use of Marlex did not lead to serious 
septic complications. Local wound infec­
tions were managed easily, at home, with 
attentive local therapy. Marlex replace­
ment did not interfere with subsequent 
treatment with radiotherapy or hyperther­
mia and did not preclude reoperation for 
intra-abdominal recurrence or bowel 
obstruction. Finally, in isolated abdomi­
nal wall recurrence major resection may 
be curative. Thus, we believe that even in 
the face of intestinal contamination, there 
is a definite role for aggressive surgical 
management of abdominal wall metas- 
tases using Marlex mesh for recon­
struction.
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Host-Defence Mechanisms in Surgical Patients: 
Case Report of Reduced Polymorphonuclear Neutrophil 
and Antibody Functions Associated With Surgical Sepsis
The authors evaluated the host-defence 
capability of a 33-year-old woman with a 
history of poor wound healing, gastroin­
testinal fistulas and bacterial and fungal 
sepsis after abdominal operations. The 
following tests gave normal results: 
hemoglobin, blood neutrophil and mono­
cyte counts, delayed hypersensitivity 
skin test, serum albumin, immunoglobulin 
and complement levels, blood T- and B- 
cell percentages, in-vitro immunoglobulin 
synthesis and body cell mass.
The following tests gave abnormal 
results: lymphocyte count, leukocyte 
adherence, in-vivo and in-vitro polymor­
phonuclear neutrophil chemotaxis, neu­
trophil bacterial killing and antibody 
response to tetanus toxoid. Decreased 
polymorphonuclear neutrophil and 
humoral immune functions could account 
for the woman's history of repeated sur­
gical sepsis. Evaluation of host-defence 
mechanisms can illuminate the cause of 
repeated episodes of sepsis.
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Les auteurs ont evalue les defenses 
immunitaires d'une femme de 33 ans 
ayant des antecedents de cicatrisation de 
plaie difficile, de fistules gastro- 
intestinales et de sepsies bacteriennes et 
fongiques apres operations abdominales. 
Les epreuves suivantes se sont averees 
normales: hemoglobine, decomptes des 
polynucleaires neutrophiles et des 
monocytes sanguins, test cutane 
d'hypersensibilite retardee, albumine, taux 
d'immunoglobulines et de complement, 
pourcentages de lymphocytes B et T, 
synthese in vitro des immunoglobulines 
et masse cellulaire corporelle.
Des anomalies importantes des tests 
suivants ont 6te observees: decompte 
leucocytaire, adherence des leucocytes, 
chimiotaxie in vivo et in vitro des poly- 
morphonucleaires neutrophiles, bact£rici- 
die des neutrophiles et reponse anticorps 
ci I'anatoxine tetanique. Une diminution 
des polymorphonucleaires neutrophiles et 
des fonctions immunitaires humorales 
peuvent expliquer I'histoire de sepsies 
chirurgicales repetees chez cette femme. 
L'evaluation des mecanismes de defense 
immunitaire peuvent gclairer la cause 
d'episodes d'infections a repetition.
Despite modern antisepsis and surgical 
techniques, postoperative sepsis remains 
a problem. Some patients present with 
repeated episodes of sepsis. In evaluating 
these patients, our research has focused 
on host-defence mechanisms. Clinical and 
research tests of immune function can be 
used to define underlying defects in host- 
defence mechanisms. In this paper we 
illustrate how such testing can be applied to the individual patient.
Host-defence mechanisms, for the pur­
pose of study, can be divided into two 
groups: antigen-specific and nonspecific. 
Antigen-specific responses may again be
divided on the basis of effector cells. 
Immune responses mediated by T lym­
phocytes are classified as cell-mediated 
functions, while those mediated by 
specific antibody produced by B lympho­
cytes are classed as humoral immune 
functions. Antigen-nonspecific host- 
defence mechanisms comprise phagocytic 
activity, predominantly mediated by poly­
morphonuclear neutrophils (PMN), and 
complement functions. These distinctions 
are arbitrary in that all body processes are 
ultimately cellular in origin, and there is 
substantial interaction between the vari­
ous arms of host-defence mechanisms.
Methods
The following routine laboratory tests 
were performed in the clinical labora­
tory of the Royal Victoria Hospital in 
Montreal: leukocyte count, including 
differential counting, measurement of 
hemoglobin, total serum protein, serum 
albumin, alpha-, beta- and gamma­
globulin levels, immunoglobulins G, A 
and M, total hemolytic complement 
(CH50) and circulating C3 levels.
Peripheral blood B lymphocytes were 
enumerated by an antibody-coated, poly­
acrylamide, bead, rosette assay.1 Data 
are shown as percentage of surface Ig- 
positive circulating lymphocytes. Serum 
antibody response to tetanus toxoid was 
determined by solid-phase radio­
immunoassay2 after the intramuscu­
lar adm inistration of 0.5 mL of 
aluminum-phosphate-adsorbed tetanus 
toxoid. The antibody response was 
defined as the ratio of antibody content 
in the day 14 post-immunization serum 
to that in the pre-immunization serum. In 
vitro IgG and IgM synthesis was meas­
ured in supernatants of the cultures of 
peripheral blood mononuclear cells as
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previously described.3 Mononuclear cells 
were cultured under standard conditions, 
either unstimulated or stimulated with 
pokeweed mitogen (PWM) (a polyclonal 
T-cell-dependent B-cell mitogen).
Delayed-type hypersensitivity (DTH) 
skin testing was performed using a stan­
dard method with five recall antigens: 
Candida, mumps skin-test antigen, puri­
fied protein derivative, Trichophyton and 
streptokinase-streptodornase. The sum of 
the mean greatest diameter of induration 
at 24 or 48 hours after injection of the five 
antigens was defined as the skin-test 
score.4 Blood T-cell percentage was 
determined using sheep erythrocyte 
rosettes treated with 2-aminoethyliso- 
thiouronium bromide.5
Polymorphonuclear neutrophil adher­
ence to nylon wool was tested by a 
modification of the MacGregor tech­
nique.6 The results are expressed as the 
percentage of total leukocytes that adhere 
to the nylon wool column. Polymor­
phonuclear neutrophil chemotaxis was 
measured in the Nucleopore assay sys­
tem.7 The PMN chemotactic migration 
is expressed as the number of cells per 
high-power field using zymosan-activated 
serum as the chemoattractant. The bac­
terial killing ability of PMNs was meas­
ured by a modification of the technique 
of Quie and colleagues.8 Bactericidal 
function was assessed at 10, 20 and 40 
minutes after mixing of pre-opsonized 
Staphylococcus aureus 502A and PMNs, 
and expressed as a percentage of bacterial 
inoculum killed by the PMNs at each 
sampling time.
The body cell mass was determined by 
the isotope dilution method.9
Case Report
A 33-year-old woman was referred to us 
because she had a long history of surgical sep­
sis, gastrointestinal fistulas and delayed wound 
healing. On physical examination she was 170 
cm tall and weighed 42.3 kg. There were mul­
tiple healed abdominal incisions, but no evi­
dence of active fistulas or inflammation. The
remainder of physical examination gave nor­
mal results.
An appendectomy performed when she was 
16 years old had taken 6 months to heal. After 
salpingo-oophorectomy and hysterectomy at 
age 28, multiple skin-grafting procedures were 
necessary to achieve wound closure. Three 
years later she had similar wound-healing 
problems after oophorectomy. No abnormal­
ities had been found except iron-deficiency ane­
mia. Subsequently she had a low-output 
enterocutaneous fistula. It was treated with 
total parenteral nutrition and was complicated 
by Candida septicemia. She then presented with 
an intra-abdominal abscess requiring surgical 
drainage. The postoperative course was com­
plicated by several episodes of gram-negative 
and Candida septicemia. At subsequent 
laparotomy to resect the still-unhealed bowel 
fistula, little inflammation and few peritoneal 
adhesions were noted. The following year she 
presented with peritonitis. Laparotomy demon­
strated peritoneal rupture of a pelvic abscess. 
The postoperative course was again compli­
cated by prolonged wound healing and 
abdominal pain. A repeat laparotomy during 
the same hospital admission showed only a 
small amount of fluid in the peritoneal cavity. 
Two months later, a large pelvic mass contain­
ing clear watery fluid was drained per rectum. 
Coliforms were cultured from this fluid and 
from all previous abscesses and fistulas.
Before referral to us she had again presented 
with an enterocutaneous fistula and intra­
abdominal abscess. Laparotomy was compli­
cated by wound abscess and cecal fistula. Speci­
mens of bowel obtained at various surgical 
procedures consistently failed to show evidence 
of inflammatory bowel disease.
Results
T-Cell Function
Although a DTH skin test is usually 
classified as a T-cell function test, the 
skin-test score in surgical patients clearly 
can be used as a global assessment of 
antibacterial host-defence capability.4 
The DTH skin-test score (45 mm) in our 
patient was normal when compared with 
those of 25 healthy control subjects (35.7 
± 0.5 [mean ± SEM]). Using generally 
accepted normal values from the litera­
ture (60% to 80%) we found that the
blood T-cell percentage was normal 
(79%).
B-Cell Function
Serum IgG and IgA levels, although 
higher than average normal data (Table 
I), were within the normal clinical labora­
tory range (IgG 2 to 12 g/L, IgA 0.50 to 
3.50 g/L). The serum IgM level was 
mildly elevated. The circulating blood B- 
cell percentage was within an accepted 
normal range. Although the pre-immu­
nization antitetanus toxoid antibody level 
was normal, consistent with a history of 
immunization by booster injection 5 years 
previously, the increase in serum antibody 
content after immunization was less than 
twofold. In a previous study,10 71% of 
healthy individuals showed a greater than 
10-fold increase and 88% showed a 
greater than 2-fold increase in antiteta­
nus toxoid antibody content after immu­
nization.
The pattern of in-vitro immoglobulin 
synthesis was normal (Table I). In 
unstimulated cultures, peripheral blood 
mononuclear cells produced small 
amounts of both IgG and IgM. In PWM- 
stimulated cultures, less imunoglobulin 
was produced than by the cells from the 
normal donor on the same day, but the 
quantity was within a normal range (100 
to 2000 ng) and showed a satisfactory 
response to PWM stimulation.
Polymorphonuclear Neutrophil Function
While the circulating blood PMN count 
was close to normal, percentage adher­
ence to nylon wool was substantially 
increased (Table II). In-vivo chemotaxis, 
measured as cell delivery to a modified 
Rebuck skin window chamber,11 was 
depressed compared with'that in other 
preoperative surgical patients. Similarly, 
in-vitro chemotaxis was notably reduced. 
Bactericidal function of PMNs against 
the test organism Staphylococcus aureus 
502A was reduced at all time intervals 
compared with a simultaneously tested, 
normal-cell donor.
Preincubation of PMNs with 10'6M 
acetylsalicylic acid or 10'9M levamisole12 
failed to correct in-vitro chemotaxis. The 
possible existence of plasma inhibitors of 
chemotaxis was investigated by prein­
cubating normal PMNs in patient plasma. 
No significant difference was found.
Complement and Miscellaneous Tests
Tests of complement levels gave nor­
mal results (Table III). Moderately severe 
lymphocyte depletion and normal cir­
culating monocyte counts were obtained. 
Despite a low serum albumin level, nutri­
tional status, as assessed by determination 
of body cell mass using an isotope dilu­
tion method, was normal.
T a b le — B -C e ll F u n c t io n
T e s t P a t ie n t N o rm a l
S e r u m  im m u n o g lo b u lin s , g /L *
Ig G 1 5 . 6 9 8 . 5 4  ±  0 . 3 8
Ig M 2 . 5 3 1 .3 1  ±  0 . 1 0
Ig A 2 . 9 3 1 .4 1  ±  0 . 1 7
B lo o d  B c e lls , % 9 7 - 1 7
A n t i t e ta n u s  to x o id re s p o n s e 1 .9  fo ld >  1 0  f o ld 9
(r a t io  in c re a s e )
In -v it r o  im m u n o g lo b u lin  s y n th e s is , n g t
6 0  ± 1 2S p o n ta n e o u s : Ig G 3 4  ±  5
Ig M 4 3  ±  3 4 5  ± 8
P W M s t im u la t e d : IgG 4 7 5  ±  1 7 8 6 0  ± 3 2
Ig M 3 1 3  ±  3 8 1 3 3 3  ±  5 3
" N o r m a l  v a lu e s  a re  m e a n s  ±  S E M  f r o m  p re v io u s  s tu d y 4 o f  2 5  h e a lth y  c o n tro l s u b je c ts .  
t N o r m a l  v a lu e s  a re  m e a n s  ±  S E M  fo r  t r ip l ic a te  c u ltu re  w e l ls  f r o m  s im u lta n e o u s ly  c u ltu re d  m o n o n u c le a r  
c e lls  f r o m  h e a lth y  c o n tro l d o n o r .
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Discussion
There are three determinants of infec­
tion: the environment, bacteria and the 
host. Despite advances in environmental 
m anipulation, such as asepsis and 
im proved surgical technique, and 
developments in antimicrobial therapy, 
postoperative sepsis remains a problem. 
Attention has therefore been directed to 
the evaluation of host-defence mechan­
isms. A hierarchy of tests is now availa­
ble for the immunobiologic evaluation of 
patients, ranging from those commonly 
available in specialized research facilities. 
In the work-up of a patient with repeated 
episodes of sepsis, these tests can be used 
to answer the question, Are there iden­
tifiable abnormalities of host-defence 
mechanisms that could contribute to an 
increased susceptibility to infection?
Immunologic deficiencies are usually 
divided into those that are primary, or 
congenital, and those that are acquired, 
or secondary to another disease process. 
The evaluation of the immunocompro­
mised patient proceeds from history and 
physical examination to laboratory inves­
tigation of T and B lymphocyte, PMN 
and complement functions.13
Delayed-type hypersensitivity, although 
usually considered a test of T-cell func­
tion, is clearly a means of globally assess­
ing host defence.4 Indeed, a predictive 
equation, including the skin-test score, 
has recently  been introduced by 
Christou14 as a means of calculating an 
individual patient’s risk of septic-related 
death. According to this formula, the risk 
of death in our patient was 0.04. Despite
the recurrence of septic complications, 
this low risk is in agreement with the con­
tinued survival of this patient. Repeated 
episodes of sepsis in this woman proba­
bly occurred because of isolated defects 
in immunity, rather than the global 
acquired immunosuppression frequently 
seen in surgical patients.
Additional tests of T-cell function are 
available: analysis of T-helper and 
suppressor-cell subsets with monoclonal 
antibodies, dinitrochlorobenzene skin 
testing, rejection of skin grafts, thymic 
hormone assay and lymphocyte-trans- 
formation studies can add information 
about the functional state of lympho­
cytes. Assays for lymphokine activity are 
on the horizon.
In the assessment of B-cell function, 
the sine qua non is a normal antibody 
response to immunization. Our patient 
showed a reduced humoral immune 
response to vaccination with tetanus tox­
oid. Because the antibody response to 
protein antigens, such as tetanus toxoid, 
depends on normal T-helper-cell func­
tion, it is unknown whether this 
represents T-cell failure or intrinsic B-cell 
dysfunction.
The pattern of in-vitro immunoglobu­
lin synthesis in this woman was normal. 
The results of such mononuclear cell cul­
tures reflect a complex set of interactions 
between B cells and T-helper and suppres­
sor cells. Mononuclear cells from surgi­
cal patients with depressed skin-test reac­
tivity and increased risk of septic 
mortality produce increased amounts of 
immunoglobulin spontaneously.3 They 
frequently show an absent or reversed
response to stimulation with PWM, a T- 
cell-dependent, B-cell mitogen, suggest­
ing abnormalities in the balance of regula­
tory T cells. The data in this subject indi­
cate normal function of T-helper cells for 
immunoglobulin synthesis and an absence 
of PWM-inducible suppressor cells.
Additional tests that could be consi­
dered in the evaluation of B-cell function 
include bone-marrow examination, 
lymph-node biopsy, antibody levels to 
“ n a tu ra l”  antigens and antibody 
response to polysaccharide or other rela­
tively T-cell-independent antigens.
The PMN is the principal cell in the 
defence against bacteria. Alterations in 
neutrophil function in surgical patients 
have been described and are associated 
with an increased risk of sepsis and 
death.15 Adherence is a nonspecific test, 
frequently increased in a variety of con­
ditions. Chemotaxis, an essential PMN 
function, is decreased after major 
trauma16 and in patients with a reduced 
DTH skin-test score.15 In these patients, 
levamisole and acetylsalicyclic acid 
restored the acquired defect in chemotaxis 
to normal.12 Failure to do so in our 
patient suggests that the defect in neu­
trophil motility was primary.
Cell delivery to skin abrasions can be 
used to study in-vivo chemotaxis.11 The 
decreased cell delivery in this patient 
could result in failure to localize infection 
during the early decisive period,17 with 
subsequent tissue invasion. Reduced bac­
terial killing, aggravated by low levels of 
opsonins due to deficient humoral immu­
nity, could account for the increased sus­
ceptibility to recurrent sepsis.
Finally, the question of treatment 
arises. It is known that malnutrition, 
trauma, surgery, burns and malignant 
disease13 variably alter host immunity. 
Although intuitive, it is not clear at 
present that the management of these 
conditions restores host-defence mechan­
isms. As a general principle, simple resto­
ration of normal physiology is likely an 
important positive immunomodulator.18 
Beyond that, it is not yet clear what role 
drugs and biologic agents will play in the 
future management of the compromised 
host.19 It is clear, however, that the first 
step is to understand the problem both in 
populations and in the individual patient.
We acknowledge the assistance of Dr. H. 
Shizgal in performing the isotope dilution study 
of body cell mass, the technical work of D. 
Charrete, L. Chiasson and B. Kapadia and the 
secretarial assistance of N. Theoret.
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Table II—Polymorphonuclear Neutrophil Function
Test Patient Normal
Blood PMN count, X 109/L 2.4 3.6 + 0.2*
Adherence, % 72.6 65.5 + 1.8*
In-vivo chemotaxis, X 106/mL 1.18 ± 0.04 2.04 + 0.46t
In-vitro chemotaxis
(cells/high-power field)! 12.8 ± 1.5 37.0 + 2.5
Bacterial killing, %§
10 min - 7 13
20 min 4 16
40 min 25 39
'Means ± SEM from previous study4 of 25 healthy control subjects.
tMean + SEM of previously collected data11 from surgical patients preoperatively.
4Arithmetic mean ± SEM of determinations on two separate occasions: normal data are the average 
for simultaneously performed assays using normal donor cells.
§Normal data are from control cells run simultaneously with patient cells.
Table III—Complement and Miscellaneous Tests
Test Patient Normal*
Complement C3, g/L 1.04 1.05 + 0.25
Total hemolytic complement (CH50), U/mL Normal 186 +13
Hemoglobin, g/L 142 143 + 3
Lymphocytes, X 109/L 0.70 2.06 + 0.13
Monocytes, X 109/L 0.30 0.35 + 0.03
Total protein, g/L 64 74 + 1
Serum albumin, g/L 38 44 ± 1
’ Means ± SEM taken from previous study4 of 25 healthy control subjects.
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Systemic Candidiasis in a Surgical 
Intensive Care Unit
Treatment for system ic candidiasis has 
often been withheld because of the 
nephrotoxicity of standard amphotericin 
B therapy, particularly in immuno- 
depressed patients. The authors describe 
their experience between 1981 and 
1983  with 29  such patients in the inten­
sive care unit who were treated with 
low-dose amphotericin B. The diagnosis 
was made when endophthalmitis or per­
sistent fungemia w as present, or when 
Candida w as cultured from three or more 
body sites. The daily dose of amphoteri­
cin B w as 0.3 to 0.5 mg/kg. Treatment 
w as accompanied by a mean increase in 
the serum creatinine value of 2 6 %  in 
patients who did not undergo dialysis 
before therapy, but this did not lead to 
renal failure. The overall death rate was 
7 2 .4 % . Non-survival appeared to be 
associated with an inadequate total 
dosage (less than 6 mg/kg); survivors 
received a mean total dose of 5 7 0  mg. A  
retrospective analysis of positive 
peritoneal cultures failed to support their 
previously reported significance.
The authors conclude that, in some 
instances, low-dose amphotericin B will 
effectively treat system ic candidiasis, 
resulting in little renal impairment, and 
that the criteria for such treatment 
require re-evaluation.
On s 'abstient frequemment de traiter la 
candidiase generalisee a cause de la
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nephrotoxicite de la therapie convention- 
nelle a I'amphotericine B, particuliere- 
ment chez le patient immunodeprime.
Les auteurs decrivent I'experience qu 'ils 
ont conduite entre 1981 et 1983  chez 
29  de ces patients aux so ins intensifs, 
utilisant de I'amphotericine B a faible 
dose. Le diagnostic a ete pose en pre­
sence d ’une endophthalmie ou d 'u n  fon- 
gemie persistante, ou quand du Candida  
etait cultive de trois localisations anato- 
m iques ou plus. La dose quotidienne 
d'amphotericine B a varie de 0.3 a 0.5 
mg/kg. Chez les patients qui n'avaient 
pas ete soum is a une dialyse prealable, 
ce traitement a ete accom pagne d 'une  
augmentation moyenne de la creatinine- 
mie de 2 6 %  mais n 'a  pas provoque 
d 'insuffisance renale. Le taux global de 
mortalite a ete de 7 2 .4 % .  Le deces a 
paru relie a une dose cumulative totale 
insuffisante (de m oins de 6 mg/kg); les 
survivants ont recu une dose totale 
moyenne de 57 0  mg. Une analyse 
retrospective des cultures peritoneales 
positives n 'a  pas reussi a demontrer 
I'importance qu 'on  leur a deja pretee.
Les auteurs concluent qu 'en certaines 
circonstances, I'amphotericine B a faible 
dose est efficace contre la candidiase 
generalisee et cause peu d 'insuffisance 
renale. Les criteres de traitement se doi- 
vent d'etre reevalues.
Systemic candidal infections are now 
more frequently recognized as contribut­
ing to the death of patients after opera­
tion, particularly those with multiple- 
organ-failure syndromes and systemic 
bacterial sepsis.
In the past, treatment was often with­
held or delayed because of the nephrotox­
icity associated with standard amphoteri­
cin B therapy, the dosage schedule for 
which was taken from those used in the 
treatment of other fungal infections, par­
ticularly in immunodepressed patients.1,2
Recently Solomkin and associates3 
recommended low-dose amphotericin B 
therapy (a total dose of 6 to 8 mg/kg in 
daily doses of 0.3 to 0.5 mg/kg) for sys­
temic candidal infections, because it could 
sterilize positive fungal cultures with lit­
tle nephrotoxicity.
This study reviews our experience with 
patients in the surgical intensive care unit 
of the Toronto General Hospital who 
were considered to have systemic candidi­
asis and were treated with low-dose 
amphotericin B, as recommended by 
Solomkin and colleagues.
Patients and Methods
The charts of patients admitted to the 
surgical intensive care unit at Toronto 
General Hospital from 1981 to 1983 inclu­
sive were reviewed to find patients who 
had systemic candidiasis, according to 
one of the following criteria: evidence of 
endophthalmitis; fungemia 24 hours after 
intravascular lines were removed; culture 
of Candida from three or more body 
sites. There were 34 patients of whom 29 
received low-dose amphotericin B therapy 
(group 1). This consisted of a test dose 
of 1 mg followed by daily incremental 
5-mg doses up to a maximum daily dose 
of 0.3 to 0.5 mg/kg intravenously. All 
patients were pre-treated with 50 mg of 
Benadryl and 50 to 100 mg hydrocorti­
sone intravenously. Sometimes they also 
received 50 to 100 mg of Demerol 
intramuscularly.
A second group of 27 patients in whom 
Candida was cultured from abdominal
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abscesses, peritoneal drainage or from 
swabs of the peritoneal cavity at 
laparotomy were examined retrospec­
tively. Eleven received amphotericin B 
when, as noted above, the positive 
peritoneal cultures formed a part of the 
cri eria for systemic candidiasis. The 16 
remaining patients were not given 
amphotericin B and formed group 2.
Results
Group 1
Of the 29 patients in this group who 
received amphotericin B there were 8 sur­
vivors (death rate 72.4%). Comparisons 
between survivors and nonsurvivors are 
noted in Table I. Fungemia was present 
in 45% of patients—50% of the survivors 
and 43% of nonsurvivors. Endophthalmi­
tis was present in 41% overall—38% of 
survivors and 43% of nonsurvivors. Cul­
ture of Candida from three or more body 
sites (exclusive of stool, mouth, vagina 
and blood) was positive in 75% of sur­
vivors and in 48% of nonsurvivors. 
Malignant disease was present more often 
in survivors (25%) than nonsurvivors 
(14%). The same was true for associated 
bacteremia (63% versus 48%).
The mean time between diagnosing the 
candidiasis and instituting therapy was 
7.9 days in survivors versus 6.5 days in 
nonsurvivors. Four survivors had 
documented renal failure before therapy 
was started. The other four showed a 
mean increase in serum creatinine value 
of 22% after completion of therapy. Of 
the nonsurvivors, 12 (57%) had pre­
treatment renal failure; the remaining 9 
had a mean increase in serum creatinine 
value of 28%.
All survivors received the recom­
mended total dosage of amphotericin B 
(more than 6 mg/kg), being given a mean 
total dose of 570 mg, but only 38% of 
nonsurvivors received the recommended 
dosage, with a mean total dose of 356 mg.
Group 2
Of the 16 patients with positive 
peritoneal cultures who received no 
specific antifungal treatment, 10 survived. 
None of the 16 patients had evidence of 
endophthalmitis or fungemia. Three of 
the 10 survivors had cultures positive for 
Candida from three different body sites. 
On reviewing the case histories of these 
patients, there was no evidence of sepsis 
(prolonged fever, leukocytosis or a sep­
tic hemodynamic profile) to alert the phy­
sician to the possibility of systemic can­
didiasis. In contrast all of the six 
nonsurvivors exhibited a progressive 
downhill septic course. Two of them had 
cultures positive for Candida from three 
body sites. The death rate in this group 
was 37.5%.
Discussion
Diagnosis
The certain clinical diagnosis of sys­
temic candidiasis is often difficult. 
Besides the growth of Candida from 
biopsy specimens, accepted criteria for 
diagnosis include endophthalmitis, posi­
tive blood cultures 24 hours after removal 
of intravascular lines and culture of Can­
dida from three or more separate body 
sites.3,4 These three criteria formed the 
basis for diagnosis of candidiasis and for 
treatment with amphotericin B in our 
series.
Because of autopsy findings of dissemi­
nated candidiasis associated with negative 
antemortem blood cultures,5-7 and of 
negative optical findings in patients with 
fungemia, recent reports3,4 have sup­
ported the use of systemic antifungal ther­
apy with low-dose amphotericin B based 
solely on positive cultures from three 
body sites. Although positive cultures 
from multiple sites may reflect only mas­
sive colonization rather than infection, it 
was notable that of the 19 patients who 
met this criterion, 11 (58%) also had fun­
gemia or endophthalmitis. Moreover, the 
death rate of the subgroup who had posi­
tive cultures at three sites as the sole indi­
cation for treatment was 57% (4 of 7) and 
a number of patients with fungemia had 
positive cultures at multiple sites before 
documentation of Candida in the blood. 
These data support contentions in the 
recent literature3’4 that isolation of Can­
dida from three separate body sites is 
presumptive evidence of systemic can­
didiasis.
It has been suggested4,8 that the cul­
ture of Candida from the peritoneal 
cavity should, by itself, be indicative of 
systemic candidiasis. Review of our 16 
patients who had positive cultures from 
peritoneal abscesses, swabs and drainage
showed that the death rate was 37.5% (10 
survived without treatment) which is 
much lower than one would expect if 
positive peritoneal cultures truly reflected 
systemic candidiasis.
On the basis of this retrospective analy­
sis, we would question culture of Candida 
from peritoneal fluid alone is diagnostic 
of systemic candidiasis. We contend, 
however, that patients with sepsis whose 
septic state continues after appropriate 
surgical intervention and adequate anti­
biotic therapy should be treated with low- 
dose amphotericin B if they have perito­
neal cultures positive for Candida.
Renal Function
Only one patient required dialysis after 
initiation of amphotericin B therapy. This 
patient, like others, had many reasons for 
deteriorating renal function (bacterial sep­
sis, aminoglycoside therapy and multiple 
episodes of hypotension).
The mean increase in the serum creati­
nine value of 22% in survivors and 28% 
in nonsurvivors was not considered 
important in light of the multiplicity of 
nephrotoxic factors present.
It seems clear that what little effect 
there was on renal function should not 
preclude the use of low-dose amphoteri­
cin B therapy in these critically ill patients. 
Dialysis is not a contraindication to the 
use of amphotericin B; four of our eight 
survivors required dialysis before systemic 
antifungal therapy was begun and all had 
return of adequate renal function. Deteri­
oration in renal function is likely a result 
of the septic state or other nephrotoxic 
drugs and should not discourage the con­
tinued use of amphotericin B in low 
dosage.
Treatment
Of the factors considered in Table I,
T a b le  1— C om parison  o f S urv ivors  and N o n su rv ivo rs  in th e  G roup of 
P atie n ts  T re a te d  W ith  A m p h o teric in  B
Fea tu re
S u rv ivo rs  
(n -  8 )
N onsurv ivors  
(n -  2 1 )
M e a n  age, y r ± SD 5 0 .4  ± 1 3 .4 5 4 .7  ± 1 6 .2
Frequency o f m a lig n a n t d isease , no. (% ) 2 ( 2 5 ) 3 ( 1 4 )
A sso ciated  b a c te re m ia , no. (% | 5 ( 6 3 ) 1 0 ( 4 8 )
C rite ria  fo r  t re a tm e n t, no. (% |
Blood cu ltu re 4 ( 5 0 ) 9 ( 4 3 )
E n d o p h th a lm itis 3 ( 3 8 ) 9 1 4 3 )
Positive c u ltu re  fro m  3  s ites 6 ( 7 5 ) 1 0 ( 4 8 )
T im e  in te rv a l, d ± SD
1 s t cu ltu re  to  th e ra p y 1 2 .4  ± 1 2 .6 1 1 .9  ± 1 0 .4
C riteria  m e t to  th e ra p y 7 .9  ± 8 .8 5 .5  ± 6 .5
T h erap y  to  d e a th - 2 8 .7
P re -tre a tm e n t d ia lys is , no. (% l 4 ( 5 0 ) 1 2 ( 5 7 )
Inc iden ce o f ren a l fa ilu re , no (% ) 0 1 1111
M e a n  in c re a s e  in serum  c re atin in e  va lu e , % 2 2 2 8
M e a n  to ta l dose o f am p h o te ric in  B, m g ± S D * 5 7 0  ± 1 7 2 3 5 6  ± 3 4 9
M e t  reco m m en d ed  dosage sch edu le , no. (%) 8 ( 1 0 0 ) 8 ( 3 8 )
'D if fe re n c e  is s ig n ifican t a t  p <  0 .0 5  (unpaired /- te s t ) .
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patients with systemic candidiasis who 
meet the treatment criteria we have out­
lined, receive low-dose amphotericin B 
therapy. After a 1-mg test dose, daily 
increments of 5 to 10 mg should be given, 
depending on the severity of sepsis, to a 
daily dose 0.5 mg/kg until a cumulative 
dose of 6 to 8 mg/kg is reached.
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Chest-Tube Thoracostomy Causing 
Homer’s Syndrome
Horner's syndrome developing early after 
lung biopsy is reported in a 42-year-old 
woman. At the end of the procedure a 
thoracostomy tube was inserted with its 
tip at the T 1 -2  posterior intercostal 
space. The authors conclude that direct 
injury to the second order preganglionic 
neuron in the vicinity of the stellate gan­
glion caused the Horner's syndrome. 
They recommend placing the tip of the 
thoracostomy tube below the level of the 
second rib posteriorly to prevent this 
complication.
On decrit le cas d'une femme de 42 ans 
chez qui un syndrome de Horner est 
apparu peu de temps apres une biopsie 
pulmonaire. A la fin de I'intervention, un 
tube de thoracostomie avait ete insere 
dont le bout passait par I'espace inter­
costal posterieur T 1 -2 . Les auteurs con- 
cluent qu'une blessure directe au neu­
rone preganglionnaire de second ordre a 
proximite du ganglion stellaire a cause le 
syndrome de Homer. Ils recommandent 
de placer le bout du tube de thoracosto­
mie posterieurement sous le niveau de la 
deuxieme cote, afin de prevenir cette 
complication.
Horner’s syndrome of oculosympathetic 
paresis (miosis, ptosis, hemifacial 
anhydrosis and apparent enophthalmos) 
may result from any lesion that interrupts 
the three-neuron sympathetic pathway 
from the hypothalamus to the orbit.1 In 
the largest series analysing its cause and 
localization (216 cases in a general patient 
population),2 the preganglionic second- 
order neuron was involved in 90% of 
cases, usually by malignant tumour.
However, the syndrome is also increas-
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ingly recognized as a transient or perma­
nent iatrogenic event. We report a case 
of Horner’s syndrome secondary to 
thoracostomy, in which the distal end of 
the chest tube lay close to the pleural apex 
posteriorly.
Case Report
A previously healthy 42-year-old white 
woman was seen at another hospital because 
of a sore throat, fever (body temperature 38.5° 
C) and cervical lymphadenopathy, followed in 
a few days by cough productive of yellow spu­
tum and by increasing dyspnea. Broad- 
spectrum antibiotics were prescribed but she 
experienced progressive respiratory failure and 
3 weeks later was referred to the intensive care 
unit of the Ottawa General Hospital. Exami­
nation of the chest revealed poor air entry at 
both lung bases with scattered crepitations. A 
chest film showed extensive alveolar infiltrates. 
A lung biopsy was considered necessary 
because of her continued deterioration, despite 
the use of broad-spectrum antiobiotics.
Through an anterior thoracotomy, wedge 
biopsies of the left lingula and lower lobe were 
obtained. At the conclusion of procedure, a 
chest tube (32 French Argyle thoracic catheter) 
was inserted through the left eighth intercostal 
space in the midaxillary line. Twenty-four 
hours later left-sided Horner’s syndrome was 
noted: there was 3 mm ptosis in the primary 
direction of gaze, 2 mm anisocoria and slight 
hemifacial anhydrosis (Fig. 1). Instillations of 
cocaine (10% solution) and epinephrine 
(1/1000 solution) had no effect on the miotic 
pupil.3 Visual fields, fundi and extraocular 
movements were normal. Other neurologic 
findings were normal; in particular, there was 
no evidence of brachial plexopathy or 
radiculopathy. An anteroposterior chest film 
showed the tip of the thoracostomy tube lying 
at the Tl-2 intercostal space in the left paraver­
tebral gutter (Fig. 2). The tube was promptly 
repositioned and removed 48 hours later, but 
the oculosympathetic paresis persisted. Other­
wise the patient made an excellent recovery 
from pneumonia due to Mycoplasma (serum 
titre 1/640). Follow-up at 7 months revealed 
a persisting but slightly improved Horner’s syn­
drome.
Discussion
The list of surgical procedures linked 
with the development of Horner’s syn­
drome is growing. It includes: lower cer-
FIG. 1—Patient’s eyes 7 days after lung 
biopsy showing moderate left ptosis and 
miosis.
FIG. 2—Anteroposterior chest film show­
ing tip of chest tube at T l-2  intercostal space.
FIG. 3—Diagram showing three-neuron 
ocular sympathetic pathway. Arrow points to 
probable site of injury in our case.
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vical and upper dorsal sympathectomy, 
stellate ganglion block, cordotomy, 
tumour excision, thyroidectomy, phreni- 
cotomy, percutaneous catheterization of 
the carotid artery or internal jugular vein, 
caudal anesthesia, obstetric extradural 
block and interscalene brachial plexus 
block.4 We could find only two previous 
reports in the literature linking Horner’s 
syndrome to placement of a thora­
costomy tube. The first case followed a 
left lower lobectomy for chest trauma and 
persisted at follow-up 3 months later.4 
The second followed a Sugiura procedure 
and resolved completely in 3 weeks.5
The pathogenesis probably relates to 
the close anatomic relation of the apical 
pleura and ocular sympathetic pathway. 
The second-order preganglionic neurons 
are located in the ciliospinal centre of 
Budge and their axons leave the spinal 
cord in the C8 and T1 ventral roots (Fig. 
3). The fibres then course through the 
first thoracic and inferior cervical ganglia 
and ascend to the superior cervical gan­
glion where they synapse with the third- 
order neurons. Fleishman and col­
leagues4 have demonstrated in histologic 
sections that only a thin layer of connec­
tive tissue, the endothoracic fascia, 
separates the parietal pleura from the stel­
late ganglion. In our case, one can read­
ily envisage the tip of the chest tube 
producing repeated, direct-pressure 
trauma to the first thoracic ganglion dur­
ing breathing movements. It is note­
worthy that this complication occurred 
within 1 day of tube insertion and per­
sisted despite its prompt repositioning.
Unless specifically indicated by the clin­
ical situation, we suggest that the chest- 
tube tip should not be placed in close 
proximity to the apical pleura. A location 
inferior to the second rib posteriorly is the 
one least likely to lead to the development 
of iatrogenic Horner’s syndrome.
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BOOK REVIEWS 
continued from page 173
I think that this book should be available for 
orthopedic residents and young orthopedists 
who will find in it first-hand experience that 
they can put to use in their daily practice.
The experienced orthopedist will find up-to- 
date information that provides him with differ­
ent management alternatives for those complex 
cases in which the standard treatment cannot 
easily be applied.
I recommend this text without reservation.
J orge Basora, md
Department of Orthopedics,
Centre Hospitalier Universitaire,
Sherbrooke, PQ,
J 1H 5N4
SURGICAL MANAGEMENT. Edited by 
Selwyn Taylor, Geoffrey D. Chisholm, 
Niall O’Higgins and Robert Shields. 
918 pp. Illust. William Heinemann Medical 
Books Ltd., London, 1984. $99. (US). 
ISBN 0-433-32208-X.
This is a very interesting book in many aspects 
and was a pleasure to review. Its aims are 
clearly stated by the editors in the foreword: 
“ to cover the subjects that constitute the daily 
task of a general surgeon in, for example, a 
district hospital...” . This aim is evident in its 
organization. About one third of the book is
continued on page 211
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SESAP V Critique
IT E M S  195-197
Opportunistic infection is a common complication among patients with multiple trauma, and severe debilitating illness 
associated with an immunosuppressed state. Many of these patients have been treated with broad-spectrum antibiotics, 
altering the natural body flora. Although once considered a skin contaminant, Staphylococcus epidermidis has become 
an important pathogen among seriously ill patients and is a frequent cause of central venous catheter sepsis. S. epidermi­
dis is resistant to most antistaphylococcal drugs, but is usually sentitive to vancomycin. Fungemia due to Candida albicans 
is also observed among critically ill patients and as a central venous catheter contaminant. When invasive candidiasis is 
present, the treatment of choice is amphotericin B.
195 C 196 197 [a ]
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Surgical Treatment of Lung Cancer: 
Promise and Problems of Early Diagnosis
Recent studies have shown that the sur­
vival of patients with lung cancer is 
improved if the tumour is resected 
before it becomes larger than 3 cm in 
diameter and before it spreads to lymph 
nodes. While this suggests a positive 
benefit from early detection, recent 
mass-screening studies have claimed 
that the benefit obtained from this proce­
dure is illusory because it relates to a 
lead-time bias. This study reports the 
results of surgical resection of 143 
primary lung cancers. The data con­
firmed that the predicted 5-year survival 
was greatest (74%) following resection 
of lesions that were less than 3 cm in 
diameter without node involvement. 
Analysis showed that the age of these 
patients was 63 ± 8 years, the same as 
in patients with larger tumours and more 
extensive node involvement. This sug­
gests that tumours progress rapidly from 
a stage at which resection is beneficial 
to stages at which it is not. Although it 
is desirable that tests predict the 
presence of small tumours, the high 
requirements for sensitivity and specific­
ity at current prevalence rates for lung 
cancer make this goal impractical.
Des etudes recentes ont revele que la 
survie des patients atteints de cancer 
pulmonaire s'ameliore quand la tumeur 
est resequee avant que son diamfetre 
depasse 3 cm et avant qu'il envahisse 
les ganglions lymphatiques. Alors que 
ceci paraTt indiquer les effets positifs 
d'une detection precoce, des etudes
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recentes de depistage systematique ont 
conclu que les avantages pretes a cette 
intervention sont illusoires car ils decou- 
lent d'un biais lie au delai de diagnostic. 
Cette etude decrit les resultats de la 
resection chirurgicale dans 143 cas de 
cancer primitif du poumon. Les donnees 
confirment que la survie h 5 ans est la 
meilleure (74%) apres resection de 
tumeurs de moins de 3 cm de diametre 
qui n'ont pas encore atteint les ganglions 
lymphatiques. L'analyse revele que I'age 
moyen de ces patients etait de 63 ± 8 
ans, le meme que les porteurs de 
tumeurs plus grosses ayant envahi les 
ganglions. Ceci indique que les tumeurs 
evoluent rapidement d'un stade ou la 
resection est salutaire vers un stade ou 
elle ne Test pas. Bien qu'il soit souhaita- 
ble de predire par des tests la presence 
de petites tumeurs, les exigences elevees 
en termes de sensibilite et de specificite 
compte tenu de la prevalence actuelle du 
cancer du poumon rendent ce but peu 
realiste.
The purpose of this report is to discuss 
the benefit of treating lung cancer when 
the lesions are small and have not spread 
to regional lymph nodes. The study was 
carried out in British Columbia, a 
province with a population of 2.6 million 
people that reports approximately 1200 
new lung carcinomas per year, giving a 
crude prevalence rate of 200 per 100 000 
people. During the past 5 years our insti­
tution, which serves a wide cross-section 
of this population, has attempted to 
evaluate the benefits of resection. The 
report concentrates on the value of resec­
tion for lesions of a specific type and 
stage. The relation of lung function to the 
structure of the nontumorous lung is 
reported elsewhere.
Patients and Methods
The study was based on 163 patients
who underwent resection for lung carci­
noma at our institution between 1978 and 
1983. Sixteen of these were lost to follow­
up, and 4 more were excluded because 
they were found to have small (oat) cell 
carcinoma, so this report concerns 143 
patients with non-oat-cell bronchogenic 
carcinoma.
All patients were asked to answer a 
detailed questionnaire that documented 
smoking habits, occupational histories 
and symptoms. All underwent specialized 
pulmonary function testing. The tumour 
in the resected specimen was measured 
and histologically typed and the spread 
to draining lymph nodes was systemati­
cally examined.
Type o f  Resection
There were 116 lobectomies, 23 pneu­
monectomies and 4 wedge resections. A 
lobectomy was performed on the right 
lung 78 times (54 upper, 22 lower, 2 mid­
dle) and on the left lung 38 times (22 
upper, 16 lower). Pneumonectomy was 
performed 6 times on the right and 17 
times on the left.
Pathological Study
The surgeons sampled and labelled the 
appropriate nodes in the mediastinum 
using the American Thoracic Society 
nomenclature.1 The lung specimen was 
fixed by inflating with either formalde­
hyde or glutaraldehyde through the bron­
chial tree and then immersing the speci­
men in this fixative, using a special tank 
that held the pressure in the airways at 25 
cm of fixative. The lungs were examined 
after 24 hours of fixation, and the hilar 
and intrapulmonary lymph nodes were 
dissected, labelled and examined histolog­
ically. The lungs were then sliced sagit- 
tally so that the tumour could be located, 
measured and sampled for histologic 
examination.
A histologic type was assigned to each 
tumour using the World Health Organi­
zation nomenclature.2 There were 75
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squamous cell cancers, 55 adeno- or bron- 
choalveolar carcinomas, 5 adenosqua­
mous carcinomas and 8 large cell carci­
nomas.
Staging
The tumours were staged using the 
American Thoracic Society1 criteria; 105 
tumours were stage I, 18 stage II and 20 
stage III. Lymph-node involvement was 
found in 7 cases of stage I disease (T1N1) 
and 12 cases of stage III.
Statistical Analysis
Survival probabilities were estimated 
using the method of Coldman and 
El wood.3
Results
Table I shows the distribution of lung 
cancer by stage with respect to age and 
sex and predicted 5-year survival. Fifty- 
seven patients were in the 60- to 69-year 
age range but 13 were younger than 50 
years and 1 was younger than 40. The 
overall male to female ratio was 2.8:1 and 
varied from 2:1 in the fifth decade to 
3.4:1 in the seventh decade.
Table II shows that the 75 squamous 
cell carcinomas were divided between 64 
men (85%) and 11 women (15%), while 
the 55 cases of adenocarcinoma were seen 
in 32 men (58%) and 23 women (42%). 
There were no statistically significant 
differences in smoking history for 
patients who had the major cell types, 
although the patients with large cell 
tumours may have smoked less.
The predicted survival curve for all 143 
patients (Fig. 1) shows that the calculated 
probability of survival was 54% at 3 years 
and 49% at 5 years. The data for differ­
ent stages of the disease (Fig. 2) show that
the predicted 3- and 5-year survivals were 
both 62% in stage I cases, 34% and 23% 
for stage II and 29% and 0% for stage 
III.
The predicted survival for stage I dis­
ease was further analysed (Fig. 3); it was 
74% for tumours less than 3 cm in 
diameter without node involvement. 
Patients with larger tumours without 
node involvement had a predicted survival 
of 57% and the predicted survival in stage 
I disease was lowest (43%) when nodes 
were involved.
The predicted 5-year survival rates for 
patients with squamous cell cancer and 
adenocarcinoma in stage I disease were 
similar (68% and 60% respectively). 
Patients with stage I, large cell cancers 
tended to have a lower survival (33% at 
3 years) but the number was small. 
Although relatively few of our patients 
had stage II or stage III disease, the sur­
vival rates of these patients were lower 
than in those with stage I tumours.
Discussion
Several studies4-5 have shown an 
increase in the survival of patients with 
lung cancer if the tumour is resected when 
it is smaller than 3 cm in diameter and 
before the disease has spread to the lymph 
nodes. However, recent screening 
studies6-8 contradicted this, claiming that 
the benefit is illusory because it relates to 
a lead-time bias.
The results of the present study are con­
sistent with those of other reports6-9 
showing that lung cancer occurs slightly 
more often in the right lung, with the 
upper lobes accounting for a high percen­
tage of all resections. Our results show 
that lobectomy was the predominant 
operative procedure (in 116 [81 %] of 143 
cases) with 76 lobectomies being per­
formed on the upper lobes (54 right, 22 
left). The remaining 40 lobectomies were
performed on the right lower lobe (22), 
right middle lobe (2) and left lower lobe 
(16). Pneumonectomies accounted for 23 
(16%) cases (6 right, 17 left).
The overall operative death rate was 
4.9%, 8.7% after pneumonectomy and 
4.3% after lobectomy. These rates com­
pare favourably with those in other 
reports where the overall operative death 
rate ranged from 2% to 8%,5-10-13 and 
pneumonectomy carried an operative risk 
of 6% to 12%.10-12
Tumour Types
There were 75 cases of squamous cell 
cancer and 55 cases of adenocarcinoma 
for a ratio of 1.4:1—not statistically 
different (Table II). Women had a greater
FIG. 1—Overall survival probabilities for all 
143 patients.
FIG. 2—Influence of stage on survival.
FIG. 3—Survival curves for subtypes of 
stage 1. T1N1 lesions have worst prognosis, 
again showing influence of node involvement.
Table 1 -S ta g e  of Cancer in Relation to  P atient Age, Smoking History  
and Survival (M ean ± Standard Error]
S tage
No. of 
patients Age, yr
Smoking history, Predicted 5-yr 
cigarette-yr survival, %
I - T 1 N 0 38 6 2 .7  ± 8 .3 1 0 8 7  ± 6 7 9 74
T 2 N 0 60 6 2 .7  ± 9 .0 1 4 1 2  + 1 7 29 57
T 1 N 1 7 6 3 .3  ± 4 .9 1 2 7 7  ± 5 1 3 43
II 18 6 0 .6  ± 1 2 .0 9 4 0  ± 5 7 4 23
III 20 6 2 .8  ± 9 .5 1681 ± 2 0 7 8 0
Table II —M ale to  Female Ratio of Histologic Types of Lung Cancer
Tum our type
M ale, 
no. (%)
Female, 
no. (%)
Smoking history, 
cigarette-yr*
Squam ous
Bronchoalveolar
6 4  (85) 11 (15) 1 2 0 4  ± 6 9 9
adenocarcinom a 3 2  (58) 23  (42) 9 4 7  + 6 5 8
Adenosquam ous 4 ( 8 0 ) 1 (20) 1 2 6 4  + 6 0 3
Large cell 3 (3 7 ) 5 (6 3 ) 4 3 7  ± 105
'F ig u re s  are means ± standard error.
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ratio of adenocarcinoma and large cell 
cancer to squamous cell carcinomas than 
did men. Belcher,13 the first to recognize 
the increasing incidence of adenocarci­
nomas, found that the ratio of squamous 
carcinoma to adenocarcinoma declined 
steadily from 1962 to 1975 but the per­
centage of large and small carcinomas 
remained fairly constant. An increased 
number of adenocarcinomas has also 
been reported,4-s’9’12’14,15 although two 
studies11,15 have shown a predominance 
of squamous cell carcinoma. Vincent and 
colleagues16 suggested that the increase 
in adenocarcinoma might result from 
changing histopathologic criteria, occupa­
tional and environmental factors, and an 
increasing incidence of carcinoma in 
women. This suggestion is supported by 
our study in which adenocarcinoma 
accounted for 23 of the 40 tumours found 
in women (Table II).
FIG. 4—Influence of node involvement on 
survival.
Tumour Staging and Survival
Stage I carcinomas comprise three 
groups: tumours less than 3 cm in 
diameter with no node involvement 
(T1N0), tumours greater than 3 cm and 
no node involvement (T2N0) and small 
tumours with local node involvement 
(T1N1). Our data show that the predicted 
5-year survival was 74% for T1N0, 57% 
for T2N0, and 43% for T1N1 lesions, 
with an overall survival of 62% (Figs. 1 
and 3). This is consistent with several 
other reports,1’11’12'17 showing that the 
T1N0 lesions had the best 5-year survival 
at 55% to 80%, while for T1N1 lesions 
survival ranged from 25% to 50%, and 
T2N0 tumours had an intermediate sur­
vival ranging from 40% to 60%.
Patients with stage II or III disease 
have a much worse prognosis. The 
present study shows that the 3-year sur­
vival probability of patients with stage II 
disease was 34%, which was only slightly 
better than the 29% survival of stage III 
patients (Fig. 2). These rates are compara­
ble to those of other reports of a 3-year 
survival of 40%9’17 and a 5-year survival 
of approximately 20% to 40%.1,9 Stage 
III disease accounted for approximately 
30% of resections in one study1 and car­
ried a 5-year survival of only 25%.
A major question in assessing these 
findings is whether the predicted 5-year 
survivals are a result of a lead-time bias 
in detecting the tumour. If this were so, 
one might expect the T1N0 lesions to be 
found in substantially younger people 
than the more advanced tumours. The
fact that our data showed no difference 
in age between the groups suggests that 
the tumour progresses from stage I to 
stage III rapidly, so there should be value 
in detecting the tumour as early as possi­
ble in the T1N0 stage.
The Value o f  Early Detection
The bracketed numbers in Table III 
show the sensitivity and specificity 
requirements for predictive values of 
50%, 60%, 70%, 80% and 90% in a 
population with a prevalence of lung 
cancer of 200 cases per 100 000 people 
(i.e., 1200 cases in a population of 2.5 
million). While these requirements 
become less as the prevalence goes up they 
remain high even in the very highest risk 
groups. For example, even with a preva­
lence of 4000 per 100 000 (20 times that 
for lung cancer in our province), a speci­
ficity of 97% is required for a predictive 
value of only 50%. This means that mass 
screening to detect lung cancer with tests 
that lack this level of specificity and sen­
sitivity are unlikely to be of value. In 
several large mass-screening studies,3-5 
cytologic evaluation, a highly specific test, 
did not add significantly to radiologic 
interpretations in diagnosing lung cancer, 
and even in the additional detected cases, 
the staging and survival were the same as 
in the cases detected by roentgenography 
alone. The fact that several centres, 
including our own, are now showing 
improved survival when tumours are 
found and resected at the T1N0 stage 
should serve as a spur to find tumours at
Table III—Specificity and Sensitivity Required for Predictive Values of 
50% to 90% in Population with Prevalance of Lung Cancer of 2001100 000
„ ... Sensitivity, %Specificity, ----------------------------------------------------------------------------------------------------------- - —
% 50 60 70 80 85 90 91 92 93 94 95
50.0 0 0 0 0 0 0 0 0 0 0 0
60.0 0 0 0 0 0 0 0 0 0 0 0
70.0 0 0 0 1 1 1 1 1 1 1 1
80.0 0 1 1 1 1 1 1 1 1 1 1
90.0 1 1 2 2 2 2 2 2 2 2 2
91.0 1 1 2 2 2 2 2 2 2 2 2
93.0 1 2 2 2 2 3 3 3 3 3 3
95.0 2 2 3 3 3 3 4 4 4 4 4
97.0 3 4 4 5 5 6 6 6 6 6 6
99.0 9 11 12 14 15 15 15 16 16 16 16
99.1 10 12 13 15 16 17 17 17 17 17 17
99.3 13 15 17 19 20 20 21 21 21 21 21
99.5 17 19 22 24 25 27 27 27 27 27 27
99.7 25 29 32 35 36 38 38 38 38 39 39
99.90 [50] 55 58 62 63 64 65 65 65 65 66
99.91 53 57 61 64 65 67 67 67 67 68 68
99.92 56 [60] 64 67 68 69 70 70 70 70 70
99.93 59 63 67 70 71 72 72 72 73 73 73
99.94 63 67 [70] 73 74 75 75 75 76 76 76
99.95 67 71 74 76 77 78 78 79 79 79 79
99.96 71 75 78 [80] 81 82 82 82 82 82 83
99.97 77 80 82 84 85 86 86 86 86 86 86
99.98 83 86 86 89 89 [90] 90 90 90 90 90
99.99 91 92 93 94 94 95 95 95 95 95 95
100 100 100 100 100 100 100 100 100 100 100 100
Reproduced in part from: Galen RS, Gambino SR: Beyond Normality: the Predictive Value and Efficiency o f Medical Diagnosis, Wiley, New York, 1975.
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this stage. However, it is clear that these 
tests will be useful only if they have high 
sensitivity and specificity and are concen­
trated on the groups with the highest 
prevalence of the disease.
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Coffee Consumption and Fibrocystic Breasts: 
an Unlikely Association
Caffeine and other methylxanthines have 
recently come under scrutiny as sub­
stances that may cause breast tissue to 
undergo fibrocystic changes. The authors 
present a retrospective 5-year study of 
358 women with fibrocystic breast dis­
ease and a 6-month prospective study of 
72 women with this condition. Although 
methylxanthine consumption was cons­
tant, the clinical findings in semiannual 
or monthly examinations in both studies 
were inconsistent. On the basis of their 
results and a review of available studies, 
the authors believe there is no scientific 
basis for an association between the 
consumption of methylxanthines and the 
development of fibrocystic breast 
disease.
La cafeine et autres methylxanthines ont 
recemment fait I'objet d'un examen 
minutieux afin de determiner si ces subs­
tances pouvaient provoquer des change- 
ments fibrokystiques du tissu mammaire. 
Les auteurs presentent une etude retros-
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pective sur une periode de 5 ans de 358 
femmes souffrant de maladie fibrokysti- 
que du sein, ainsi qu'une etude prospec­
tive de 6 mois chez 72 femmes atteintes 
de cette affection. Bien que la consom- 
mation de methylxanthine soit demeuree 
constante les examens cliniques bi- 
annuels ou mensuels ont revele dans les 
deux etudes des resultats contradictoi- 
res. A partir de leurs resultats et a la 
revue des etudes disponibles, les auteurs 
croient qu'il n'existe pas de fondement 
scientifique a I'existence d'une associa­
tion entre la consommation de 
methylxanthines et le developpement de 
la maladie fibrokystique du sein.
In the past 20 years, no health warning 
has had a more measurable impact on the 
coffee-consuming public than the anec­
dotal report1 that linked methylxanthine 
intake with a condition commonly called 
“ fibrocystic breast disease” . Over the last 
2 years clinicians have exhibited a grow­
ing appreciation of a widespread and 
essentially harmless condition,2,3 prevail­
ing in a clinically recognizable form in 
50% of American women and in a histo­
logically detectable form in 90%.2
Previous reports linking coffee con­
sumption with myocardial infarcation,4 
bladder cancer5 and pancreatic cancer,6 
found instant outlet in the lay press, but 
they were not followed by a decrease in 
coffee consumption. Nevertheless, many 
physicians have been surprised at the 
readiness with which women have 
accepted advice, mainly from ladies’ jour­
nals, to reduce caffeine intake from var­
ious sources: soft drinks, chocolate and 
cookies, certain drugs, tea and coffee. 
The results of voluntary abstention from
these sources of methylxanthine have 
been equivocal: some women have tem­
porarily been free of breast discomfort or 
experienced spontaneous disappearance 
of nodules, but others have noticed no 
changes. The purpose of this report is to 
analyse the natural history of fibrocystic 
disease in women whose intake of 
methylxanthine is constant. The first part 
reviews the evolution of changes among 
358 women who were considered to have 
fibrocystic breasts and were followed-up 
every 6 months for 5 years. This study 
was completed in 1979, the year Minton’s 
report1 on caffeine and benign breast 
disease was published. No previous arti­
cle had ever suggested an association 
between coffee and diseases of the breast. 
The second part is a prospective study 
carried out in 1982 of 72 women with pal­
pable breast cysts. Their caffeine intake 
was recorded on a monthly basis and pur­
posely kept constant.
Patients and Methods
Study 1
This was a retrospective chart analysis 
of 358 patients, examined at a time when 
there was no concern about a potential 
association between coffee consumption 
and breast disease.
From 1974 to 1979, women between 35 
and 74 years of age were examined for 
benign and malignant breast disease. In 
all, 10 000 women, whose physicians had 
attested to absence of palpable lesions, 
were recruited into the Breast Cancer 
Demonstration Project at Duke Medical 
Center. The chosen patients were re­
examined every 6 months until surgery
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was performed when the diagnosis of 
fibrocystic breast disease was confirmed 
histologically.
The clinical findings and menstrual sta­
tus were abstracted from the charts at 
each recorded visit; in some women as 
few as 3 and in others as many as 10 
follow-up visits were made over the 5-year 
period. The records of women with men­
strual activity were separated from those 
of menopausal women. The average age 
at the end of the study of the first group 
was 49 years and the second was 59 years. 
Findings were classified as follows:
• Always positive: clinical examination 
revealed the same or a similar description 
of findings in the same quadrant of one 
or both breasts throughout the observa­
tion period.
• Unidirectional change: patients were 
described as having undergone a single or 
unidirectional change, that is, from nor­
mal to abnormal in the same breast or 
vice versa, or from a single lesion to mul­
tiple lesions, or from a single node to 
diffuse nodularity or vice versa. The 
essential criterion was that once these 
changes had occurred, they remained 
unchanged until surgery.
• Fluctuations: findings changed back
and forth from one examination to the 
next, for example, from negative first to 
positive and then back to negative, or 
from a single mass to multiple masses and 
back to a single one or from diffuse 
nodularity to a single nodule and then 
again back to diffuse nodularity.
The clinicians had an opportunity to 
read the reports of the previous exami­
nations, confirming or updating earlier 
results. Study forms required uniform 
reporting on location, size, mobility and 
texture of lesions. The women were 
instructed not to come for their clinic 
visits if they were premenstrual, so it was 
unnecessary to relate clinical findings to 
the individual’s menstrual cycle.
Study 2
The purpose of the second study was 
to evaluate the clinical course of fibrocys­
tic breast disease over a 6-month period, 
recording the women’s usual methylxan- 
thine intake in an employed population. 
In 72 women, fibrocystic breasts were 
diagnosed by clinical examination during 
a cancer screening program at Cannon 
Mills in Kannapolis, NC; the women 
agreed to return for monthly follow-up 
examination. Mean age was 48 years
(range from 24 to 65 years). The examiner 
who performed the breast examination 
was unaware of previous findings. For 
each nodule, the position, size, texture 
and mobility were recorded. A question­
naire on methylxanthine consumption 
from beverages (15 questions), foods (9 
questions) and caffeine-containing drugs 
(6 questions) was completed at each visit. 
Data collected included method of prepa­
ration, serving size and frequency of con­
sumption. Methylxanthine content was 
obtained from several sources.7,8
The number of nodules that disap­
peared was considered separately from 
those that disappeared but recurred over 
the 6 months. Cysts were counted and the 
numerical change during the observation 
period was recorded. With the clock-face 
image as a guide and division of the breast 
into 12 sections (hours), “ no change” in 
the position of a given nodule was 
assumed when its location was recorded 
either in the same position or ± 1 hour 
from the location previously noted.
Results
Study 1
The most important observation was 
that 41% of the premenopausal women 
and 51% of the menopausal women 
showed fluctuations (Table I). When 
unidirectional changes are combined with 
these fluctuations, a clear picture of the 
“ waxing and waning” condition emerges. 
Only 29% of women in the premeno­
pausal and 18% in the menopausal group 
had findings similar from one examina­
tion to the next during the study.
Overall, 31% had changes recorded as 
“ unidirectional” either improving or 
worsening over the 5-year period, and 
47% had fluctuating changes. These find­
ings suggest that more than 70% of 
women with histologically proven 
fibrocystic breast disease show change 
with breast examinations 6 to 12 months 
apart. Stable clinical findings in fibrocys­
tic breasts over a long period appear to 
be the exception rather than the rule, at 
least in this retrospective study. It is 
highly unlikely that these women made 
any major change in methylxanthine 
intake during the study period.
Study 2
This study attempted to achieve more 
precise measurements of change than 
those recorded retrospectively, by using 
the clock-face diagram to locate breast 
nodules.
During the study period, 90% of left 
breasts and 83% of right breasts showed 
changes in position or number of nodules 
(Table II). All nodules disappeared from 
13% of the right breasts and from 17% 
of the left. In 28% of left breasts and 
39% of right breasts, the nodules disap-
Table 1--Study 1. Clinical Findings Over 5 Years in 153 Premenopausal 
and 205 Menopausal Women With Fibrocystic Breasts
Findings
Premenopausal, 
no. (%)
Menopausal, 
no. (%)
Always positive 
Unidirectional change 
Fluctuations
44 (29) 
46 (30) 
63 (41)
3 6 (18 ) 
64 (31) 
105 (51)
Table II—Study 2. Clinical Findings Over 6 Months 
Fibrocystic Breasts*
in 72 Women With
Findings
Left breast, 
no. (%)
Right breast, 
no. (%)
Both 
breasts, 
no. (%)
Cysts present at baseline 50 (69) 58 (81) 108 (75)
Cysts disappeared 9(13) 12(17) 21 (15)
Cysts disappeared then reappeared 20 (28) 28 (39) 48 (33)
Cysts changed in number only 32 (44) 19(26) 51 (35)
Cysts changed in position and number 65 (90) 60 (83) 125 (87)
'Reprinted, in part, by permission from Heyden S, Muhlbarer LH: Prospective study of "fibrocystic
breast disease" and caffeine consumption. Surgery 1984; 96: 47 9 -4 83 .
Table Ill-S tudy 2. Daily Methylxanthine Consumption (mg) in 72 
Women With Fibrocystic Breasts* t
First month, Last month,
Source mean ± SE mean ± SE Maximum
Coffee 121.35 ± 18.77 145.17 ± 19.73 915.0
Tea 64.48 ± 8.56 44.96 ± 6.88 36.0
Soft drinks 29.02 ± 4.31 28.48 ± 4.73 157.7
Drugs 3.84 ± 1.68 2.91 ± 1.34 64.0
Candies 0.23 ± 0.07 0.20 ± 0.05 3.3
Food 0.08 ± 0.13 0.18 ± 0.05 7.3
Totals! 230.06 ± 19.51 225.80 ± 22.25 960.0
‘ Reprinted, in part, by permission from Heyden S, Muhlbarer LH: Prospective study of "fibrocystic 
breast disease" and caffeine consumption. Surgery 1984; 96: 4 7 9 -4 83 . 
tThe result of self-reported intake of methylxanthines.
tAverage individual methylxanthine consumption (total from all sources). Overall methylxanthine con­
sumption decreased by only 4.3 mg/d between the first and the last examination (NS).
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peared only to reappear during the 6 
months. The total methylxanthine intake 
did not change significantly, although 
caffeine consumption from coffee 
increased by 24 mg/d between the first 
and last examination (Table III).
Discussion
The results of these two studies offer 
no support for the claim that caffeine is 
associated with benign breast disease.
Clinically, the important point in the 
prospective study was the spontaneous 
disappearance of breast nodules without 
any relation to the methylxanthine con­
sumption. Equally relevant was the obser­
vation that breasts examined did not 
undergo nodular changes over the 6 
months. Another indicator is the number 
of cysts counted from one examination 
to the next and changes in their position.
All these measurements demonstrate a 
high degree of unreliability of clinical 
findings over such a brief observation 
period.
For the purpose of the second study it 
was important that the methylxanthine 
intake of the study population did not 
change. The change in total consumption 
between the first and last examination was 
a decrease of only 4.3 mg/d.
Thus, for a condition in which stabil­
ity of clinical findings is the exception, it 
would be difficult to associate certain 
habits (i.e., methylxanthine consumption 
or abstention from it) with the presence 
or absence of benign breast disease. A 
number of women might, by chance, have 
breast lesions while consuming 
methylxanthines or no lesions while 
abstaining from them.
Review o f  Literature
Patients with fibrocystic breast disease 
are advised to abstain from coffee, cola 
drinks, tea and chocolate.1 This recom­
mendation is based on a preliminary 
study of 47 women with fibrocystic 
breasts: 13 of 20 who stopped consum­
ing beverages containing methylxanthines 
experienced complete disappearance of all 
palpable breast nodules within 1 to 6 
months. No long-term follow-up of this 
group has been reported.
Later, the same group9 found that in 
37 women with fibrocystic breast disease, 
the condition resolved when they stopped 
using m ethylxanthine-containing 
products.
From our findings in the retrospective 
study, it could be expected that 70% of 
prem enopausal or even 80% of 
menopausal women would show “ wax­
ing and waning” of their condition and, 
of these, a considerable number by 
chance might have negative clinical find­
ings after initial positive ones. The nature 
of “ waxing and waning” , which is the 
predominant feature of this chronic con-
210
dition, precludes any conclusion that 
there is a causal association between giv­
ing up the Ijabit and becoming asympto­
matic.
Following these publications,1'9 five 
studies10-14 were reported, by other inves­
tigators, on the same subject.
One10 reported on 72 women with 
fibrocystic breast disease on a 
methylxanthine-free diet and 68 patients 
who did not change their dietary habits. 
Among a subsample from whom breast 
fluid specimens were obtained, no rela­
tion was found between changes in breast- 
fluid caffeine levels and improvement of 
fibrocystic breast disease. “Absolute 
changes in clinically palpable breast find­
ings in the abstaining group were minor.” 
In addition, “ comparison of before-after 
mammograms offered little support for 
the methylxanthine hypothesis” .
The second study11 was of 323 women 
with palpable benign lesions of the breast 
and 1458 women free of palpable nod­
ules. No difference in coffee and tea con­
sumption between the two groups was 
noted. “These findings do not support the 
recent suggestion of Minton et al that 
methylxanthine ingestion is causally 
related to benign breast disease or breast 
cancer.”
Methylxanthine consumption among 
210 women with fibrocystic breast lesions 
and 241 breast cancer patients was the 
object of a third investigation.12 In com­
paring the patients’ daily intake with that 
of controls, the authors found no signifi­
cant differences in the consumption of 
coffee or tea. For both benign and malig­
nant breast disease, the risk was slightly 
higher for those who drank one to three 
cups per day than for those who drank 
seven or more.
In a case-control study13 of 854 
women in whom benign breast disease 
was diagnosed histologically, 755 
matched surgical controls and 723 
matched neighbourhood controls, no 
association was noted between coffee 
consumption and benign breast disease. 
The estimated mean intake of methylxan­
thines was similar: 302, 312 and 313 mg 
for cases, surgical controls and neigh­
bourhood controls, respectively. No evi­
dence of a dose response was noted.
In contrast, only one hospital-based 
case-control study14 showed a positive 
association with coffee consumption. In 
634 women with fibrocystic breast disease 
and 1066 control women, the authors 
reported as unclear why an association 
between symptoms and caffeine con­
sumption was found only among the con­
trols; “we, of course do not know which 
controls may have undiagnosed fibrocys­
tic disease” .
Because of the uncertainty expressed by 
the authors concerning the status of the 
control women, their results are of doubt­
ful value, especially in view of the
widespread prevalence of fibrocystic 
breast changes which, according to 
autopsy reports, involve 90% of women 
in our society. On the basis of the reports 
mentioned, the Council on Scientific 
Affairs of the American Medical Associ­
ation concluded: “ There is currently no 
scientific basis for associating methylxan­
thine consumption with fibrocystic dis­
ease of the breast. Indeed, it has been sug­
gested that lumpy, fibrous breast tissue 
in women is normal and represents a 
response to physiological hormonal var­
iation.” 15
Minton has taken his hypothesis one 
step further on the assumption that 
“ breast cancer occurs in patients with 
fibrocystic breast disease four to six times 
more often than in women with normal 
breasts” . In an animal experiment, he and 
his colleagues16 showed that caffeine and 
a fat diet enhanced the development of 
mammary tumours in the DMBA-treated 
rats. Indirect support for this new 
hypothesis is claimed from epidemiologic 
studies supposed to have shown indepen­
dently a correlation with breast cancer in 
countries where there is documented high 
caffeine and high fat consumption. “Our 
analyses of their independent reports 
show that the countries reporting the 
highest incidence of breast and other 
cancers are countries where both high fat 
diets and high caffeine consumption have 
occurred simultaneously.” 16 
One must separate the issues addressed 
in this statement on coffee consumption. 
The basic premise that the risk of breast 
cancer is increased four to six times in 
women with fibrocystic breasts is no 
longer tenable. A recent editorial3 found 
it high time to empty the “ fibrocystic dis­
ease” waste basket and thereby mitigate 
the anxiety of a large number of women 
who no longer need to be concerned 
about the risk of breast cancer. After sur­
gical excision of noncancerous breast tis­
sue, approximately 70% of women with 
fibrocystic breasts could not be consi­
dered at high risk. Only about 4% would 
be identified as high-risk persons. But, as 
H utter3 reminds us, histopathologic 
findings do not tell the whole story. A 
more meaningful picture is revealed by 
combining histologic findings with age 
and family history of breast cancer. 
Women over 55 years of age with non­
proliferative lesions have a reduced risk 
(0.3 times), while those with proliferative 
lesions have a higher risk (2.2 times). 
Women with cysts are not at increased 
risk unless they have a positive family his­
tory of breast cancer, in which case their 
risk rises threefold.
Before one can associate the develop­
ment of breast cancer with “ high coffee 
and high fat” consumption, one has to 
account for the missing link, the nonex­
isting causal association between coffee 
intake and benign breast conditions. Is it
VOLUME 29, NO. 3, M A Y  1986 /  THE CANADIAN JOURNAL OF SURGERY
reasonable to associate a very common 
habit (coffee drinking) with such a 
widespread disorder when there is no bio­
logically plausible connection between the 
two and when experimental evidence is 
lacking?
A dietary case-control study17 of 818 
breast-cancer patients compared 
methylxanthine intake from all sources 
with matched surgical and neighbour­
hood controls. In addition, analysis was 
done in relation to fat consumption. 
Neither methylxanthine consumption nor 
the amount or quality of fat showed any 
association with breast cancer.
A study18 o f 2651 women with newly 
diagnosed breast cancer failed to disclose 
any association between breast cancer and 
coffee consumption when data were com­
pared with those from noncancerous con­
trol women.
As others have previously disproved in 
pancreatic cancer,19 bladder cancer20 and 
renal cancer,21 we conclude that in breast 
cancer coffee is not a carcinogen.
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BOOK REVIEWS 
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devoted to surgery of the alimentary tract, the 
major part of the general surgeon’s practice. 
Other sections include the urogenital tract and 
transplantation (80 pages); heart, lungs and 
blood vessels (88 pages) and the endocrine sys­
tem (43 pages). Interestingly, breast, head and 
neck diseases are discussed in the section on 
tumours of those areas (26 pages) and trauma 
and surgical technique are addressed in a com­
bined section (107 pages), almost reminiscent 
of a “ miscellaneous” section. The book ends 
with a 71-page section on patient care, which 
1 would have preferred at the beginning.
As a practising general surgeon with a spe­
cial interest in emergency surgery, I identified 
particularly with the sections covering the 
alimentary tract, trauma and patient care. In 
the first, two very complete chapters are 
devoted to the acute abdomen, offering many 
useful approaches and recommendations, and 
another deals exclusively with incisions and 
drains. The rest of the alimentary tract section 
is covered in an anatomical order. A chapter 
on pediatric and neonatal surgery is included. 
1 found a section on surgery in tropical coun­
tries most helpful in view of the recent influx 
of immigrants from Central America and the 
Far East.
The section on trauma avoided an inventory 
of organ injuries and instead concentrated, 
appropriately, on the assessment of the criti­
cally injured patient. It provides excellent 
guidelines on how to organize emergency 
department action and assess and treat head 
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dysuria, oliguria, anuria, hematuria, urgency, dyspnea, trem- 
our, vertigo, tiredness, jaundice, vision troubles, drug fever, 
alopecia, epistaxis, black tongue, elevated BUN, NPN, serum 
creatinine or urinary protein and anaphylactoid reactions. 
Rare: goiter, diuresis and hypoglycemia have occurred with 
sulfonamides.
Dosage and Administration
INTRAVENOUS
Parenteral therapy is indicated if patient cannot take oral 
medication or if high serum concentrations are required 
rapidly.
PARENTERAL TREATMENT SHOULD BE TERMINATED AND 
ORAL TREATMENT INSTITUTED AS SOON AS POSSIBLE. 
CAUTION -  'BACTRIM' FOR INFUSION MUST BE DILUTED IN 
STERILE D5W, RINGER'S OR NaCI 0.9% SOLUTION PRIOR 
TO ADMINISTRATION. DIRECT INTRAVENOUS INJECTION 
NOT RECOMMENDED. DO NOT MIX WITH OTHER DRUGS OR 
SOLUTIONS. For method of dilution and infusion administra­
tion, see Package Insert.
Pneumocystis carinii pneumonitis:
Children and adults: 5 mg trimethoprim/kg +  20 mg 
sulfamethoxazole/kg q.i.d. until oral therapy can be 
instituted.
Serious systemic infections:
Adults: 160to240m gtrim e thoprim  +  800to 1200 mg sulfa­
methoxazole (10-15ml ‘Bactrim1 for Infusion)every 6 ,8o r 12 
hours, depending on severity of infection.
Children: 5 to 10 mg trim ethoprim /kg/day +  25 to 50 mg 
sulfamethoxazole/kg/day in 2-4 equally divided doses.
PATIENTS WITH IMPAIRED RENAL FUNCTION 
Not recommended if creabnine clearance (CICr) less than 
15 m l/m in . A t CICr 15-30m l/m in : 1/2 usual regimen. A t CICr 
above 30 m l/m in : usual regimen.
Supply
Adult tablets: 80 mg trimethoprim and 400 mg sulfa­
methoxazole. Bottles of 100 and 500. Unit dose: boxes of 100. 
DS tablets: 160 mg trimethoprim and 800 mg sulfamethox­
azole. Bottles of 100 and 250. Pediatric tablets: 20 mg 
trim ethoprim  and 100 mg sulfamethoxazole. Bottles of 100. 
Suspension: Cherry-flavoured, 40 mg trimethoprim and 
200 mg sulfamethoxazole, per 5 m l. Bottles of 20 ,1 00  and 
400 m l. Solution for Infusion: Each ml contains 80 mg 
sulfamethoxazole and 16 mg trimethoprim, for infusion with 
D5W, Ringer's o r NaCI 0.9%  solution. Packs o f 10 x 5 m l 
vials, single 30 ml vials and 10 x 5 ml ampoules.
Product Monograph available on request.
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novantrone
Mitoxantrone Hydrochloride Injection 
For Intravenous Infusion Only 
ANTINEOPLASTIC 
CAUTION
NOVANTRONE' IS A POTENT DRUG AND SHOULD BE USED ONLY BY PHYSI­
CIANS EXPERIENCED WITH CANCER CHEMOTHERAPEUTIC DRUGS (SEE 
WARNINGS AND PRECAUTIONS). BLOOD COUNTS SHOULD BE TAKEN AT FRE­
QUENT INTERVALS PRIOR, DURING AND POST THERAPY. CARDIAC MONITOR­
ING IS ADVISED IN THOSE PATIENTS WHO HAVE RECEIVED PRIOR ANTHRACY- 
CLINES, PRIOR MEDIASTINAL RADIOTHERAPY OR WITH PRE-EXISTING 
CARDIAC DISEASE.
PHARMACOLOGICAL ACTION
Although its mechanism of action has not been determined, mitoxantrone is a DNA- 
reactive agent. It induces nuclear aberrations with chromosome scattering in cell 
cultures (human colon carcinoma line) and is a potent inhibitor of RNA and DNA 
synthesis. Compared on an equimolar basis, mitoxantrone is seven times more 
potent than doxorubicin in inhibiting the uptake of 3H-uridine and four times more 
potent in inhibiting the uptake of 3H-thymidine by mouse lymphoma L5178Y cells in 
vitro.
INDICATIONS
NOVANTRONE' is indicated for chemotherapy in patients with carcinoma of the 
breast, including locally advanced and metastic disease. Also for relapsed adult 
leukemia and lymphoma patients with hepatoma.
CONTRAINDICATIONS
NOVANTRONE* is contraindicated in patients who have demonstrated prior hyper­
sensitivity to anthracyclines.
WARNINGS
Since NOVANTRONE* produces myelosuppression [see ADVERSE EFFECTS], it 
should be used with caution in patients in poor general condition or with pre-existing 
myelosuppression.
Cases of functional cardiac changes, including congestive heart failure and 
decreases in left ventricular ejection fraction have been reported. These cardiac 
events have occurred almost exclusively in patients who have had prior treatment 
with anthracyclines, prior mediastinal radiotherapy or with pre-existing heart disease. 
Cardiac monitoring is advisable in such patients. It is suggested that cardiac monitor­
ing also be performed in other patients during therapy exceeding 160 mg/m2 
(approximately 12 courses) of NOVANTRONE*, as experience during prolonged 
treatment is limited.
NOVANTRONE* may impart a blue-green colouration to the urine for 24 hours 
after administration, and patients should be advised to expect this during active 
therapy. A reversible blue coloration in the sclerae has been reported in two cases. 
Safe use of NOVANTRONE* in pregnancy has not been established. No information 
is available concerning the presence of NOVANTRONE* in the milk of nursing 
mothers. Safety for intrathecal use of NOVANTRONE* has not yet been established 
PRECAUTIONS
Full blood counts should be undertaken serially during a course of treatment. Dosage 
adjustments may be necessary based on these counts [see DOSAGE section].
It is recommended that NOVANTRONE’  not be mixed in the same infusion with 
other drugs. [See DRUG COMPATIBILITY section],
ADVERSE EFFECTS
NOVANTRONE * is clinically well tolerated, demonstrating a low overall incidence of 
adverse events, particularly those of a severe, irreversible or life-threatening nature.
Some degree of leucopenia is to be expected following recommended doses of 
NOVANTRONE*. With dosing every 21 days, suppression of WBC counts below 
1000/mm3 is infrequent; leucopenia is usually transient, reaching its nadir at about 10 
days after dosing, with recovery usually occurring by the 21st day. Thrombocytope­
nia can occur, and anaemia occurs less frequently. Myelosuppression may be more 
severe and prolonged in patients having had extensive prior chemotherapy or radio­
therapy or in debilitated patients.
The most commonly encountered side effects are nausea and vomiting, although 
in the majority of cases these are mild (WHO Grade 1) and transient. Alopecia may 
occur, but is most frequently of minimal severity and reversible on cessation of 
therapy.
Other side effects which have occasionally been reported include allergic reactions 
(one with anaphylaxis), abdominal pain, amenorrhoea, anorexia, constipation, 
diarrhoea, dyspnoea, fatigue, weakness, fever, gastrointestinal bleeding, stomatitis/ 
mucositis, and non-specific neurological side effects. Tissue necrosis following 
extravasation has been reported rarely.
Changes in laboratory test values have been observed infrequently e g 
increased liver enzyme levels, elevated serum creatinine and blood urea nitrogen 
levels (with occasional reports of severe impairment of hepatic function in patients 
with leukemia).
Cardiovascular effects, which have only occasionally been of clinical significance, 
include decreased left ventricular ejection fraction (determined by ECHO or MUGA 
scan), EKG changes and acute arrhythmia. Congestive heart failure has been 
reported. Such cases generally responded well to treatment with digitalis and/or 
diuretics. In patients with leukemia there is an increase in the frequency of cardiac 
events, the direct role of NOVANTRONE* in these cases is difficult to assess, since 
most patients had received prior therapy with anthracyclines and since their course is 
frequently complicated by anemia, fever, sepsis, and intravenous fluid therapy.
In leukemia patients treated with a single course of 12 mg/m21. V. daily x 5 days, the 
following drug-related toxicities occured: moderate or severe jaundice or hepatitis in 
8%, moderate nausea or vomitting in 8%, moderate or severe stomatitis/mucositis in 
9-29%, diarrhea in 9-13%, and moderate or severe alopecia in 11%,
CLINICAL RESULTS 
Introduction
Clinical trials experience has established the dosage range, efficacy and safety pro­
file of NOVANTRONE.
A single dose can be given intermittently every three or four weeks. The recom­
mended initial treatment dose in good risk patients is 14 mg/m2.
Efficacy
Breast
Efficacy data are available on 349 patients with locally advanced or metastatic breast 
carcinoma. Results are dependent on many predisposing factors including prior 
chemotherapy and/or radiotherapy, the health of the patients, sites of metastases,
and dose of the agent employed. In a European multi-centre first-line single-agent trial 
using an initial dose of 14 mg/m2, the overall response rate was 39% which com­
pared favourably to doxorubicin therapy at a dose of 60-75 mg/m2 when given to 
patients with similar stage disease. In an ongoing study of a direct comparison with 
doxorubicin, given as second-line therapy to breast cancer patients who failed a 
standard first-line combination, response rates are 27% for NOVANTRONE and 23% 
for doxorubicin. The mean duration of response observed after NOVANTRONE was 
greater than those reported after doxorubicin. Responses have been seen in all major 
sites of metastases including lymph nodes, lung, bone, skin and viscera, in patients 
both with and without prior hormonal therapy. Available data suggest that 
NOVANTRONE is comparable in efficacy with doxorubicin in the treatment of 
advanced breast cancer. Myelosuppression with 21-day treatment intervals is com­
parable with that observed with doxorubicin. Multiple courses of single-agent 
NOVANTRONE therapy, in some cases for longer than twelve cycles have been 
administered with excellent tolerance and a good response. NOVANTRONE showed 
incomplete cross-resistance with doxorubicin since responses have been observed 
in patients in whom doxorubicin had failed or who relapsed after response to that 
drug. A continuing large-scale clinical trials program with combination therapy also 
demonstrated early positive results for efficacy and safety. In seven studies over 100 
cycles of combination therapy have been given to 77 patients.
Additional Indications
A total of 966 patients have been treated with NOVANTRONE * for three other indica­
tions of which 259 patients had non-Hodgkin's lymphona (NHL). 546 had leukemia, 
and 161 had hepatocellular carninoma (HOC). The following summarizes the accrual 
of these 966 patients:
Indication
NHL
Leukemia
(including pediatric cases)
HOC
Lederle-Sponsored 
Studies 
(No. Treated)
186
282
75
543
Independent Studies 
Reported in the 
Literature 
(No. Treated)
73
264
JS 6
423
NON-HODGKIN’S LYMPHOMA. Three key studies evaluated single agent 
NOVANTRONE * in 148 patients with relapsed or refractory advanced NHL at a dose 
of 14 mg/m2, IV, every 3 weeks. Of 127 patients evaluable for response in two trials, 
there were 10 complete responses (CR) and 42 partial responses (PR) producing an 
overall therapeutic response rate of 41%. The median duration of responses in the 
multicenter study (122 evaluable patients) was 195 days. Many patients’ responses 
lasted in excess of one year. Responses were seen in all histological subtypes of 
NHL. Response to NOVANTRONE* was independent of prior chemotherapy and 
independent of whether the patient received prior doxorubicin. This demonstrated a 
lack of complete cross-resistance between NOVANTRONE * and other drugs includ­
ing anthracyclines.
NOVANTRONE* was evaluated in combination with other agents for the treatment 
of NHL. A total of 28 patients were treated with different regimens. A first-line compar­
ative trial of the combination of intermediate dose METHOTREXATE with LEUCOV- 
ORIN rescue + bleomycin + doxorubicin + cyclophosphamide + vincristine + 
dexamethasone (m-BACOD) versus the same combination with 10 mg/m2 
NOVANTRONE* replacing doxorubicin (m-BNCOD) has shown activity: 4 PRs in 6 
evaluable patients with m-BNCOD and 3 PRs in 6 with m-BACOD. The combination 
of NOVANTRONE* at 10 mg/m2, daily for 3 days, + vincristine + dexamethasone 
(NOD) produced 3 PRs in 5 evaluable patients. A first-line comparative trial of the 
combination of cyclophosphamide + vincristine + prednisone + doxorubicin 
(CHOP) versus the same combinations with 10 mg/m2 NOVANTRONE* replacing 
doxorubicin (CNOP) has only recently begun.
NOVANTRONE* at 5 mg/m2, daily for 3 days every 3 weeks produced oneCR and 
2 PRs in 8 evaluable patients with NHL; ten patients were enrolled. Several other 
studies reported in the literature and not sponsored by Lederle support the activity of 
NOVANTRONE* in the treatment of NHL.
LEUKEMIA. Four key studies sponsored by Lederle evaluated single agent 
NOVANTRONE* in 181 adult patients with refractory or relapsed acute non- 
lymphocytic leukemia (ANLL) or chronic myelogenous leukemia in blast crisis (B- 
CML) at doses ranging from 8 to 12 mg/m2, IV, daily for 5 days, every 3 weeks. A dose 
response effect was evident. Optimal activity was seen at a dose of 12 mg/m2, daily for 
5 days. At this dose level, there were 19 CRs in 49 evaluable adult patients with ANLL 
in relapse producing an overall response rate of 39%. The median duration of com­
plete response in the largest (121 patients) single agent study was 98 days. Several 
patients had remissions lasting in excess of one year. There were four studies com­
prising 63 patients in which NOVANTRONE* was evaluated in combination with 
other agents in the treatment of leukemia. The highest complete remission rate of 
49%  (11 CRs in 23 eva luable patients w ith AN LL) was ob ta ined when 
NOVANTRONE* at 10 to 12 mg/m2, daily for 3 days, was combined with cytosine 
arabinoside at 100 mg/m2 daily for 7 days. When NOVANTRONE * at 10 mg/m2, daily 
for 5 days was combined with the same dose of cytosine arabinoside, it produced 2 
CRs in 8 evaluable patients. Treatment of patients with acute lymphoblastic leukemia 
using 10 mg/m2 NOVANTRONE*, daily for 3 days, + vincristine + prednisone 
produced 10 responses in 16 evaluable patients, for a response rate of 62.5%.
Activity was also seen in B-CML. Since no standard therapy exists for this disease 
and bone marrow is never truly normal in this disorder, both CRs and PRs were 
considered evidence of efficacity. The optimal dose of NOVANTRONE* was 12 
mg/m2, daily for 5 days, producing 6 responses in 17 evaluable patients.
Experience in pediatric leukemia patients is limited. Twenty-four patients were 
treated with 6 to 8 mg/m2 NOVANTRONE *, daily for 5 days. There were 3 responses 
in 24 evaluable children.
Fourteen adult leukemia patients received 20 to 37 mg/m2 NOVANTRONE* once 
every two weeks. No therapeutic responses were observed using this schedule.
Several other studies reported in the literature and not sponsored by Lederle 
support the activity of NOVANTRONE* in the treatment of ANLL and B-CML.
HEPATOCELLULAR CARCINOMA. Three clinical trials sponsored by Lederle have 
been conducted using NOVANTRONE* in the therapy of HCC. NOVANTRONE* 
was administered to 65 patients intravenously at 12 mg/m2 every 3 weeks in two 
studies, and in one study with 10 patients at 6 to 10 mg/m2/day by continuous hepatic 
artery infusion for three consecutive days, every 3 weeks. Considering the short life 
span of patients presenting with HCC, a response of stable disease was included 
along with PRs and CRs in assessing efficacy. In these three studies, the overall 
therapeutic response rate was 46.7% (11 CRs and PRs + 10 stable disease in 45 
evaluable patients). Activity was confirmed in other studies not sponsored by Lederle 
Durations of response were variable among these studies and ranged between 3 and 
52 weeks.
Safety
Data on the overall safety profile of NOVANTRONE (based on 989 patients) demon­
strated advantages of NOVANTRONE compared to the anthracyclines with respect 
to both the quality of life and the long-term safety of patients. The majority of side 
effects with NOVANTRONE are m ild in nature. Removal of patients from 
NOVANTRONE treatment for reasons of toxicity has been rare in clinical studies. A 
number of patients have reported no side effects at all. In addition, the relatively low 
risk of serious side effects has permitted treatment of patients on an out-patient basis. 
The most common acute effects were nausea and/or vomiting (only 3.5% severe or 
very severe with NOVANTRONE, compared to 10-15% reported with doxorubicin), 
stomatitis/mucositis (only 0.3% severe or very severe with NOVANTRONE) and 
alopecia (only 0.9% severe or very severe, and 15% overall with NOVANTRONE 
compared with 85% severe or very severe and 100% overall reported with doxoru­
bicin), Serious local reactions have been reported rarely following extravasation of 
NOVANTRONE at the infusion site.
With respect to myelosuppression, initial NOVANTRONE doses of 14 mg/m2 every 
three weeks are well tolerated in good-risk patients. Severe degrees of myelosup­
pression have been rare. The median white cell nadir in a European second-line 
study was 2.5x103; in a European first-line study only 4.8% (2/42) of patients experi­
enced a nadir of less than 1,000. The nadir usually occurs around day 10 or 11 and 
returns to normal baseline value by day 21, in time for the next course of treatment. 
After multiple courses of NOVANTRONE, white blood cell and platelet nadirs show no 
further decrease beyond those observed in the first few cycles, indicating no cumula­
tive or permanent effects of NOVANTRONE on marrow reserves.
NOVANTRONE* had an exceptional safety profile and was well-tolerated by 
patients treated for NHL, leukemia and hepatoma, as well as for breast cancer. 
However, due to the pathophysiology of leukemia and the higher doses of 
NOVANTRONE* employed, the safety profile differed from that seen in NHL and in 
hepatoma (see ADVERSE EFFECTS). The most severe and life-threatening events,
i.e. bleeding and infection, are well described morbid complications of acute 
leukemia. Many of the episodes of hepatic dysfunction were probably related to the 
increased bilirubin load and increased exposure to hepatitis viruses as a result of the 
multiple transfusions of blood products necessary in the proper treatment of this 
disorder.
Cardiotoxicity
Adverse cardiac experiences have been infrequent. In contrast, doxorubicin has 
been reported to produce chronic cardiomyopathy and irreversible congestive heart 
failure in up to 11% of patients given nine or more courses of that drug at the usual 
dose schedule (60 mg/m2 every three weeks). W hether or not related to 
NOVANTRONE, only 119 cardiac-related episodes have been reported from a total 
data-base of more than 3,200 treated patients, including only 29 (0.9%) reports of 
clinical congestive heart failure, of which only one had no other known predisposing 
factors. The risk of cardiotoxicity is increased with prior anti-neoplastic drug or radia­
tion therapy. In patients without predisposing factors, development of congestive 
heart failure with NOVANTRONE therapy is rare.
Clinical experience suggests there is no need to lower the dose for patients with 
existing renal or hepatic disease.
In summary, NOVANTRONE" is well tolerated and provides a better quality of life 
for patients compared with doxorubicin and yet shows comparable efficacy.
NOVANTRONE has been used alone or in combination in patients with or without 
prior chemotherapy, as well as in those who have received prior adjuvant therapy. It is 
less cardiotoxic than anthracyclines such as doxorubicin and thus represents a clear 
therapeutic advance over currently available compounds.
SYMPTOMS AND TREATMENT OF OVERDOSAGE
There is no known specific antidote for NOVANTRONE. As would be expected from 
the pharmacological actions of the drug, haematopoietic, gastrointestinal, hepatic 
and renal toxicity may be seen, depending on the dosage given and the physical 
condition of the patient. The management of overdosage is symptomatic and sup­
portive and patients should be monitored closely. (See also the sections ‘ WARN­
INGS", “ PRECAUTIONS” and "ADVERSE REACTIONS").
DOSAGE
Breast Cancer, Lymphoma, Hepatoma
The recommended initial dosage for use as a single agent is 14 mg/m2 of body 
surface area, given as a single intravenous dose, which may be repeated at 21-day 
intervals. A lower initial dose (12 mg/m2 or less) is recommended in patients with 
inadequate marrow reserves due to prior therapy or poor general condition.
Dosage modification and timing of subsequent dosing should be determined by 
clinical judgement depending on the degree and duration of myelosuppression. If 
21-day white blood cell and platelet counts have returned to adequate levels, prior 
doses can usually be repeated. The following Table indicates a guide to dosing based 
on myelosuppression.
WBC AND 
PLATELET NADIR
TIME TO 
RECOVERY
IF WBC NADIR >  1 500 RECOVERY
AND <21 DAYS
PLATELET NADIR >  50 000
IF WBC NADIR >  1 500 RECOVERY 
AND >21 DAYS
PLATELET NADIR > 5 0  000
IF WBC NADIR <1 500 ANY DURATION 
OR
PLATELET NADIR < 5 0  000
IF WBC NADIR <1 000 ANY DURATION
OR
PLATELET NADIR < 25  000_______________
SUBSEQUENT DOSING
REPEAT PRIOR DOSE OR 
INCREASE BY 2 mg/m2 IF 
MYELOSUPPRESSION NOT 
CONSIDERED ADEQUATE 
WITHHOLD UNTIL RECOVERY 
THEN REPEAT PRIOR DOSE
DECREASE BY 2 mg/m2 FROM 
PRIOR DOSE AFTER RECOVERY
DECREASE BY 4 mg/m2 FROM 
PRIOR DOSE AFTER RECOVERY
Combination Therapy for Breast Cancer, Lymphoma
NOVANTRONE * has been given in various combination regimens with the following 
cytotoxic agents for the treatment of breast cancer and lymphomas: cyclophos­
phamide, fluorouracil, vincristine, vinblastine, bleomycin, METHOTREXATE (stan­
dard dose or 200 mg/m2 with LEUCOVORIN rescue) and glucocorticoids.
As a guide, when used in combination chemotherapy with another myelosuppres- 
sive agent, the initial dose of NOVANTRONE* should be reduced by 2-4 mg/m2 
below the doses recommended above for single agent usage; subsequent dosing, 
as outlined above, depends on the degree and duration of myelosuppression. 
Dosage for Patients with Acute Leukemia in Relapse
The recommended dosage for induction is 12 mg/m2 of body surface area, given as a 
single intraveneous dose daily for five consecutive days (total of 60 mg/m2).
In clinical studies, with a dosage of 12 mg/m2 daily for 5 days, patients who 
achieved a complete remission did so as a result of the first induction course.
Re-induction upon relapse may be attempted with NOVANTRONE * and again the 
recommended dosage is 12 mg/m2 daily x 5.
Combination Therapy for Leukemia
NOVANTRONE *, together with cytosine arabinoside, has been used successfully for 
the treatment of both first line and second line patients with acute non-lymphocytic 
leukemia
For induction, the recommended dosage is 10-12 mg/m2 of NOVANTRONE* for 3 
days and 100 mg/m2 of cytosine arabinoside for 7 days (the latter given as a continu­
ous 24 hour infusion).
If a second course is indicated, then the second course is recommended with the 
same combination at the same daily dosage levels but with NOVANTRONE * give for 
only 2 days and cytosine arabinoside for only 5 days.
If severe or life-threatening non-hematological toxicity is observed during the first 
induction course, the second induction course should be withheld until the toxicity 
clears.
Note regarding pediatric usage: Experience in pediatric patients is limited; how­
ever, complete remissions have been observed with NOVANTRONE * as single agent 
therapy at a dosage of 8 mg/m2 daily for 5 days.
ADMINISTRATION OF SOLUTION
NOVANTRONE* solution should be diluted to at least 50 mL with either Sodium 
Chloride for Injection (USP) or 5% Dextrose for Injection (USP). This solution should 
be introduced slowly into the tubing of a freely-running intravenous infusion of 
Sodium Chloride for Injection (USP) or 5% Dextrose for Injection (USP) administered 
over not less than three to five minutes intravenously. If extravasation occurs, the 
administration should be stopped immediately and restarted in another vein. The 
nonvesicant properties of NOVANTRONE minimize the possibility of severe reactions 
following extravasation, however, tissue necrosis has been reported rarely.
NOVANTRONE should be administered by individuals experienced in the use of 
anti neoplastic therapy.
Caution in the handling and preparation of NOVANTRONE solutions must be 
exercised and the use of protective eyeglasses, gloves and other protective clothing 
is recommended. (See “ GUIDELINES FOR SAFE USE BY HOSPITAL PERSON­
NEL” section.)
STORAGE DIRECTIONS
NOVANTRONE should be stored at room temperature-DO NOT FREEZE. With 
recommended storage, NOVANTRONE remains stable for two (2) years.
Following preparation of the infusion, the diluted solution should be stored at room 
temperature and used within 24 hours. Any original solution which remains in the vial 
should be discarded. NOTE: LIKE THE ORIGINAL SOLUTIONS, THE DILUTIONS 
SHOULD ALSO NOT BE FROZEN.
DRUG COMPATIBILITY
NOVANTRONE* should not be administered concommitantly with heparin since a 
precipitate may form. Until specific compatibility data are available, it is recom­
mended that NOVANTRONE* not be mixed in the same infusion with other drugs. 
GUIDELINES FOR SAFE USE BY HOSPITAL PERSONNEL-CONSULT THE 
PACKAGE INSERT.
CHEMISTRY
Composition
NOVANTRONE* mitoxantrone hydrochloride, a synthetic anthracenedione, is a 
potent antineoplastic agent. Its molecular formula is C222H28N40 62HCI and its molec­
ular weight is 517.4. It is a hygroscopic dark blue solid supplied as a sterile, aqueous 
solution containing mitoxantrone hydrochloride equivalent to 2 mg/mL mitoxantrone 
free base, with sodium chloride, sodium acetate, and acetic acid as inactive ingredi­
ents. The product does not contain antibacterial preservatives. Its structural formula 
appears below.
H H
HO O NCH2CH2NCH2CH2OH
Molecular Formula: C22H28N40 6.2 HCi 
Molecular Weight: 517 4
Chemical Name: 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)aminol-ethyl]amino]-
9,10-anthracenedione dihydrochloride
AVAILABILITY
NOVANTRONE mitoxantrone hydrochloride injection is supplied as a sterile aqueous 
solution at a concentration equivalent to 2 mg mitoxantrone free base per mL, and is
available in the following vial sizes:
10 mL/vial (20 mg) Product C o d e .....................................................................9393-34
12.5 mL/vial (25 mg) Product Code...................................................................9393-72
Identification
Glass vials containing 10 and 12.5 mL of a clear, dark blue solution.
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Life Salvage With Fibrin Glue in Three Cases of 
Exsanguinating Hemorrhage
Fibrin glue, although widely used in 
Europe for a decade, has not been com­
mercially available in North America 
because its fibrinogen component is 
obtained from multiple, pooled, human 
blood donors with the subsequent 
increased risk of blood transmissible dis­
eases. Techniques developed recently to 
isolate fibrinogen from single-donor 
plasma will circumvent these potential 
hazards. In Canada the use of fibrin glue 
has not been widespread even though 
biologic fibrin glue can be made from 
components readily available within most 
hospitals.
Equal amounts of cryoprecipitate from 
fresh frozen plasma and bovine thrombin 
will combine within 2 minutes to form 
the fibrin glue. Simultaneous injections 
of each component at bleeding sites 
form a film of the glue that will effec­
tively control even small arterial bleed­
ing. The authors present three case 
reports to illustrate how use of the glue 
can save lives in cases of exsanguinating 
hemorrhage. They discuss the multiple 
applications of the fibrin glue which they 
believe will soon be part of the arma­
mentarium of all Canadian surgeons.
Bien que son usage soit largement repan- 
due en Europe depuis une decennie, la 
code de fibrine n'est pas offerte commer- 
cialement en Amerique du Nord parce 
que son contenu en fibrinogene provient 
de pools de plasmas obtenus de multi­
ples donneurs; il en decoule un risque 
accru de maladie transmise par voie san­
guine. Des techniques recentes ont per- 
mis d'isoler le fibrinogene du plasma 
d'un donneur unique reduisant d'autant 
les risques potentiels. Au Canada, la 
colie de fibrine n'a pas ete largement uti- 
lisee meme si une colle de fibrine biologi-
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que peut etre fabriquee a partir de com- 
posantes facilement obtenues dans la 
plupart des hopitaux.
Des quantites etales de cryoprecipite 
de plasmas frais congeles et de throm- 
bine bovine reagissent en 2 minutes pour 
former la code de fibrine. Des injections 
simultanees de chacune des composan- 
tes sur un foyer hemorragique forment 
un film de code capable meme d'arreter 
le saignement de petites arteres. Les 
auteurs decrivent trois cas pour illustrer 
comment I'emploi de cette code peut 
sauver des vies dans les cas d'exsangui- 
nation hemorragique. lls commentent les 
multiples applications de la code de 
fibrine qu'ils croient devoir venir s'ajou- 
ter bientot a I'arsenal therapeutique des 
chirurgiens canadiens.
Fibrin glue has been used in a variety of 
surgical specialties. Plastic surgeons, over 
40 years ago, found fibrin glue helpful in 
reanastomosing nerves.1 Although  
microsurgical techniques have supplanted 
this function, it is still used in skin graft­
ing and as an adjunct to microvascular 
surgery.2 Orthopedic surgeons have used 
the glue in hip surgery, cartilage and bone 
grafting and tendon repairs.3 General 
surgeons have stopped bleeding from 
spleen and liver lacerations4 and used it 
to seal intestinal anastomoses.5 Perhaps 
the widest applications are in cardiovas­
cular and thoracic surgery. Fibrin glue has 
been used as a sealant in persistent pneu­
mothoraces,5-6 postoperative thoracic 
duct leaks,7 tracheal8 and esophageal 
anastomoses and transbronchial plugging 
o f bronchopleural cutaneous fistulas.5 
Vascular grafts and anastomoses have 
been sealed with a thin coating of fibrin 
glue.6’911 This agent, of course, does not 
replace meticulous surgical techniques, 
but it can be used in novel ways and, as 
will be discussed, in catastrophic bleeding.
Materials and Methods
The fibrin glue technique mimics the 
final common pathway in coagulation 
(Fig. 1). Fibrinogen is converted by 
thrombin into fibrin monomers that are 
strengthened by the action of Factor XIII 
into a cross-linked fibrin polymer mesh 
which, with interwoven blood compo­
nents, results in a hemostatic plug.12 The 
fibrin mesh acts to promote wound heal­
ing by attracting migrating fibroblasts 
and stimulating the formation of granu­
lation tissue.13 In vivo, enzymes of cellu­
lar origin such as leukocyte elastase 
(thought to be important in prolonged 
bleeding following cardiopulmonary 
bypass) activate plasminogen to a proteo­
lytic enzyme plasmin that will degrade the 
fibrin scaffolding. For this reason some 
European centres add fibrinolytic inhibi­
tors such as aprotinin (Trasylol) to the 
preglue.1214 We have not found this 
necessary and have never had problems 
with delayed bleeding secondary to 
fibrinolysis.
FIG. 1—Coagulation cascade demonstrating sites of glue interaction.
VOLUM E 29, NO. 3, M A Y  1986 /  THE CANADIAN JOURNAL OF SURGERY214
The technique used by the Canadian 
Red Cross Society to produce cryoprecipi- 
tate from fresh frozen plasma will con­
centrate fibrinogen as well as the other 
coagulation factors including Factor XIII 
(which is important as a pre-glue compo­
nent), Factor VIII, von Willebrand’s dis­
ease factor and fibronectin.15 This tech­
nique is normally used to treat the specific 
coagulation disorders of hemophilia, von 
Willebrand’s disease and hypofibrino- 
genemia, but we have capitalized on its 
fibrinogen and Factor XIII components 
to produce a glue to control bleeding at 
local sites in patients with exsanguinating 
hemorrhage. The fibrinogen concentra­
tion of fresh frozen plasma is approxi­
mately 2.6 g/L and this will be doubled 
to quadrupled by the cryoprecipitant tech­
nique.16 Bovine thrombin (Thrombinar, 
USV Canada Inc., Mississauga, Ont.) 
with one ampoule of calcium chloride 
constitutes the second component of the 
epoxy (Fig. 2).
The two components, if drawn up in 
separate plastic syringes, can be injected 
simultaneously at the bleeding site. Excess 
thrombin and cryoprecipitate are kept 
separately in sterile stainless-steel bowls. 
Equal amounts of each component are 
injected simultaneously at bleeding sites 
or suture lines. We used 100 mL of each 
component on adult patients bleeding 
from multiple needle holes in aortic 
anastomoses.
Some European investigators have 
devised an elaborate pressurized dual­
nozzle system, analogous to a paint 
sprayer, to produce a thin fibrin film.17 
Initially a transparent gel (fibrin 
monomer) forms that, with the action of 
Factor XIII and calcium chloride, will 
polymerize into an opaque glue. The reac­
tion begins immediately and is complete 
in approximately 2 minutes. The rapid­
ity of clotting can be varied by adjusting 
the concentration of thrombin.3 With 
the highly concentrated European fibrino­
gen and the recently described North 
American technique of Dresdale and col-
Fig. 2—Components of fibrin glue: (1) 
Cryoprecipitate contains fibrinogen and Fac­
tor XIII; 20 units are diluted with normal saline 
to total volume of 200 mL. (2) Two vials (5000 
units/vial) of thrombin are mixed with one 
ampoule of calcium chloride giving total 
volume of 50 mL. Cryoprecipitate and 
thrombin-calcium mixture are injected simul­
taneously. Fibrin glue is formed within 2 minu­
tes of ingredients coming into contact.
leagues,16 1 to 2 mL of pre-glue fibrino­
gen and 1 to 2 mL of thrombin can be 
directed at specific bleeding sites, leaks or 
fistulas. Calcium chloride, which we used, 
may not be necessary as calcium is part 
of the commercial bovine thrombin.
The following case reports illustrate our 
experience with fibrin glue in saving the 
lives of three patients who had exsan­
guinating hemorrhage.
Case Reports
Case 1
A previously healthy 71-year-old man 
presented with a type A (ascending aorta only) 
aortic dissection and severe aortic insufficiency, 
confirmed by angiography. He had no history 
of bleeding disorders and he was not taking any 
medications. Femorofemoral bypass was 
initiated after median sternotomy. A large col­
lection of blood was found within the 
pericardium. The patient was heparinized, 
attaining an activated clotting time of more 
than 600 seconds. Cardiopulmonary bypass 
was instituted and the patient cooled to 28°C. 
After the aortic dissection and true lumen had 
been opened and inspected, it was decided to 
repair the valve with pledgeted sutures at each 
commissure.
A tubular graft stent was inset in the true 
lumen. This was fixed in place and the aorta 
repaired over it with pledgeted sutures. The 
patient was rewarmed and the cross-clamp 
released after 72 minutes. The heart resumed 
normal sinus rhythm with a competent aortic 
valve. Bleeding from every suture hole was sub­
stantial. Attempts at repair created even more 
bleeding through the friable aortic tissue. 
Cardiopulmonary bypass was discontinued and 
lines were removed. Heparin was reversed to 
the point of a normal activated clotting time. 
Total bypass time was 134 minutes. Bleeding 
persisted at more than 200 mL/min so 
cryoprecipitate and thrombin were prepared 
and injected simultaneously on to various 
bleeding sites. Approximately 100 mL of each 
component was needed, but the bleeding 
ceased, the patient was stabilized and the oper­
ation was completed without further compli­
cations.
Case 2
A 67-year-old hypertensive man presented 
with a type A aortic dissection similar to that 
in case 1. A composite graft was used to replace 
the aortic valve, and the coronary arteries were 
reimplanted into the Dacron-velour graft. 
Bleeding persisted at the coronary and distal 
aortic graft anastomoses. After bypass was dis­
continued and the heparinized state reversed, 
bleeding persisted. He received 18 units of 
blood and 15 units of plasma, which depleted 
all sources. Fibrin glue was applied with suc­
cess, arresting the hemorrhage promptly. The 
patient’s recovery was smooth.
Case 3
A 4-year-old child underwent repair of a pul­
monary stenosis with an intact ventricular sep­
tum. A subclavian-to-pulmonary artery shunt 
had been performed previously. A Dacron- 
velour conduit was fashioned from the right 
ventricle to the pulmonary artery. Despite
preclotting, the graft leaked, most profusely 
around suture lines. Fibrin glue was used suc­
cessfully after all blood-bank stores were 
depleted of packed cells. The child did well 
postoperatively.
All three patients recovered with no 
further complications. There was no 
hypersensitivity , fib rino lysis or 
coagulopathy following the use of fibrin 
glue and no infection. At 9 months 
follow-up after the last patient’s opera­
tion, all were alive and well.
Discussion
Fibrin gluing offers new solutions to 
old problems not necessarily in accor­
dance with traditional surgical concepts. 
As a natural extension of this glue’s 
hemostatic properties, its greatest use has 
been in the field of cardiovascular sur­
gery. In this context it was introduced in 
1976 by Spangler18 and used by Akrami 
and associates in 197819 for sealing 
prosthetic vascular grafts. Both woven 
and highly porous knitted grafts can be 
reliably pre-sealed, and this is now the 
preferred method of sealing grafts in 
many European centres.6 The technique 
is effective in systemically anticoagulated 
patients or in those who have known 
coagulopathies,6 and it does not require 
a completely dry surgical field. Follow­
ing the death of a patient from exsangui- 
nation through the pores of a left 
ventricular-aortic conduit in 1979, two 
Toronto investigators17 developed a 
preclotting technique using thrombin and 
cryoprecipitate, but it was not widely used 
because of the high cost. With the advent 
of fibrin presealing, knitted grafts that 
currently have limited application because 
of their excessive porosity will replace the 
low-porosity woven grafts because of 
their superior handling, suturing and 
healing capabilites.14,16,20
Glues have been used to approximate 
aortic dissections,13 to fix kinked coro­
nary grafts6,10 for prophylactic sealing of 
vascular anastomoses and needle punc­
ture sites before clamp removal,6,13 and 
for the control of various forms of bleed­
ing in the operative field when conven­
tional suturing techniques fail (i.e., with 
poor tissues that will not hold sutures) or 
would be dangerous.2’9’13 The glue works 
well on venous bleeding, low-pressure, 
diffuse oozing and even small arterial 
bleeding can be reliably stopped.6 It can 
be used in conjunction with collagen 
fleeces (Avitene, Gelfoam) in a moist 
field.3’6-810,13-14
With the dissemination of knowledge, 
the gluing process and the availability of 
fibrinogen economically prepared from 
single-donor, fresh frozen plasma, fibrin 
glue will soon be part of the armamen­
tarium of all Canadian surgeons and will 
save lives as we have demonstrated.
VOLUME 29, NO. 3, M A Y  1986 /  THE CANADIAN JOURNAL OF SURGERY 215
(^ Mefoxin
(sterile cefoxitin sodium, Frosst Std.)
ANTIBIOTIC
ACTION
In v itro  s tu d ie s  dem onstrate  that the 
bactericidal action of cefoxitin, a cephamycin 
derived from cephamycin C, results from the 
inhibition of bacterial cell wall synthesis. 
Evidence suggests that the methoxy group in 
the 7a p o s itio n  is respons ib le  fo r the 
resistance of cefoxitin to degradation by 
bacterial beta-lactamases.
INDICATIONS AND CLINICAL USES 
TREATMENT
The treatment of the following infections when 
due to susceptible organisms:
1 -  In tra -abdom ina l in fec tions such as
peritonitis and intra-abdominal abscess
2 - G yn e co log ica l in fe c tio n s  such as
endometritis and pelvic cellulitis
3 -  Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and 
Serratia spp.)
5 - Lower respiratory tract infections
6 - Bone and joint infections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections 
Appropriate culture and susceptibility studies 
should be performed to determ ine the 
susceptibility of the causative organism(s) to 
MEFOXIN*. Therapy may be started while 
awaiting the results of these tests, however, 
modification of the treatment may be required 
once these results become available. 
O rganism s pa rticu la rly  appropria te  fo r 
therapy with MEFOXIN* are:
Gram positive
Staphylococci, penicillinase producing and 
non-producing
Streptococci excluding enterococci 
Gram negative (beta-lactamase producing 
and non-producing strains)
E. coli
K l e b s i e l l a  sp e c ie s  ( in c lu d in g  K. 
pneumoniae)
Proteus, indole positive and negative 
Haemophilus influenzae 
Providencia species 
Anaerobes 
Bacteroides fragilis
MEFOXIN* may also be appropriate for the 
treatment of infections involving susceptible 
strains of both aerobic and anaerobic bacteria. 
Clinical experience has demonstrated that 
MEFOXIN* can be administered to patients 
who are a lso rece iv ing  c a rb e n ic ill in , 
gentamicin, tobramycin, or amikacin (see 
PRECAUTIONS and ADMINISTRATION) 
Intravenous Administration 
The intravenous route is preferable fo r 
p a t ie n ts  w ith  b a c te re m ia , b a c te r ia l 
septicemia, or other severe or life-threatening 
infections, or for patients who may be poor 
risks because of lowered resistance resulting 
from  such  d e b ilita t in g  c o n d it io n s  as 
malnutrition, trauma, surgery, diabetes, heart 
failure, or malignancy, particularly if shock is 
present or impending.
PROPHYLACTIC USE
MEFOXIN* may be administered periopera- 
tively (preoperatively, intraoperatively and 
postoperative ly) to patients undergoing 
vaginal or abdominal hysterectomy and 
abdominal surgery when there is a significant 
risk of postoperative infection or where the 
occurrence of postoperative infection is 
considered to be especially serious.
In patients undergoing cesarean section, 
intraoperative (after clamping the umbilical 
cord) and postoperative use of MEFOXIN* 
may reduce the incidence of surgery related 
postoperative infections.
Effective prophylactic use depends on the 
time of administration. MEFOXIN* usually 
should be given one-half to one hour before 
the operation. Prophylactic administration 
should usually be stopped within 12 hours. It 
has been generally reported that continuing 
adm in istra tion of any an tib io tic  beyond 
*®T rademark
24 hours fo llow ing surgery increases the 
possibility of adverse reactions but, in the 
majority of surgical procedures, does not 
reduce the incidence of subsequent infection. 
If signs of postsurgical infection should 
appear, specimens for culture should be 
obtained for identification of the causative 
organism(s) so that appropriate therapy may 
be instituted.
CONTRAINDICATIONS
MEFOXIN* is contraindicated in persons who 
have shown hypersensitivity to cefoxitin or to 
the cephalosporin group of antibiotics.
WARNINGS
Before therapy with MEFOXIN* is instituted, 
careful inquiry should be made to determine 
whether the patient has had previous hyper­
s e n s it iv ity  re a c tio n s  to M EFO XIN *, 
cephalosporins, penicillins or other drugs. 
MEFOXIN* should be given with caution to 
penicillin-sensitive patients.
There is some clinical and laboratory evidence 
o f partia l c ro ss -a lle rg e n ic ity  between 
cephamycins and the other beta-lactam 
antibiotics, penicillins and cephalosporins. 
Severe reactions (including anaphylaxis) have 
been reported  w ith most beta-lactam  
antibiotics.
Pseudomembranous colitis has been reported 
with virtually all antibiotics. This colitis can 
range from mild to life threatening in severity. 
Antibiotics should therefore be prescribed 
with caution in individuals with a history of 
gastrointestinal disease, particularly colitis. It 
is im portant to consider a diagnosis of 
pseudomembranous colitis in patients who 
develop diarrhea in association with antibiotic 
use. While studies indicate that a toxin 
produced by Clostridium diffic ile  is one 
primary cause of antibiotic-associated colitis, 
other causes should also be considered.
Any patient who has demonstrated some form 
of allergy, particularly to drugs, should receive 
antibiotics including MEFOXIN* with caution. 
If an allergic reaction to MEFOXIN* occurs, 
adm in is tra tio n  of the drug should be 
d iscon tinued . Serious hypersensitiv ity  
reactions may requ ire  trea tm ent w ith 
epinephrine and other emergency measures. 
PRECAUTIONS
The total daily dosage should be reduced 
when MEFOXIN* is administered to patients 
with transient or persistent reduction of 
urinary output due to renal insufficiency (see 
DOSAGE AND ADMINISTRATION) because 
h igh  and p ro longed  serum a n tib io tic  
concentrations can occur from usual doses.
In patients treated with MEFOXIN* a false­
positive reaction to glucose in the urine may 
occur with Benedict’s or Fehling’s solutions 
but not w ith the use of specific glucose 
oxidase methods.
Using the Jaffe Method, falsely high creatinine 
values in serum may occu r if serum 
concentrations of cefoxitin exceed 100 Arg/mL. 
Serum samples from patients treated with 
MEFOXIN* should not be analyzed fo r 
creatinine if withdrawn within two hours of 
drug administration.
Increased nephrotoxicity has been reported 
fo llow ing concomitant administration of 
c e p h a lo s p o r in s  and a m in o g ly c o s id e  
antibiotics.
The safety of MEFOXIN* in the treatment of 
infections during pregnancy has not been 
es tab lished . If the  a d m in is tra tio n  of 
MEFOXIN* to pregnant patients is considered 
necessary, its use requires that the anticipated 
benefits be weighed against possible hazards 
to the fetus. Reproductive and teratogenic 
studies have been performed in mice and rats 
and have revealed no evidence of impaired 
fertility or harm to the fetus due to MEFOXIN*. 
Cefoxitin has been observed in the milk of 
nursing mothers receiving the drug. 
Prolonged use of MEFOXIN* may result in the 
overgrowth of non-susceptible organisms. 
Repeated evaluation of the patient's condition 
is essential and if super-infection occurs 
during therapy, appropriate measures should 
be taken. Should an organism become 
resistant during antibiotic therapy, another 
antibiotic should be substituted.
In children 3 months of age or older, higher 
doses of MEFOXIN* (100mg/kg/day and 
above) have been associated w ith an 
increased incidence of eosinophilia and 
elevated SGOT.
ADVERSE REACTIONS
MEFOXIN* is generally well tolerated. Adverse 
reactions rare ly required cessation of 
treatment and usually have been mild and 
transient.
Local Reactions
T h ro m b o p h le b it is  has occu rred  w ith  
intravenous administration. Some degree of 
pain and tenderness is usually experienced 
after intramuscular injections using water. 
Induration has occasionally been reported. 
Allergic
M aculopapular rash, urticaria , pruritus, 
eosinophilia, fever and other allergic reactions 
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can 
appear during or after antibiotic treatment. 
Nausea and vomiting have been reported 
rarely.
Blood
T ra n s ie n t e o s in o p h ilia , le u ko p e n ia , 
neutropenia, hemolytic anemia, and thrombo­
cy to p en ia  have been reported. Some 
individuals, particularly those with azotemia, 
may develop positive direct Coombs tests 
during therapy with MEFOXIN*.
Liver Function
Transient elevations in SGOT, SGPT, serum 
LDH, and serum alkaline phosphatase have 
been reported.
Kidney
Elevations in serum creatinine and/or blood 
urea nitrogen levels have been observed. As 
with the cephalosporins, acute renal failure 
has been reported rarely. The role of 
MEFOXIN* in changes in renal function tests 
is d i f f ic u l t  to  assess, s ince  fa c to rs  
predisposing to prerenal azotemia or to 
impaired renal function have often been 
present.
TREATMENT OF OVERDOSE
Other than general supportive treatment, no 
specific antidote is known. MEFOXIN* can be 
eliminated by dialysis in patients with renal 
insufficiency.
DOSAGE AND ADMINISTRATION
MEFOXIN* may be administered in tra ­
venously or intramuscularly when required. 
(See complete monograph for full details on 
ADMINISTRATION and RECONSTITUTION.) 
TREATMENT DOSAGE 
Adults
The usual adult dosage is 1 g or 2g of 
MEFOXIN* every 6 to 8 hours. Dosage and 
route of administration should be determined 
by severity of infection, susceptibility of the 
causative organisms, and condition of the 
patient. The usual adult dosages are shown in 
the Table below.
Usual Adult Dosage
T y p e  o f  
o f  in f e c t io n
D a i ly
D o s a g e
F r e q u e n c y  
a n d  R o u t e
U n c o m p l ic a t e d  
f o r m s *  o f  in ­
f e c t io n s  s u c h  a s  
p n e u m o n ia ,  
u r in a r y  t r a c t  
in f e c t io n ,  s o f t  
t is s u e  in f e c t io n
3 - 4  g 1 g  e v e r y  6 - 8  h  
I .V .  o r  I .M .
M o d e r a t e ly  
s e v e r e  o r  s e v e r e  
i n f e c t io n s
6 - 8  g 1 g  e v e r y  4  h
o r
2  g  e v e r y  6 - 8  h I .V .
In f e c t io n s  
c o m m o n ly  
n e e d in g  a n t i ­
b io t ic s  in  h ig h e r  
d o s a g e  ( e .g .  g a s  
g a n g r e n e )
1 2 9 2  g  e v e r y  4  h
o r
3  g e v e r y  6  h  I .V .
’ I n c l u d i n g  p a t i e n t s  in  w h o r r  
a b s e n t  o r  u n l i k e l y
i b a c t e r e m i a  is
Therapy may be started while awaiting the 
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic 
streptococcal infectionsshould be maintained 
for at least 10 days to guard against the risk of 
rheumatic fever or glomerulonephritis. In 
staphylococcal and other infections involving 
a collection of pus, surgical drainage should 
be carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN* may be used in patients with 
reduced renal function but a reduced dosage
should be employed and it is advisable to 
monitor serum levels in patients with severe 
impairment.
In adults with renal insufficiency, an initial 
loading dose of 1 g to 2 g should be given. 
A fte r  a lo a d in g  dose, the fo llo w in g  
recommendations for maintenance dosage 
may be used as a guide:
R E N A L C R E A T IN IN E
F U N C T IO N C L E A R A N C E D O S E F R E Q U E N C Y
m L /m in
Mild
im pairm ent
Moderate
50-30 1-2 9 every 8-12 h
impairment
Severe
29-10 1-2 9 every 12-24 h
impairment 9-5 0.5-1 g every 12-24 h
Essentially 
no function <5 0.5-1 g every 24-48 h
In the patient undergoing hemodialysis, the 
loading dose of 1 -2 g should be given after 
each hemodialysis, and the maintenance dose 
should be given as indicated in the Table 
above.
Neonates (Including Premature Infants), 
Infants and Children (See WARNINGS for 
Neonates under ADMINISTRATION in the 
complete monograph.)
Premature Infants 
with Body Weights 
Above 1500 g 20-40 m g /k g  every 12 h I.V.
Neonates
0 - 1 week o f age
1- 4 w eeks o f age
20-40 m g / kg every 12 h I.V. 
20-40 m g /k g  every 8 h I.V.
Infants
1 m on th  to  2 years 
o f age
20-40 m g /k g  every 6 h or 
every 8 h I.M. o r I.V.
Children 20-40 m g /k g  every 6 h or 
every 8 h I.M. o r I.V.
In severe infections, the total daily dosage in 
infants and children may be increased to 
200 mg/kg, but not to exceed 12 g per day. 
MEFOXIN* is not recommended for the ther­
apy of meningitis. If meningitis is suspected, 
an appropriate antibiotic should be used.
At present there is insu ffic ien t data to 
recommend a specific dosage for children 
with impaired renal function. However, if the 
administration of MEFOXIN* is deemed to be 
essential the dosage should be modified 
consistent with the recommendations for 
adults (see Table above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of 
MEFOXIN is recommended as follows: 
Vaginal or abdominal hysterectomy and 
abdominal surgery
2 g a d m in is te re d  in tra m u s c u la r ly  or 
in tra v e n o u s ly  ju s t p r io r  to  su rg e ry  
[approximately one-half to one hour before 
initial incision).
The second and third 2 g doses should be 
administered at 2-6hour intervals after the 
initial dose.
Cesarean Section
The first dose of 2 g should be administered 
intravenously as soon as the umbilical cord 
has been clamped. The second and third 
2 g doses should be given intravenously or 
intramuscularly four hours and eight hours 
after the first dose.
AVAILABILITY
MEFOXIN* (sterile cefoxitin sodium, Frosst 
Std.) is supplied as sterile powder in boxes of 
10 vials:
No. 3356 1 g cefoxitin as sodium salt 
No. 3357 2 g cefoxitin as sodium salt
Storage
MEFOXIN* in the dry state should be stored 
below 30° C.
PRODUCT MONOGRAPH AVAILABLE 
ON REQUEST
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BOOK REVIEWS 
continued from page 211
injuries, and it offers an interesting review of 
missile injuries.
The section on surgical technique offers an 
overview of microsurgery, surgery of the hand 
and a chapter on hernia repairs that I found 
very detailed. In the section on patient care, 
excellent descriptions of fluid, electrolyte and 
nutritional support, blood replacement, 
hemostasis and infections in surgery are all 
included.
To test the value of this book in daily surgi­
cal practice, I reviewed questions 1 encountered 
in my office during the previous month. These 
included problems in the handling of biliary 
tree calculi, treatment of thrombosed hemor­
rhoids, perianal abscesses and chronic pan­
creatic pain. I was pleasantly surprised to find 
all of them addressed in this book. I was, 
however, disappointed at the dogmatic 
approach followed in most cases, outlining the 
authors’ approach without discussion or anal­
ysis of alternative methods or justification of 
the approach taken and almost never listing 
references on the subject. In my estimation, 
this is the major flaw in an otherwise excellent 
book.
In summary, 1 was pleased with the 
approach taken in this book. Lengthy physio­
logical explanations, better left to physiology 
treatises, were avoided, and specific, everyday, 
practical surgical problems were addressed. 
The editors also felt the need to review more 
specialized subjects on the grounds that general 
surgeons are often involved, directly or 
indirectly, in such situations. The reviews are 
concise yet contain a wealth of information. 
The book is well written and easy to read. The 
style, very uniform despite the 50 contributors, 
is a credit to the editors. 1 recommend the 
book.
Luis Oppenheimer, md, frcsc
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TRANSPLANTATION OF LYOPHILIZED 
CARTILAGE IN MAXILLO-FACIAL 
SURGERY. Experimental Foundations 
and Clinical Success. Hermann F. Sailer. 
138 pp. Illust. S. Karger AG, Basel, 1983. 
$69. (US). ISBN 3-8055-3570-8.
The use of allogeneic or xenogeneic cartilage 
grafts for mechanical support or as tissue fillers 
has become increasingly popular in maxillofa­
cial surgery over the last 40 years. Many 
methods of preservation, storage and sterili­
zation of the grafting material exist. Few pub­
lications are available on the clinical or 
experimental use of lyophilized cartilage and 
these have mostly originated from Eastern 
Europe. The author has been involved in the 
use of lyophilized cartilage at the Department 
of Maxillo-Facial Surgery, University Clinic of 
Zurich, where such material has been used for 
over 20 years.
Sailer’s monograph is well written, elegantly 
organized and will prove equally useful to cli­
nicians and researchers working in this field. 
He provides a good review of existing litera­
ture. Proper histologic documentation illus­
trated by good-quality microphotographs 
forms the basis for clinical applications of 
lyophilized cartilage grafts.
With such an impressive scientific introduc­
tion, one would expect more voluminous clin­
ical descriptions and presentations, with long­
term follow-up, to gain greater acceptance for 
the material under investigation.
It is a study designed and conducted by a 
clinician with direct applications in mind and 
with a thorough knowledge of the principles 
of scientific experimentation. This particular 
combination makes the book not only educat­
ing but also easy and pleasant to read.
K. C o n r a d , m d , fr c s , f r c s c , f a c s
Cosmetic Facial Surgery Service,
Department of Otolaryngology,
Mount Sinai Hospital,
600 University Ave.,
Toronto, Ont.,
M5G 1X5
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A Fatal Pulmonary Embolus Composed 
of Gross Liver Tissue
A snowmobile accident caused a pulp 
injury to the liver and tear of the vena 
cava of a 21-year-old man. Improvement 
after fluid resuscitation, right hepatic 
lobectomy and caval repair was followed 
by sudden hemodynamic collapse and 
death. Autopsy revealed pulmonary 
embolism caused by liver tissue. 
Presumably the pieces of liver entered 
the vena cava through the tear and 
travelled to the lung when blood flow 
improved. The authors believe that this 
is the first report of fatal pulmonary 
embolism caused by macroscopic liver 
tissue.
Un accident de motoneige est a I'origine 
de lesions de la pulpe hepatique et d'une 
dechirure de la veine cave chez un 
homme de 21 ans. Une amelioration con­
secutive au retablissement des volumes 
liquidiens, a la resection du lobe hepati­
que droit et & la reparation de la veine 
cave, a ete suivi d'un collapsus hemody- 
namique brutal puis de la mort du 
patient. L'autopsie a revele une embolie 
pulmonaire causee par du tissu hepati­
que. On presume que des pieces du foie 
ont penetre dans la veine cave par la 
dechirure et ont voyage jusqu'au foie 
lorsque le debit a ete ameliord. Les 
auteurs croient qu'il s'agit de la premiere 
description connue d'un cas d'embolie 
pulmonaire fatale causee par du tissu 
macroscopique hepatique.
The commonest autogenous material 
causing pulmonary embolism is clot from 
a venous thrombus. Fat, marrow, 
amniotic fluid and tumour cells are other
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known autogenous embolic materials. 
Bacteria, air, cannulas, and even bullets 
are among recognized exogenous emboli. 
This report describes a patient who died 
o f pulmonary embolism from autogenous 
liver fragments and explains the mechan­
ism o f embolization. Although Camps1 
stated that liver cells may occasionally be 
found in the lungs o f patients with severe 
crush injury, we have not found a previ­
ous report of multiple, fatal macroscopic 
emboli composed of liver tissue.
Case Report
A 21-year-old man was thrown off a snow­
mobile, striking a fence post with his right side. 
Fie lay in the snow for about 30 minutes before 
transportation to the emergency department. 
On arrival, he was conscious and complained 
of severe right-sided abdominal pain. His blood 
pressure was 70 mm Hg systolic and the pulse 
rate 84 beats/min. The abdomen was dis­
tended, guarded and silent. Roentgenograms 
showed no thoracic or spinal injury. Frank 
blood was recovered on peritoneal tap. His 
hemoglobin level was 119 g/L. He was known 
to drink alcohol liberally, although he denied 
drinking before his accident and his breath did 
not smell of alcohol at the time of admission.
Massive fluid replacement was begun using 
colloid and crystalloid solutions (12 units of 
packed cells, 400 mL plasma and 3000 mL crys­
talloid). On his arrival in the operating room, 
his systolic blood pressure became unobtaina­
ble and remained so for about 50 minutes, dur­
ing which time bleeding sites were controlled. 
With volume replacement, the pressure slowly 
rose.
Laparotomy 30 minutes after admission rev­
ealed several litres of free blood in the 
peritoneal cavity. A pulp injury of the right 
hepatic lobe resulted in multiple liver fragments 
of various sizes floating in the intraperitoneal 
blood. The right hepatic vein was avulsed from 
the vena cava, causing a longitudinal tear in 
the latter (Fig. 1). The right adrenal gland was 
torn, leaving the adrenal vein to bleed freely. 
No other injuries were evident.
The portal pedicle was clamped, and the 
blood and hepatic debris were removed. The 
vena caval tear was isolated by a Satinsky aortic 
clamp and repaired (Fig. 2). The adrenal vein 
was ligated and a partial hepatectomy done at 
the site of liver damage. Hemostasis was con­
firmed after release of the portal pedicle clamp. 
Measured blood loss was 6000 mL.
When the patient was transferred to the 
intensive care unit he had good colour, evi­
dence of urine output, a systolic blood pres­
sure of 95 mm Hg and a pulse rate of 90 
beats/min. He was put on a respirator. Thirty 
minutes later he became cyanotic, hypotensive 
(blood pressure 40 mm Hg systolic) and 
tachycardiac (pulse rate 148 beats/min). The 
endotracheal tube was still in place, air entry 
was good bilaterally and there was no pneu­
mothorax. Absence of an obvious cause for 
this sudden moribund state in a previously sta­
ble patient suggested recurrent hemorrhage. He 
was returned to the operating room for re­
exploration, but because the vital signs were 
absent, there was no electrical activity of the 
heart and the pupils were fixed and dilated, the 
proposed laparotomy was cancelled. Cardi­
opulmonary resuscitation was initiated, but 
was unsuccessful.
Autopsy Findings
At autopsy the peritoneal cavity was 
found to contain 150 mL blood with some 
liver fragments. The parenchyma of the 
2200-g liver was pale, soft and yellow, 
compatible with severe fatty metamor­
phosis. The right adrenal gland was frag­
mented. The repair of the inferior vena 
cava was intact. A striking finding was 
the presence of a large fragment of liver 
(2 cm in diameter) lodged in the main 
right pulmonary artery (Fig. 3). In addi­
tion, there were smaller fragments in the
L o M C - l T U D l l d ^ L .  T E A R  
IM  V E N A  C A V A
FIG. 1—Schematic representation of inju­
ries to liver and inferior vena cava as seen from 
right anterolateral aspect.
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secondary branches. Sectioning of the 
lung revealed yellow liver tissue impacted 
in the lumina of the small pulmonary 
artery radicles. There was no evidence of 
head injury.
Microscopic examination revealed 
severe fatty metamorphosis of the liver. 
Lung sections showed intra-alveolar 
hemorrhage and plugs of liver occluding 
the lumina of many arteries (Fig. 4).
Discussion
To our knowledge, this is the first 
reported case of fatal pulmonary 
embolism by liver tissue. Liver cells found 
in the lungs after crush injury get there 
by an intrahepatic route; presumably dis­
ruption of intrahepatic venules allows 
crushed cells to enter the bloodstream and 
lodge in the lungs, where they may be dis­
tort-cRucSRl/sic, i/ASCULAg. 
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FIG. 2—Vascular clamp in place, controlling blood loss and isolating tear for convenient 
repair, yet leaving adequate lumen for unimpeded continuous flow during repair. Liver tissue 
within lumen is undetected. When flow improves, these particles will be carried by bloodstream 
to become pulmonary emboli.
FIG. 3—(a) Photograph and (b) line drawing of gross specimen of right lung with embolus 
in situ. Large fragment of liver tissue (arrow) is impacted in right pulmonary artery.
Fig. 4b
FIG. 4—(a) Photomicrograph of embolus in situ. LU = lung parenchyma, RPA = right 
main pulmonary artery, LE = liver embolus which completely occludes lumen of artery (origi­
nal magnification x 40) (b) Embolus (LE) at higher magnification is identified as liver tissue 
with marked fatty metamorphosis (x  100) original magnification.
covered as incidental findings during 
autopsy after death caused by associated 
injury. In our patient, the particles of liver 
probably entered the circulation extrahe- 
patically. Avulsion of the hepatic vein left 
a large rent in the vena cava through 
which free liver particles could have 
entered and presumably remained within 
its lumen during the low flow state. At 
surgery, the tear in the vena cava was iso­
lated from the lumen, leaving undetected 
the bits of liver tissue within the vessel 
(Fig. 2). Once hemostasis was achieved 
and blood loss restored, the patient’s 
hemodynamic status improved. The much 
better flow now carried these liver pieces 
through the right heart into the pulmo­
nary vascular bed, where they lodged as 
a fatal shower of large pulmonary emboli. 
This explains the sudden and unexpected 
irreversible collapse and death after 
apparently successful resuscitation and 
stabilization.
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NOTICES
Innovative Cancer Therapy 
for Tomorrow
This Chemotherapy Foundation Sympo­
sium will be held at the Sheraton Centre 
Hotel in New York, Nov. 12-14, 1986. 
Session topics will include p o st­
menopausal breast cancer, polychemo- 
therapy, differentiation chemotherapy, 
chemoimmunotherapy and new Phase II 
drugs.
For further information write the 
Director, the Page and William Black 
Post-Graduate School of Medicine, One 
Gustave L. Levy Place, New York, NY 
10029 or call (212) 650-6772.
50th Anniversary 
Surgery Course
The Department of Surgery, University 
of Minnesota Medical School is sponsor­
ing “ Trauma and Critical Care Surgery” 
as its 50th-anniversary surgery course, 
which will be held June 18-21, 1986, on 
campus.
Fees are $400 ($200 for medical resi­
dents), and the course is accredited for 
25 'h hours in Category 1 by the Ameri­
can Medical Association.
For more information contact: Office 
of CME, University of Minnesota, Box 
202, 420 Delaware St. SE, Minneapolis, 
MN 55455; (612) 373-8012.
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CLASSIFIED ADVERTISING
As a further service to its readers the Canadian Journal o f  Surgery is pleased to accept suitable classified advertisements. The deadline is 1 month before issue 
date. Regular classified rates (for each insertion): $38.00 for the first 40 words or less, additional words 45C each (additional $15.00 for frame). Special Display 
under 75 words, 2V a "  X V  $95.00. $5.00 charge (first insertion only) for CJS box numbers. Display rates available on request.
________________ ________ Copy should be mailed to the Canadian Journal o f  Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.
GENERAL SURGEON: ON
Required for surgical group.
Fu ll-tim e em p loym ent (Toronto
area)
Ideal working conditions.
All replies w ill be treated in con­
fidence.
Reply:
Box S112 CJS
________________________________________ - S 8 6 - 1 1
CLINICAL DAY IN COLOPROCTOLOGY: -  at the
Toronto General Hospital, Toronto, Canada, Fri­
day, June 13th, 1986. Guest speakers include: 
Robert Beart, Mayo Clinic: John Goligher, Leeds 
England; Richard Hunt, McMaster University: Ber­
nard Cummings, Ontario Cancer Institute, Prin­
cess Margaret Hospital. The fee is $100 
(Canadian). For more information and registration 
please contact: Dr. Zane Cohen, Toronto General 
Hospital, 9-242 Eaton North, 200 Elizabeth St., 
Toronto, ON M5G 2C4. Tel.: (416) 595-3556.
-S 8 6 -1 8
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PLASTIC SURGEON: ON — FRCS, required for 
very active metropolitan Toronto community 
hospital. General plastic surgery practice with 
emergency responsibilities especially in regards to 
hand injuries. Please send curriculum vitae to: 
Department of Plastic Surgery, Northwestern 
General Hospital, 2175 Keele St., Toronto, ON 
M6M 3Z4. -S 8 6 -1 5
GENERAL SURGEON: ON — Lakeshore tow n of 
85 000 near Toronto requires fifth  general sur­
geon. 340-bed hospital. General surgery practice 
does not include ortho, gyne, plastic, vascular or 
thoracic surgery. Position available now. Send cv 
and three reference to: Box S113 CJS.
-S 8 6 -1 4
THORACIC SURGEON: — Fully certified, tho­
racic and general surgeon wishes to relocate. 
Wide experience in all aspects of noncardiac 
thoracic surgery. Experience in surgical education 
at all levels both clinical and organizational. Aca­
demic affiliation desired. Please reply to: Box 
S 114 CJS. -S 8 6 -1 9
GENERAL SURGEON: PQ — required to join an ac­
tive department o f surgery, which includes several 
surgical subspecialties in a 140-bed acute care 
university affiliated bilingual teaching hospital. 
Candidate w ith  appropriate training will have op­
portunity to do surgical endoscopy, thoracic and 
peripheral vascular surgery. Apply to: The Direc­
tor of Professional Services, Dr. Zoltan Ferenczi, 
375 Argyle St., Sherbrooke, (Quebec), J1J 3H5. 
(819) 569-3661. -S 8 6 -1 7
OBSTETRICIAN/GYNECOLOGIST: YK -  Yukon 
Territory requires a certified FRCSC obstetri- 
cian/gynecologist w ith LMCC. Whitehorse (popu­
lation 25 000) is a vibrant community linked with 
daily je t service to  Vancouver and Edmonton. A 
consulting practice only, there is no shortage of 
hospital beds or operating room tim e. A 
knowledge of colposcopy, ultrasound and infer­
tility  workups would be an asset. Routine ob­
stetrics are handled by the family physicians and 
weekend call is provided by the general surgeon 
and therefore is optional. Whitehorse in the 
southern Yukon is located on the Yukon River. It 
is close to  mountains and lakes and within 160 
km of the world famous Kluane Park. There is ex­
cellent climbing, kayaking, canoeing, ski touring, 
hunting and fishing. The fee schedule is generous, 
(BC plus 30%), w ith  a minimal expected income 
of $250 000 gross. This is certainly the best 
OBS/GYN job in Canada and we invite you to ap­
ply to the follow ing address: Dr. Roger S. Mitch­
ell, Whitehorse Medical Service Ltd., 406 Lambert 
St., Whitehorse, YK Y1A 1Z7 or telephone collect: 
(403)667-4421 . -S 8 6 -1 6
ICU RESEARCH FELLOW: — Ewart Angus Inten­
sive Care Unit, The Wellesley Hospital. Available 
July 1, 1 986 for a one year period in an academic 
Medical-Surgical Unit. Research areas include clin­
ical epidemiology of ICU care, nutrition and 
respiratory muscle physiology. Reply to: Dr. I.M. 
Fraser, Director EAICU, 247 The Jones Bldg., 160 
Wellesley St. E., Toronto, ON M4Y 1J3 (416) 
926-7747. -S 86-04
C H A IR M A N , 
D E P A R T M E N T  OF 
IN T E N S IV E  CARE
The General Hospital, St. John's, Newfoundland is 
seeking an experienced individual to  chair its Depart­
ment of Intensive Care. The unit is located in a modern 
health sciences centre which also houses The Memori­
al University Faculty o f Medicine. It accommodates 
both medical and surgical patients.
Applicants should hold a fe llowship from  the Royal 
College o f Physicians and Surgeons o f Canada and 
have demonstrated adm inistrative ability.
Details regarding financial arrangements and an ap­
propriate University appointment can be obtained from 
the  Chairman o f the Search Committee to  whom  in­
quiries should be addressed:
Dr. David Hawkins 
Health Sciences Centre 
St. John's, Newfoundland 
A1B 3V6
(709) 737-6551 -S 8 6 -1 2
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Now indicated for the
prevention o f occlusion of the saphenous vein 
in coronary bypass procedures.
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S FTGUT
Better than catgut —  but still catgut
Meet some members 
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DISPOSABLE SKIN STAPLER
Mr No hang ups!
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V /  immediately, automatically 
■My' and completely released
regardless of direction of 
/  \  stapler movement.
''..from the b + G  wound closure system
Davis +  Geek IntroducesTHE SMOOTH ONE
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Something 
you’re used to 
without 
the problems 
you’re used to
You told us that you liked using catgut but you didn't like its 
problems. So we took catgut and made it •
• soft and supple 
.  easy to tie
. less likely to curt, ‘pigtail" and tangle
• easy to  handle and control
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